Bicyclic pyrazolyl amines as cdk2 inhibitors

ABSTRACT

The present application provides bicyclic amines of Formula (I): 
     
       
         
         
             
             
         
       
     
     or a pharmaceutically acceptable salt thereof, that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

This application claims the benefit of priority of U.S. Prov. Appln. No.63/212,840, filed Jun. 21, 2021, which is incorporated by reference inits entirety.

TECHNICAL FIELD

This application is directed to bicyclic amines which inhibitcyclin-dependent kinase 2, (CDK2) and are useful for treating cancer.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been filedelectronically in ASCII format and is hereby incorporated by referencein its entirety. Said ASCII copy, created on Jun. 20, 2022, is named20443-0738001_SEQ.txt and is 12.8 kilobytes in size.

BACKGROUND

Cyclin-dependent kinases (CDKs) are a family of serine/threoninekinases. Heterodimerized with regulatory subunits known as cyclins, CDKsbecome fully activated and regulate key cellular processes includingcell cycle progression and cell division (Morgan, D. O., Annu Rev CellDev Biol, 1997, 13:261-91). Uncontrolled proliferation is a hallmark ofcancer cells. The deregulation of the CDK activity is associated withabnormal regulation of cell-cycle, and is detected in virtually allforms of human cancers (Sherr, C. J., Science, 1996, 274(5293):1672-7).

CDK2 is of particular interest because deregulation of CDK2 activityoccurs frequently in a variety of human cancers. CDK2 plays a crucialrole in promoting G1/S transition and S phase progression. In complexwith cyclin E (CCNE), CDK2 phosphorylates retinoblastoma pocket proteinfamily members (p107, p130, pRb), leading to de-repression of E2Ftranscription factors, expression of G1/S transition related genes andtransition from G1 to S phase (Henley, S. A. and F. A. Dick, Cell Div,2012, 7(1):10). This in turn enables activation of CDK2/cyclin A, whichphosphorylates endogenous substrates that permit DNA synthesis,replication and centrosome duplication (Ekholm, S. V. and S. I. Reed,Curr Opin Cell Biol, 2000, 12(6):676-84). It has been reported that theCDK2 pathway influences tumorigenesis mainly through amplificationand/or overexpression of CCNE1 and mutations that inactivate CDK2endogenous inhibitors (e.g., p27), respectively (Xu, X., et al.,Biochemistry, 1999, 38(27):8713-22).

CCNE1 copy-number gain and overexpression have been identified inovarian, gastric, endometrial, breast and other cancers and beenassociated with poor outcomes in these tumors (Keyomarsi, K., et al., NEngl J Med, 2002, 347(20):1566-75; Nakayama, N., et al., Cancer, 2010,116(11):2621-34; Au-Yeung, G., et al., Clin Cancer Res, 2017,23(7):1862-1874; Rosen, D. G., et al., Cancer, 2006, 106(9):1925-32).Amplification and/or overexpression of CCNE1, also reportedly contributeto trastuzumab resistance in HER2+ breast cancer and resistance toCDK4/6 inhibitors in estrogen receptor-positive breast cancer(Scaltriti, M., et al., Proc Natl Acad Sci USA, 2011, 108(9):3761-6;Herrera-Abreu, M. T., et al., Cancer Res, 2016, 76(8):2301-13). Variousapproaches targeting CDK2 have been shown to induce cell cycle arrestand tumor growth inhibition (Chen, Y N., et al., Proc Natl Acad Sci USA,1999, 96(8):4325-9; Mendoza, N., et al., Cancer Res, 2003,63(5):1020-4). Inhibition of CDK2 also reportedly restores sensitivityto trastuzumab treatment in resistant HER2+ breast tumors in apreclinical model (Scaltriti, supra).

These data provide a rationale for considering CDK2 as a potentialtarget for new drug development in cancer associated with deregulatedCDK2 activity. In the last decade there has been increasing interest inthe development of CDK selective inhibitors. Despite significantefforts, there are no approved agents targeting CDK2 to date (Cicenas,J., et al., Cancers, (Basel), 2014, 6(4):2224-42). Therefore it remainsa need to discover CDK inhibitors having novel activity profiles, inparticular those targeting CDK2. This application is directed to thisneed and others.

SUMMARY

The present invention relates to, inter alia, compounds of Formula (I):

or pharmaceutically acceptable salts thereof, wherein the constituentmembers are defined herein.

The present invention further provides pharmaceutical compositionscomprising a compound described herein, or a pharmaceutically acceptablesalt thereof, and a pharmaceutically acceptable carrier.

The present invention further provides methods of inhibiting CDK2,comprising contacting the CDK2 with a compound described herein, or apharmaceutically acceptable salt thereof.

The present invention further provides methods of inhibiting CDK2 in apatient, comprising administering to the patient a compound describedherein, or a pharmaceutically acceptable salt thereof.

The present invention further provides methods of treating a disease ordisorder associated with CDK2 in a patient, comprising administering tothe patient a compound described herein, or a pharmaceuticallyacceptable salt thereof.

The present invention further provides compounds described herein, or apharmaceutically acceptable salt thereof, for use in any of the methodsdescribed herein.

The present invention further provides uses of a compound describedherein, or a pharmaceutically acceptable salt thereof, for thepreparation of a medicament for use in any of the methods describedherein.

DETAILED DESCRIPTION

The present application provides, inter alia, a compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

is a single or a double bond;

n is 0, 1, 2, 3, or 4;

Y is CR^(1a) or NR^(1b), wherein Y is adjacent to the carbon ring memberattaching Ring moiety A to the —NH— in Formula (I);

Ring moiety A is selected from C₆₋₁₀ aryl and 5-10 membered heteroaryl,wherein Ring moiety A is attached to the —NH— in Formula (I) through acarbon atom;

R^(1a) is selected from halo, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₃₋₆cycloalkyl, 4-6 membered heterocycloalkyl, OR^(a1), SR^(a1), SF₅,NR^(c1)R^(d1), C₃₋₆ cycloalkyl-C₁₋₃ alkyl, and 4-6 memberedheterocycloalkyl-C₁₋₃ alkyl, wherein said C₁₋₄ alkyl, C₁₋₄ haloalkyl,C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₃alkyl, and 4-6 membered heterocycloalkyl-C₁₋₃, alkyl are optionallysubstituted by 1, 2, 3, or 4 independently selected R^(G) substituents;

or, alternatively, R^(1a) and an R² on an adjacent ring member of Ringmoiety A, together with the ring atoms to which they are attached, formRing moiety B;

R^(1b) is selected from C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, 4-6membered heterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl, and 4-6 memberedheterocycloalkyl-C₁₋₃ alkyl, wherein said C₁₋₄ alkyl, C₁₋₄ haloalkyl,C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₃alkyl, and 4-6 membered heterocycloalkyl-C₁₋₃ alkyl are optionallysubstituted by 1, 2, 3, or 4 independently selected R^(G) substituents;

or, alternatively, R^(1b) and an R² on an adjacent ring member of Ringmoiety A, together with the ring atoms to which they are attached, formRing moiety B;

Ring moiety B is selected from C₃₋₆ cycloalkyl, 4-6 memberedheterocycloalkyl, phenyl, and 5-6 membered heteroaryl, each of which isoptionally substituted by 1, 2, 3, or 4 independently selected R³substituents;

each R^(a1), R^(c1), and R^(d1) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents;

or, any R^(c1) and R^(d1) attached to the same N atom, together with theN atom to which they are attached, form a 4-7 membered heterocycloalkylgroup, wherein the 4-7 membered heterocycloalkyl group is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(G)substituents;

each R² and R³ is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl,6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 memberedheteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl,4-10 membered heterocycloalkyl-C₁₋₄ alkyl, 5-10 membered heteroaryl-C₁₋₄alkyl, OR^(a2), SR^(a2), NHOR^(a2), C(O)R^(b2), C(O)NR^(c2)R^(d2),C(O)NR^(c2)(OR^(a2)), C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2),NR^(c2)R^(d2), NR^(c2)NR^(d2), NR^(c2)C(O)R^(b2) NR²C(O)OR^(a2),NR^(c2)C(O)NR^(c2)R^(d2), C(═NR^(e2))R^(b2), C(═NR^(e2))NR^(c2)R^(d2),NR^(c2)C(═NR^(e2))NR^(c2)R^(d2), NR^(c2)C(═NR^(e2))R^(b2),NR^(c2)S(O)NR^(c2)R^(d2), NR^(c2)S(O)R^(b2), NR^(c2)S(O)₂R^(b2),NR^(c2)S(O)(═NR^(e2))R^(b2), NR^(c2)S(O)₂NR^(c2)R^(d2), S(O)R^(b2),S(O)NR^(c2)R^(d2), S(O)₂R^(b2), S(O)₂NR^(c2)R^(d2),OS(O)(═NR^(e2))R^(b2), OS(O)₂R^(b2), S(O)(═NR^(e2))R^(b2), SF₅,P(O)R^(f2)R^(g2), OP(O)(OR^(h2))(OR^(i2)), P(O)(OR^(h2))(OR^(i2)), andBR^(j2)R^(k2), wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl are each optionallysubstituted with 1, 2, 3, or 4 independently selected R^(2A)substituents;

each R^(a2), R^(c2), and R^(d2) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl,6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 memberedheteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl,4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 memberedheteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2A) substituents;

or, any R^(e2) and R^(d2) attached to the same N atom, together with theN atom to which they are attached, form a 4-10 membered heterocycloalkylgroup, wherein the 4-10 membered heterocycloalkyl group is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(2A)substituents;

each R^(b2) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2A) substituents;

each R^(e2) is independently selected from H, OH, CN, C₁₋₆ alkyl, C₁₋₆alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₇ cycloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;

each R^(f2) and R^(g2) are independently selected from H, C₁₋₆ alkyl,C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;

each R^(h2) and R^(i2) is independently selected from H, C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl,C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄alkyl;

each R^(j2) and R^(k2) is independently selected from OH, C₁₋₆ alkoxy,and C₁₋₆ haloalkoxy;

or any R^(j2) and R^(k2) attached to the same B atom, together with theB atom to which they are attached, form a 5- or 10-memberedheterocycloalkyl group optionally substituted with 1, 2, 3, or 4substituents independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl;

each R^(2A) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl,6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 memberedheteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl,4-10 membered heterocycloalkyl-C₁₋₄ alkyl, 5-10 membered heteroaryl-C₁₋₄alkyl, OR^(a21), SR^(a21), NHOR^(a21), C(O)R^(b21), C(O)NR^(c21)R^(d21),C(O)NR^(c21)(OR^(a21)), C(O)OR^(a21), OC(O)R^(b21),OC(O)NR^(c21)R^(d21), NR^(c21)R^(d21), NR^(c21)NR^(c21)R^(d21),NR^(c21)C(O)R^(b21), NR^(c21)C(O)OR^(a21), NR^(c21)C(O)NR^(c21)R^(d21),C(═NR^(e21))R^(b21), C(═NR^(e21))NR^(c21)R^(d21),NR^(c21)C(═NR^(e21))NR^(c21)R^(d21), NR^(c21)C(═NR^(e21))R^(b21),NR^(c21)S(O)NR^(c21)R^(d21), NR^(c21)S(O)R^(b21), NR^(c21)S(O)₂R^(b21),NR^(c21)S(O)(═NR^(e21))R^(b21), NR^(c21)S(O)₂NR^(c21)R^(d21),S(O)R^(b21), S(O)NR²¹R²¹, S(O)₂R^(b21), S(O)₂NR^(c21)R^(d21),OS(O)(═NR^(e21))R^(b21), OS(O)₂R^(b21), S(O)(═NR^(e21))R^(b21), SF₅,P(O)R^(f21)R^(g21), OP(O)(OR^(h21))(OR^(i21)), P(O)(OR^(h21))(OR^(i21)),and BR^(j21)R^(k21), wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2B) substituents;

each R^(a21), R^(c21), and R^(d21) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2B) substituents;

or, any R^(c21) and R^(d21) attached to the same N atom, together withthe N atom to which they are attached, form a 4-10 memberedheterocycloalkyl group, wherein the 4-10 membered heterocycloalkyl groupis optionally substituted with 1, 2, 3, or 4 independently selectedR^(2B) substituents;

each R^(b21) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2B) substituents;

each R^(e21) is independently selected from H, OH, CN, C₁₋₆ alkyl, C₁₋₆alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₇ cycloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;

each R^(f21) and R^(g21) are independently selected from H, C₁₋₆ alkyl,C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;

each R^(h21) and R^(i21) is independently selected from H, C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl,C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄alkyl;

each R^(j21) and R^(k21) is independently selected from OH, C₁₋₆ alkoxy,and C₁₋₆ haloalkoxy;

or any R^(j21) and R^(k21) attached to the same B atom, together withthe B atom to which they are attached, form a 5- or 10-memberedheterocycloalkyl group optionally substituted with 1, 2, 3, or 4substituents independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl;

each R^(2B) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl,OR^(a22), SR^(a22), NHOR^(a22), C(O)R^(b22), C(O)NR^(c22)R^(d22),C(O)NR^(c22)(OR^(a22)), C(O)OR^(a22), OC(O)R^(b22),OC(O)NR^(c22)R^(d22), NR^(c22)R^(d22), NR^(c22)NR^(c22)R^(d22),NR^(c22)C(O)R^(b22), NR^(c22)C(O)OR^(a22), NR^(c22)C(O)NR^(c22)R^(d22),C(═NR^(e22))R^(b22), C(═NR^(e22))NR^(c22)R^(d22),NR^(c22)C(═NR^(e22))NR^(c22)R^(d22), NR^(c22)C(═NR^(e22))R^(b22),NR^(c22)S(O)NR^(c22)R^(d22), NR^(c22)S(O)R^(b22), NR^(c22)S(O)₂R^(b22),NR^(c22)S(O)(═NR^(e22))R^(b22), NR^(c22)S(O)₂NR^(c22)R^(d22),S(O)R^(b22), S(O)NR^(c22)R^(d22), S(O)₂R^(b22), S(O)₂NR^(c22)R^(d22),OS(O)(═NR^(e22))R^(b22), OS(O)₂R^(b22), S(O)(═NR^(e22))R^(b22), SF₅,P(O)R^(f22)R^(g22), OP(O)(OR^(h22))(OR^(i22)), P(O)(OR^(h22))(OR^(i22)),and BR^(j22)R^(k22), wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1,2, 3, or 4 independently selected R^(G) substituents;

each R^(a22), R^(c22), and R^(d22) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents;

or, any R^(c22) and R^(d22) attached to the same N atom, together withthe N atom to which they are attached, form a 4-7 memberedheterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl groupis optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents;

each R^(b22) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(G) substituents;

each R^(e22) is independently selected from H, OH, CN, C₁₋₆ alkyl, C₁₋₆alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^(f22) and R^(g22) are independently selected from H, C₁₋₆ alkyl,C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄alkyl;

each R^(h22) and R^(i22) is independently selected from H, C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^(j22) and R^(k22) is independently selected from OH, C₁₋₆ alkoxy,and C₁₋₆ haloalkoxy;

or any R^(j22) and R^(k22) attached to the same B atom, together withthe B atom to which they are attached, form a 5- or 6-memberedheterocycloalkyl group optionally substituted with 1, 2, 3, or 4substituents independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl;

R⁴ is independently selected from 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, OR^(a4), and NR^(c4)R^(d4),wherein said 6-10 membered aryl, 4-10 membered heterocycloalkyl, and5-10 membered heteroaryl are each optionally substituted with 1, 2, 3,or 4 independently selected R^(4A) substituents;

each R^(a4), R^(c4), and R^(d4) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl,6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 memberedheteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl,4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 memberedheteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4A) substituents;

or, any R^(c4) and R^(d4) attached to the same N atom, together with theN atom to which they are attached, form a 4-10 membered heterocycloalkylgroup, wherein the 4-10 membered heterocycloalkyl group is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(4A)substituents;

each R^(4A) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl,6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 memberedheteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl,4-10 membered heterocycloalkyl-C₁₋₄ alkyl, 5-10 membered heteroaryl-C₁₋₄alkyl, OR^(a41), SR^(a41), NHOR^(a41), C(O)R^(b41), C(O)NR^(c41)R^(d41),C(O)NR^(c41)(OR^(a41)), C(O)OR^(a41), OC(O)R^(b41),OC(O)NR^(c41)R^(d41), NR^(c41)R^(d41) NR^(c41)NR^(c41)R^(d41),NR^(c41)C(O)R^(b41), NR^(c41)C(O)OR^(a41), NR^(c41)C(O)NR^(c41)R^(d41),C(═NR^(e41))R^(b41), C(═NR^(e41))NR^(c41)R^(d41),NR^(c41)C(═NR^(e41))NR^(c41)R^(d41), NR^(c41)C(═NR^(e41))R^(b41),NR^(c41)S(O)NR^(c41)R^(d41), NR^(c41)S(O)R^(b41), NR^(c41)S(O)₂R^(b41),NR^(c41)S(O)(═NR^(e41))R^(b41), NR^(c41)S(O)₂NR^(c41)R^(d41),S(O)R^(b41), S(O)NR^(c41)R^(d41), S(O)₂R^(b41), S(O)₂NR^(c41)R^(d41),OS(O)(═NR^(e41))R^(b41), OS(O)₂R^(b41), S(O)(═NR^(e41))R^(b41), SF₅,P(O)R^(f41)R^(g41), OP(O)(OR^(h41))(OR^(i41)), P(O)(OR^(h41))(OR^(i41))and BR^(j41)R^(k41), wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents;

each R^(a41), R^(c41), and R^(d41) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents;

or, any R^(c41) and R^(d41) attached to the same N atom, together withthe N atom to which they are attached, form a 4-10 memberedheterocycloalkyl group, wherein the 4-10 membered heterocycloalkyl groupis optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents;

each R^(b41) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4B) substituents;

each R^(e41) is independently selected from H, OH, CN, C₁₋₆ alkyl, C₁₋₆alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₇ cycloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;

each R^(f41) and R^(g41) are independently selected from H, C₁₋₆ alkyl,C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;

each R^(h41) and R^(i41) is independently selected from H, C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl,C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄alkyl;

each R^(j41) and R^(k41) is independently selected from OH, C₁₋₆ alkoxy,and C₁₋₆ haloalkoxy;

or any R^(j41) and R^(k41) attached to the same B atom, together withthe B atom to which they are attached, form a 5- or 10-memberedheterocycloalkyl group optionally substituted with 1, 2, 3, or 4substituents independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl;

each R^(4B) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl,OR^(a42), SR^(a42), NHOR^(a42), C(O)R^(b42), C(O)NR^(c42)R^(d42),C(O)NR^(c42)(OR^(a42)), C(O)OR^(a42), OC(O)R^(b42),OC(O)NR^(c42)R^(d42), NR^(c42)R^(d42), NR^(c42)NR^(c42)R^(d42),NR^(c42)C(O)R^(b42), NR^(c42)C(O)OR^(a42), NR^(c42)C(O)NR^(c42)R^(d42),C(═NR^(e42))R^(b42), C(═NR^(e42))NR^(c42)R^(d42),NR^(c42)C(═NR^(e42))NR^(c42)R^(d42), NR^(c42)C(═NR^(e42))R^(b42),NR^(c42)S(O)NR^(c42)R^(d42), NR^(c42)S(O)R^(b42), NR^(c42)S(O)₂R^(b42),NR^(c42)S(O)(═NR^(e42))R^(b42), NR^(c42)S(O)₂NR^(c42)R^(d42),S(O)R^(b42), S(O)NR^(c42)R^(d42), S(O)₂R^(b42), S(O)₂NR^(c42)R^(d42),OS(O)(═NR^(e42))R^(b42), OS(O)₂R^(b42), S(O)(═NR^(e42))R^(b42), SF₅,P(O)R^(f42)R^(g42), OP(O)(OR^(h42))(OR^(i42)), P(O)(OR^(h42))(OR^(i42)),and BR^(j42)R^(k42), wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1,2, 3, or 4 independently selected R^(4C) substituents;

each R^(a42), R^(c42), and R^(d42) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4C) substituents;

or, any R^(c42) and R^(d42) attached to the same N atom, together withthe N atom to which they are attached, form a 4-7 memberedheterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl groupis optionally substituted with 1, 2, 3, or 4 independently selectedR^(4C) substituents;

each R^(b42) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(4C) substituents;

each R^(e42) is independently selected from H, OH, CN, C₁₋₆ alkyl, C₁₋₆alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^(f42) and R^(g42) are independently selected from H, C₁₋₆ alkyl,C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄alkyl;

each R^(h42) and R^(i42) is independently selected from H, C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^(j42) and R^(k42) is independently selected from OH, C₁₋₆ alkoxy,and C₁₋₆ haloalkoxy;

or any R^(j42) and R^(k42) attached to the same B atom, together withthe B atom to which they are attached, form a 5- or 6-memberedheterocycloalkyl group optionally substituted with 1, 2, 3, or 4substituents independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl;

each R^(4C) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl,OR^(a43), SR^(a43), NHOR^(a43), C(O)R^(b43), C(O)NR^(c43)R^(d43),C(O)NR^(c43)(OR^(a43)), C(O)OR^(a43), OC(O)R^(b43),OC(O)NR^(c43)R^(d43), NR^(c43)R^(d43) NR^(c43)NR^(c43)R^(d43),NR^(c43)C(O)R^(b43), NR^(c43)C(O)OR^(a43), NR^(c43)C(O)NR^(c43)R^(d43),C(═NR^(e43))R^(b43), C(═NR^(e43))NR^(c43)R^(d43),NR^(c43)C(═NR^(e43))NR^(c43)R^(d43), NR^(c43)C(═NR^(e43))R^(b43),NR^(c43)S(O)NR^(c43)R^(d43), NR^(c43)S(O)R^(b43), NR^(c43)S(O)₂R^(b43),NR^(c43)S(O)(═NR^(e43))R^(b43), NR^(c43)S(O)₂NR^(c43)R^(d43),S(O)R^(b43), S(O)NR^(c43)R^(d43), S(O)₂R^(b43), S(O)₂NR^(c43)R^(d43),OS(O)(═NR^(e43))R^(b43), OS(O)₂R^(b43), S(O)(═NR^(e43))R^(b43), SF₅,P(O)R^(f43)R^(g43), OP(O)(OR^(h43))(OR^(i43)), P(O)(OR^(h43))(OR^(i43)),and BR^(j43)R^(k43), wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1,2, 3, or 4 independently selected R^(G) substituents;

each R^(a43), R^(c43), and R^(d43) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents;

or, any R^(c43) and R^(d43) attached to the same N atom, together withthe N atom to which they are attached, form a 4-7 memberedheterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl groupis optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents;

each R^(b43) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(G) substituents;

each R^(e43) is independently selected from H, OH, CN, C₁₋₆ alkyl, C₁₋₆alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^(f43) and R^(g43) are independently selected from H, C₁₋₆ alkyl,C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄alkyl;

each R^(h43) and R^(i43) is independently selected from H, C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl;

each R^(j43) and R^(k43) is independently selected from OH, C₁₋₆ alkoxy,and C₁₋₆ haloalkoxy;

or any R^(j43) and R^(k43) attached to the same B atom, together withthe B atom to which they are attached, form a 5- or 6-memberedheterocycloalkyl group optionally substituted with 1, 2, 3, or 4substituents independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl;

Z is CR⁵ or N;

R⁵ is independently selected from H, D, halo, CN, OH, NO₂, C₁₋₄ alkyl,C₁₋₄ haloalkyl, C₂-4 alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, C₁₋₄haloalkoxy, amino, C₁₋₄ alkylamino, di(C₁₋₄ alkyl)amino, cyano-C₁₋₄alkyl, HO—C₁₋₄ alkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, C₃₋₄ cycloalkyl, thio,C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, carbamyl, C₁₋₄alkylcarbamyl, di(C₁₋₄ alkyl)carbamyl, carboxy, C₁₋₄ alkylcarbonyl, C₁₋₄alkoxycarbonyl, C₁₋₄ alkylcarbonyloxy, C₁₋₄ alkylcarbonylamino, C₁₋₄alkoxycarbonylamino, C₁₋₄ alkylaminocarbonyloxy, C₁₋₄alkylsulfonylamino, aminosulfonyl, C₁₋₄ alkylaminosulfonyl, di(C₁₋₄alkyl)aminosulfonyl, aminosulfonylamino, C₁₋₄ alkylaminosulfonylamino,di(C₁₋₄ alkyl)aminosulfonylamino, aminocarbonylamino, C₁₋₄alkylaminocarbonylamino, and di(C₁₋₄ alkyl)aminocarbonylamino; and

each R^(G) is independently selected from OH, NO₂, CN, halo, C₁₋₃ alkyl,C₂₋₃ alkenyl, C₂₋₃, alkynyl, C₁₋₃ haloalkyl, cyano-C₁₋₃ alkyl, HO—C₁₋₃alkyl, C₁₋₃ alkoxy-C₁₋₃ alkyl, C₃₋₇ cycloalkyl, C₁₋₃ alkoxy, C₁₋₃haloalkoxy, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino, thio, C₁₋₃alkylthio, C₁₋₃, alkylsulfinyl, C₁₋₃ alkylsulfonyl, carbamyl, C₁₋₃alkylcarbamyl, di(C₁₋₃ alkyl)carbamyl, carboxy, C₁₋₃ alkylcarbonyl, C₁₋₃alkoxycarbonyl, C₁₋₃ alkylcarbonyloxy, C₁₋₃ alkylcarbonylamino, C₁₋₃,alkoxycarbonylamino, C₁₋₃ alkylaminocarbonyloxy, C₁₋₃alkylsulfonylamino, aminosulfonyl, C₁₋₃, alkylaminosulfonyl, di(C₁₋₃alkyl)aminosulfonyl, aminosulfonylamino, C₁₋₃, alkylaminosulfonylamino,di(C₁₋₃ alkyl)aminosulfonylamino, aminocarbonylamino, C₁₋₃,alkylaminocarbonylamino, and di(C₁₋₃ alkyl)aminocarbonylamino.

In some embodiments, Ring moiety A is selected from phenyl and 5-10membered heteroaryl, wherein Ring moiety A is attached to the —NH— inFormula (I) through a carbon atom.

In some embodiments, Ring moiety A is phenyl, pyridin-4-yl, orimidazo[1,2-a]pyridin-6-yl.

In some embodiments, Ring moiety A is phenyl.

In some embodiments, Ring moiety A is pyridin-4-yl.

In some embodiments, Ring moiety A is imidazo[1,2-a]pyridin-6-yl.

In some embodiments, Y is N.

In some embodiments, Y is CR^(1a).

In some embodiments, R^(1a) is selected from halo, CN, C₁₋₄ alkyl, andC₁₋₄ haloalkyl; or R^(1a) and an R² on an adjacent ring member of Ringmoiety A, together with the ring atoms to which they are attached, formRing moiety B, wherein the Ring moiety B is selected from phenyl or 5-6membered heteroaryl, each of which is optionally substituted by 1, 2, 3,or 4 independently selected R³ substituents.

In some embodiments, R^(1a) is selected from halo, CN, C₁₋₄ alkyl, andC₁₋₄ haloalkyl; or R^(1a) and an R² on an adjacent ring member of Ringmoiety A, together with the ring atoms to which they are attached, formRing moiety B, wherein the Ring moiety B is phenyl, which is optionallysubstituted by 1, 2, 3, or 4 independently selected R³ substituents.

In some embodiments, R^(1a) is selected from halo, CN, C₁₋₄ alkyl, andC₁₋₄ haloalkyl.

In some embodiments, R^(1a) is selected from halo and C₁₋₄ alkyl.

In some embodiments, R^(1a) is selected from F and CH₃.

In some embodiments, R^(1a) is F.

In some embodiments, R^(1a) is CH₃.

In some embodiments, Y is CF.

In some embodiments, Y is C(CH₃).

In some embodiments, R^(1a) and an R² on an adjacent ring member of Ringmoiety A, together with the ring atoms to which they are attached, formRing moiety B.

In some embodiments, Ring moiety B is selected from phenyl or 5-6membered heteroaryl, each of which is optionally substituted by 1, 2, 3,or 4 independently selected R³, substituents.

In some embodiments, Ring moiety B is phenyl.

In some embodiments, Y is NR^(1b).

In some embodiments, R^(1b) is C₁₋₄ alkyl.

In some embodiments, each R^(a1), R^(c1), and R^(d1) is independentlyselected from H, C₁₋₆, alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl,4-7 membered heterocycloalkyl, and 5-6 membered heteroaryl, wherein saidC₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, and 5-6 membered heteroaryl are each optionallysubstituted with 1, 2, 3, or 4 independently selected R^(G)substituents.

In some embodiments, each R^(a1), R^(c1), and R^(d1) is independentlyselected from H and C₁₋₆, alkyl, wherein said C₁₋₆ alkyl is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(G)substituents.

In some embodiments, any R^(c1) and R^(d1) attached to the same N atom,together with the N atom to which they are attached, form a 4-7 memberedheterocycloalkyl group, wherein the 4-7 membered heterocycloalkyl groupis optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents.

In some embodiments, each R^(a1), R^(c1), and R^(d1) is independentlyselected from H and C₁₋₆, alkyl.

In some embodiments, each R² and R³ is independently selected from H, D,halo, CN, NO₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl,5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, 5-10membered heteroaryl-C₁₋₄ alkyl, OR^(a2), SR^(a2), C(O)R^(b2),C(O)NR^(c2)R^(d2), C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2),NR^(c2)R^(d2), NR^(c2)C(O)R^(b2), NR^(c2)C(O)OR^(a2),NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)S(O)₂R^(b2), NR^(c2)S(O)₂NR^(c2)R^(d2),S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2), wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 memberedaryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2A) substituents.

In some embodiments, each R² and R³ is independently selected from H, D,halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a2), SR^(a2), C(O)R^(b2),C(O)NR^(c2)R^(d2), C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2),NR^(c2)R^(d2), NR^(c2)C(O)R^(b2), NR^(c2)C(O)OR^(a2),NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)S(O)₂R^(b2), NR^(c2)S(O)₂NR^(c2)R^(d2),S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2), wherein said C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄alkyl are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2A) substituents.

In some embodiments, each R² and R³ is independently selected from H, D,halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₄ cycloalkyl, OR^(a2), SR^(a2),C(O)R^(b2), C(O)NR^(c2)R^(d2), C(O)OR^(a2), OC(O)R^(b2),OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), NR^(c2)C(O)R^(b2),NR^(c2)C(O)OR^(a2), NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)S(O)₂R^(b2),NR^(c2)S(O)₂NR^(c2)R^(d2), S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2), whereinsaid C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₃₋₄ cycloalkyl are each optionallysubstituted with 1, 2, 3, or 4 independently selected R^(2A)substituents.

In some embodiments, each R² and R³ is independently selected from H,halo, CN, C₁₋₆, alkyl, C₁₋₆ haloalkyl, OR^(a2), SR^(a2), NR^(c2)R^(d2),S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2), wherein said C₁₋₆ alkyl and C₁₋₆haloalkyl are each optionally substituted with 1, 2, 3, or 4independently selected R^(2A) substituents.

In some embodiments, each R² and R³ is independently selected from halo,CN, C₁₋₆, alkyl, C₁₋₆ haloalkyl, OR^(a2), SR^(a2), NR^(c2)R^(d2),S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2), wherein said C₁₋₆ alkyl and C₁₋₆haloalkyl are each optionally substituted with 1 or 2 independentlyselected R^(2A) substituents.

In some embodiments, each R² and R³ is independently selected from halo,CN, C₁₋₆, alkyl, C₁₋₆ haloalkyl, OR^(a2), S(O)₂R^(b2), andNR^(c2)R^(d2), wherein said C₁₋₆ alkyl and C₁₋₆ haloalkyl are eachoptionally substituted with 1 or 2 independently selected R^(2A)substituents.

In some embodiments, each R² and R³ is independently selected from C₁₋₆alkyl and S(O)₂R^(b2), wherein said C₁₋₆ alkyl and C₁₋₆ haloalkyl areeach optionally substituted with 1 or 2, independently selected R^(2A)substituents.

In some embodiments, each R² is independently selected from H, halo,C₁₋₆ alkyl, and S(O)₂R^(b2), wherein said C₁₋₆ alkyl is optionallysubstituted with 1 or 2 independently selected R^(2A) substituents.

In some embodiments, each R² is independently selected from H, CH₃,HO—CH₂—, (CH₃)₂N—CH₂—, and CH₃S(O)₂-.

In some embodiments, each R² is H.

In some embodiments, each R² is CH₃.

In some embodiments, each R² is HO—CH₂-.

In some embodiments, each R² is (CH₃)₂N—CH₂-.

In some embodiments, each R² is CH₃S(O)₂-.

In some embodiments, each R^(2A) is independently selected from halo,CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl,4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-10 membered heteroaryl-C₁₋₄ alkyl,OR^(a21), SR^(a21), C(O)R^(b21) C(O)NR^(c21)R^(d21), C(O)OR^(a21),OC(O)R^(b21), OC(O)NR^(c21)R^(d21), NR^(c21)R^(d21),NR^(c21)C(O)R^(b21), NR^(c21)C(O)OR^(a21), NR^(c21)C(O)NR^(c21)R^(d21),NR^(c21)S(O)NR^(c21)R^(d21), NR^(c21)S(O)R^(b21), NR^(c21)S(O)₂R^(b21),NR^(c21)S(O)₂NR^(c21)R^(d21), S(O)₂R^(b21), and S(O)₂NR^(c21)R^(d21),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 memberedaryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2B) substituents.

In some embodiments, each R^(2A) is independently selected from halo,CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a21), SR^(a21), C(O)R^(b21),C(O)NR^(c21)R^(d21), C(O)OR^(a21), OC(O)R^(b21), OC(O)NR^(c21)R^(d21),NR^(c21)R^(d21), NR^(c21)C(O)R^(b21), NR^(c21)C(O)OR^(a21),NR^(c21)C(O)NR^(c21)R^(d21), NR^(c21)S(O)NR^(c21)R^(d21),NR^(c21)S(O)R^(b21), NR^(c21)S(O)₂R^(b21), NR^(c21)S(O)₂NR^(c21)R^(d21),S(O)₂R^(b21), and S(O)₂NR^(c21)R^(d21), wherein said C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄alkyl are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2B) substituents.

In some embodiments, each R^(2A) is independently selected from halo,CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₄ cycloalkyl, OR^(a21), SR^(a21),C(O)R^(b21), C(O)NR^(c21)R^(d21), C(O)OR^(a21), OC(O)R^(b21),OC(O)NR^(c21)R^(d21), NR^(c21)R^(d21), NR^(c21)C(O)R^(b21),NR^(c21)C(O)OR^(a21), NR^(c21)C(O)NR^(c21)R²¹,NR^(c21)S(O)NR^(c21)R^(d21), NR^(c21)S(O)R^(b21), NR^(c21)S(O)₂R^(b21),NR^(c21)S(O)₂NR^(c21)R^(d21), S(O)₂R^(b21), and S(O)₂NR^(c21)R^(d21),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₃₋₄ cycloalkyl are eachoptionally substituted with 1, 2, 3, or 4 independently selected R^(2B)substituents.

In some embodiments, each R^(2A) is independently selected from halo,CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, OR^(a21), SR^(a21), C(O)R^(b21),C(O)NR^(c21)R^(d21), C(O)OR^(a21), OC(O)R^(b21), OC(O)NR^(c21)R^(d21),NR^(c21)R^(d21), NR^(c21)C(O)R^(b21), NR^(c21)C(O)OR^(a21),NR^(c21)C(O)NR^(c21)R^(d21), NR^(c21)S(O)NR^(c21)R^(d21),NR^(c21)S(O)R^(b21), NR^(c21)S(O)₂R^(b21), NR^(c21)S(O)₂NR^(c21)R^(d21),S(O)₂R^(b21), and S(O)₂NR^(c21)R^(d21), wherein said C₁₋₆ alkyl and C₁₋₆haloalkyl are each optionally substituted with 1, 2, 3, or 4independently selected R^(2B) substituents.

In some embodiments, each R^(2A) is independently selected from halo,CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, 4-6 memberedheterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, OR^(a21), NR^(c21)R^(d21) and S(O)₂R^(b21),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, 4-6 memberedheterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, and 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl are each optionally substituted with 1, 2,3, or 4 independently selected R^(2B) substituents.

In some embodiments, each R^(2A) is independently selected from H, halo,CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, OR^(a21), SR^(a21),NHOR^(a21), C(O)R^(b21), C(O)NR^(c21)R^(d21), C(O)OR^(a21),OC(O)R^(b21), OC(O)NR^(c21)R^(d21), NR^(c21)R^(d21),NR^(c21)C(O)R^(b21), NR^(c21)C(O)OR^(a21), NR^(c21)C(O)NR^(c21)R^(d21),NR^(c21)S(O)₂R^(b21), NR^(c21)S(O)₂NR^(c21)R^(d21), S(O)₂R^(b21), andS(O)₂NR^(c21)R^(d21).

In some embodiments, each R^(2A) is independently selected from halo,CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, OR^(a21), and NR^(c21)R^(d21), whereinsaid C₁₋₆ alkyl and C₁₋₆ haloalkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(2B) substituents.

In some embodiments, each R^(2A) is independently selected from OR^(a21)and NR^(c21)R^(d21).

In some embodiments, R^(2A) is —OH.

In some embodiments, R^(2A) is —N(CH₃)₂.

In Some Embodiments:

each R^(a2), R^(c2), and R^(d2) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2A) substituents; and

each R^(b2) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6,membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(2A) substituents.

In Some Embodiments:

each R^(a2), R^(c2), and R^(d2) is independently selected from H, C₁₋₆alkyl, and C₁₋₆ haloalkyl, wherein said C₁₋₆ alkyl and C₁₋₆ haloalkylare each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2A) substituents; and

each R^(b2) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl, which are each optionally substituted with 1, 2, 3, or 4independently selected R^(2A) substituents.

In Some Embodiments:

each R^(a2), R^(c2), and R^(d2) is independently selected from H, C₁₋₆alkyl, and C₁₋₆ haloalkyl; and

each R^(b2) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl.

In Some Embodiments:

each R^(a21), R^(c21), and R^(d21) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2B) substituents;

each R^(b21) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2B) substituents;

each R^(2B) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a22), SR^(a22), C(O)R^(b22),C(O)NR^(c22)R^(d22), C(O)OR^(a22), OC(O)R^(b22), OC(O)NR^(c22)R^(d22),NR^(c22)R^(d22), NR^(e22)C(O)R^(b22), NR^(c22)C(O)OR^(a22),NR^(c22)C(O)NR^(c22)R^(d22), NR^(c22)S(O)₂R^(b22),NR^(c22)S(O)₂NR^(c22)R^(d22), S(O)₂R^(b22), and S(O)₂NR^(c22)R^(d22),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(G) substituents;

each R^(a22), R^(c22), and R^(d22) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents; and

each R^(b22) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(G) substituents.

In Some Embodiments:

each R^(a21), R^(c21), and R^(d21) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2B) substituents;

each R^(b21) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2B) substituents;

each R^(2B) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a22), SR^(a22), C(O)R^(b22),C(O)NR^(c22)R^(d22), C(O)OR^(a22), OC(O)R^(b22), OC(O)NR^(c22)R^(d22),NR^(c22)R^(d22), NR^(c22)C(O)R^(b22), NR^(c22)C(O)OR^(a22),NR^(c22)C(O)NR^(c22)R^(d22) NR²²S(O)₂R^(b22), NR²²S(O)₂NR^(c22)R^(d22),S(O)₂R^(b22), and S(O)₂NR^(c22)R^(d22);

each R^(a22), R^(c22), and R^(d22) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl; and each R^(b22) is independentlyselected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl.

In Some Embodiments:

each R^(a21), R^(c21), and R^(d21) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl, wherein said C₁₋₆ alkyl and C₁₋₆haloalkyl are each optionally substituted with 1, 2, 3, or 4independently selected R^(2B) substituents;

each R^(b21) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2B) substituents;

each R^(2B) is independently selected from H, halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, OR^(a22), SR^(a22), C(O)R^(b22), C(O)NR^(c22)R^(d22),C(O)OR^(a22), OC(O)R^(b22), OC(O)NR^(c22)R^(d22), NR^(c22)R^(d22),NR^(c22)C(O)R^(b22) NR^(c22)C(O)OR^(a22) NR^(e22)C(O)NR^(c22)R^(d22),NR^(c22)S(O)₂R^(b22), NR^(c22)S(O)₂NR^(c22)R^(d22), S(O)₂R^(b22), andS(O)₂NR^(c22)R^(d22);

each R^(a22), R^(c22), and R^(d22) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and

each R^(b22) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl.

In Some Embodiments:

each R^(a21), R^(c21), and R^(d21) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2B) substituents;

each R^(b21) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2B) substituents;

each R^(2B) is independently selected from H, D, halo, CN, C₁₋₆ alkyl,C₁₋₆ haloalkyl, OR^(a22), C(O)R^(b22), C(O)NR^(c22)R^(d22),C(O)OR^(a22), OC(O)R^(b22), NR^(c22)R^(d22), NR^(c22)C(O)R^(b22),S(O)₂R^(b22), and S(O)₂NR^(c22)R^(d22);

each R^(a22), R^(c22), and R^(d22) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and

each R^(b22) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl.

In Some Embodiments:

each R^(a21), R^(c21), and R^(d21) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl; and

each R^(b21) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl.

In Some Embodiments:

each R^(a21), R^(c21), and R^(d21) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and

each R^(b21) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl.

In Some Embodiments:

each R^(a21), R^(c21), and R^(d21) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1 or 2 independently selected R^(2B)substituents;

each R^(b21) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1 or 2 independently selectedR^(2B) substituents;

each R^(2B) is independently selected from H, D, halo, CN, C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₄, cycloalkyl, OR^(a22), NR^(c22)R^(d22), andS(O)₂R^(b22);

each R^(a22), R^(c22), and R^(d22) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and

each R^(b22) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl.

In some embodiments, each R^(a21), R^(c21), and R^(d21) is independentlyselected from H, C₁₋₆, alkyl, and C₁₋₆ haloalkyl, wherein said C₁₋₆alkyl and C₁₋₆ haloalkyl are each optionally substituted with 1 or 2independently selected R^(2B) substituents;

each R^(b21) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl, which are each optionally substituted with 1 or 2independently selected R^(2B) substituents; and

each R^(2B) is independently selected from H, D, halo, CN, C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₄, cycloalkyl, OH, and N(C₁₋₆ alkyl)₂.

In some embodiments, each R^(a21), R^(c21), and R^(d21) is independentlyselected from H, C₁₋₆, alkyl, and C₁₋₆ haloalkyl; and

each R^(b21) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl.

In some embodiments, n is 0, 1, or 2.

In some embodiments, n is 0 or 1.

In some embodiments, n is 0.

In some embodiments, n is 1.

In some embodiments, n is 2.

In some embodiments, R⁴ is independently selected from phenyl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, OR^(a4), andNR^(c4)R^(d4), wherein said phenyl, 4-10 membered heterocycloalkyl, and5-10 membered heteroaryl are each optionally substituted with 1, 2, 3,or 4 independently selected R^(4A) substituents.

In some embodiments, R⁴ is independently selected from 4-10 memberedheterocycloalkyl and OR^(a4), wherein said 4-10 memberedheterocycloalkyl is optionally substituted with 1, 2, 3, or 4independently selected R^(4A) substituents.

In some embodiments, R⁴ is independently selected from phenyl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, and OR^(a4),wherein said phenyl, 4-10 membered heterocycloalkyl, and 5-10 memberedheteroaryl are each optionally substituted with 1, 2, 3, or 4independently selected R^(4A) substituents.

In some embodiments, R⁴ is independently selected from phenyl, 5-10membered heteroaryl, and OR^(a4), wherein said phenyl and 5-10 memberedheteroaryl are each optionally substituted with 1, 2, 3, or 4independently selected R^(4A) substituents.

In some embodiments, R⁴ is selected from isopropoxy, phenyl,pyridin-4-yl, 2-oxy-benzo[d]oxazol-(3H)-7-yl, and 1H-indazol-5-yl,wherein said phenyl, pyridin-4-yl, 2-oxy-benzo[d]oxazol-(3H)-7-yl, and1H-indazol-5-yl are each optionally substituted with 1, 2, 3, or 4independently selected R^(4A) substituents.

In some embodiments, each R^(4A) is independently selected from halo,CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl,4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-10 membered heteroaryl-C₁₋₄ alkyl,OR^(a41), SR^(a41), C(O)R^(b41), C(O)NR^(c41)R^(d41), C(O)OR^(a41),OC(O)R^(b41), OC(O)NR^(c41)R^(d41), NR^(c41)R^(d41) NR^(c41)C(O)R^(b41),NR^(c41)C(O)OR^(a41) NR^(c41)C(O)NR^(c41)R^(d41)NR^(c41)S(O)NR^(c41)R^(d41), NR^(c41)S(O)R^(b41), NR^(c41)S(O)₂R^(b41),NR^(c41)S(O)₂NR^(c41)R^(d41), S(O)₂R^(b41), and S(O)₂NR^(c41)R^(d41),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 memberedaryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents.

In some embodiments, each R^(4A) is independently selected from halo,CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a41), SR^(a41), C(O)R^(b41),C(O)NR^(c41)R^(d41), C(O)OR^(a41), OC(O)R^(b41), OC(O)NR^(c41)R^(d41),NR^(c41)R^(d41), NR^(c41)C(O)R^(b41), NR^(c41)C(O)OR^(a41),NR^(c41)C(O)NR^(c41)R^(d41), NR^(c41)S(O)NR^(c41)R^(d41),NR^(c41)S(O)R⁴¹, NR^(c41)S(O)₂R^(b41), NR^(c41)S(O)₂NR^(c41)R^(d41),S(O)₂R^(c41), and S(O)₂NR^(c41)R^(d41), wherein said C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄alkyl are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4B) substituents.

In some embodiments, each R^(4A) is independently selected from halo,CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, 4-6 memberedheterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, OR^(a41), NR^(c41)R^(d41) and S(O)₂R⁴¹,wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, 4-6 memberedheterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, and 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl are each optionally substituted with 1, 2,3, or 4 independently selected R^(4B) substituents.

In some embodiments, each R^(4A) is independently selected from halo,CN, C₁₋₆ alkyl, and 4-6 membered heterocycloalkyl-C₁₋₄ alkyl, whereinsaid C₁₋₆ alkyl and 4-6 membered heterocycloalkyl-C₁₋₄ alkyl are eachoptionally substituted with 1, 2, 3, or 4 independently selected R^(4B)substituents.

In Some Embodiments:

each R^(a4), R^(c4), and R^(d4) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4A) substituents;

or, any R^(c4) and R^(d4) attached to the same N atom, together with theN atom to which they are attached, form a 4-10 membered heterocycloalkylgroup, wherein the 4-10 membered heterocycloalkyl group is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(4A)substituents.

In Some Embodiments:

each R^(a4), R^(c4), and R^(d4) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, and C₃₋₄ cycloalkyl, wherein said C₁₋₆ alkyl,C₁₋₆ haloalkyl, and C₃₋₄ cycloalkyl are each optionally substituted with1, 2, 3, or 4 independently selected R⁴ substituents;

or, any R^(c4) and R^(d4) attached to the same N atom, together with theN atom to which they are attached, form a 4-7 membered heterocycloalkylgroup, wherein the 4-7 membered heterocycloalkyl group is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(4A)substituents.

In some embodiments, each R^(a4), R^(c4), and R^(d4) is independentlyselected from H, C₁₋₆, alkyl, and C₁₋₆ haloalkyl.

In Some Embodiments:

each R^(a41), R^(c41), and R^(d41) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents;

each R^(b41) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4B) substituents;

each R^(4B) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl,OR^(a42), SR^(a42), C(O)R^(b42), C(O)NR^(c42)R^(d42), C(O)OR^(a42),OC(O)R^(b42), OC(O)NR^(c42)R^(d42), NR^(c42)R^(d42),NR^(c42)C(O)R^(b42), NR^(c42)C(O)OR^(a42), NR^(c42)C(O)NR^(c42)R^(d42),NR^(c42)S(O)₂R^(b42), NR^(c42)S(O)₂NR^(c42)R^(d42), S(O)₂R^(b42), andS(O)₂NR^(c42)R^(d42), wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1,2, 3, or 4 independently selected R^(4C) substituents;

each R^(a42), R^(c42), and R^(d42) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4C) substituents;

each R^(b42) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(4C) substituents;

each R^(4C) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl,OR^(a43), SR^(a43), C(O)R^(b43), C(O)NR^(c43)R^(d43), C(O)OR^(a43),OC(O)R^(b43), OC(O)NR^(c43)R^(d43), NR^(c43)R^(d43) NR^(c43)C(O)R^(b43)NR^(c43)C(O)OR^(a43), NR^(c43)C(O)NR^(c43)R^(d43), NR^(c43)S(O)₂R^(b43),NR^(c43)S(O)(═NR^(e43))R^(b43), NR^(c43)S(O)₂NR^(c43)R^(d43),S(O)₂R^(b43), and S(O)₂NR^(c43)R^(d43), wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(G) substituents;

each R^(a43), R^(c43), and R^(d43) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents; and

each R^(b43) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(G) substituents.

In Some Embodiments:

each R^(a41), R^(c41), and R^(d41) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 memberedaryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents;

each R^(b41) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl,5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(4B) substituents;

each R^(4B) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a42), SR^(a42), C(O)R^(b42),C(O)NR^(c42)R^(d42), C(O)OR^(a42), OC(O)R^(b42), OC(O)NR^(c42)R^(d42),NR^(c42)R^(d42), NR^(c42)C(O)R^(b42), NR^(c42)C(O)OR^(a42),NR^(c42)C(O)NR^(c42)R^(d42), NR^(c42)S(O)₂R^(b42),NR^(c42)S(O)₂NR^(c42)R^(d42), S(O)₂R^(b42), and S(O)₂NR^(c42)R^(d42),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(4C) substituents;

each R^(a42), R^(c42), and R^(d42) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4C) substituents;

each R^(b42) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4C) substituents;

each R^(4C) is independently selected from H, D, halo, CN, C₁₋₆ alkyl,C₁₋₆ haloalkyl, and C₃₋₄ cycloalkyl, OR^(a43), NR^(c43)R^(d43), andS(O)₂R⁴³;

each R^(a43), R^(c43), and R^(d43) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and

each R^(b43) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl.

In Some Embodiments:

each R^(a41), R^(c41), and R^(d41) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents;

each R^(b41) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4B) substituents;

each R^(4B) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a42), SR^(a42), C(O)R^(b42),C(O)NR^(c42)R^(d42), C(O)OR^(a42), OC(O)R^(b42), OC(O)NR^(c42)R^(d42),NR^(c42)R^(d42), NR^(c42)C(O)R^(b42), NR^(c42)C(O)OR^(a42),NR^(c42)C(O)NR^(c42)R^(d42), NR^(c42)S(O)₂R^(b42),NR^(c42)S(O)₂NR^(c42)R^(d42), S(O)₂R^(b42), and S(O)₂NR^(c42)R^(d42),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(4C) substituents;

each R^(a42), R^(c42), and R^(d42) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4C) substituents;

each R^(b42) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4C) substituents;

each R^(4C) is independently selected from H, D, halo, CN, C₁₋₆ alkyl,C₁₋₆ haloalkyl, and C₃₋₄ cycloalkyl, OR^(a43), NR^(c43)R^(d43), andS(O)₂R^(b43);

each R^(a43), R^(c43), and R^(d43) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and

each R^(b43) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl.

In Some Embodiments:

each R^(a41), R^(c41), and R^(d41) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents;

each R^(b41) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4B) substituents;

each R^(4B) is independently selected from H, D, halo, CN, C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₄, cycloalkyl, OR^(a42), NR^(c42)R^(d42), andS(O)₂R^(b42);

each R^(a42), R^(c42), and R^(d42) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and

each R^(b42) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl.

In some embodiments, each R^(4A) is independently selected from F, CN,CH₃, HO—CH₂—, and pyrrolidinyl-CH₂-.

In some embodiments, Z is CR⁵.

In some embodiments, R⁵ is selected from H, halo, CN, C₁₋₄ alkyl, C₁₋₄haloalkyl, OH, C₁-3 alkoxy, C₁₋₃ haloalkoxy, amino, C₁₋₃ alkylamino,di(C₁₋₃ alkyl)amino, cyano-C₁₋₄ alkyl, HO—C₁₋₄ alkyl, C₁₋₃ alkoxy-C₁₋₄alkyl, and C₃₋₄ cycloalkyl.

In some embodiments, R⁵ is selected from H, halo, CN, C₁₋₃ alkyl, andC₁₋₃ haloalkyl.

In some embodiments, R⁵ is H or halo.

In some embodiments, R⁵ is H or F.

In some embodiments, R⁵ is H.

In some embodiments, Z is CH.

In some embodiments, Z is N.

In Some Embodiments:

is a double bond;

n is 0, 1, 2, 3, or 4;

Ring moiety A is selected from phenyl and 5-10 membered heteroaryl,wherein Ring moiety A is attached to the —NH— in Formula (I) through acarbon atom;

Y is CR^(1a);

R^(1a) is selected from halo, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₃₋₆cycloalkyl, 4-6 membered heterocycloalkyl, OR^(a1), SR^(a1), SF₅,NR^(c1)R^(d1), C₃₋₆ cycloalkyl-C₁₋₃ alkyl, and 4-6 memberedheterocycloalkyl-C₁₋₃ alkyl, wherein said C₁₋₄ alkyl, C₁₋₄ haloalkyl,C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₃alkyl, and 4-6 membered heterocycloalkyl-C₁₋₃, alkyl are optionallysubstituted by 1, 2, 3, or 4 independently selected R^(G) substituents;

or, alternatively, R^(1a) and an R² on an adjacent ring member of Ringmoiety A, together with the ring atoms to which they are attached, formRing moiety B;

Ring moiety B is selected from C₃₋₆ cycloalkyl, 4-6 memberedheterocycloalkyl, phenyl, and 5-6 membered heteroaryl, each of which isoptionally substituted by 1, 2, 3, or 4 independently selected R³substituents;

each R^(a1), R^(c1), and R^(d1) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents;

each R² and R³ is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl,6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 memberedheteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl,4-10 membered heterocycloalkyl-C₁₋₄ alkyl, 5-10 membered heteroaryl-C₁₋₄alkyl, OR^(a2), SR^(a2), NHOR^(a2), C(O)R^(b2), C(O)NR^(c2)R^(d2),C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2),NR^(c2)C(O)R^(b2), NR^(c2)C(O)OR^(a2), NR^(c2)C(O)NR^(c2)R^(d2),S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2), wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 memberedaryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2A) substituents;

each R^(a2), R^(c2), and R^(d2) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2A) substituents;

each R^(b2) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(2A) substituents;

each R^(2A) is independently selected from H, halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₁₀ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkylphenyl-C₁₋₄ alkyl, 4-7membered heterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄alkyl, OR^(a21), SR^(a21), NHOR^(a21), C(O)R^(b21), C(O)NR^(c21)R^(d21),C(O)OR^(a21), OC(O)R^(b21), OC(O)NR^(c21)R^(d21), NR^(c21)R^(d21),NR^(c21)C(O)R^(b21), NR^(c21)C(O)OR^(a21), NR^(c21)C(O)NR²¹R²¹,NR^(c21)S(O)₂R^(b21), NR^(c21)S(O)₂NR^(c21)R^(d21), S(O)₂R^(b21), andS(O)₂NR^(c21)R^(d21), wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2B) substituents;

each R^(a21), R^(c21), and R^(d21) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2B) substituents;

each R^(b21) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2B) substituents;

each R^(2B) is independently selected from H, halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₇ cycloalkyl, OR^(a22), SR^(a22), NHOR^(a22), C(O)R^(b22),C(O)NR^(c22)R^(d22), C(O)OR^(a22), OC(O)R^(b22), OC(O)NR^(c22)R^(d22),NR^(c22)R^(d22), NR^(c22)C(O)R^(b22), NR^(c22)C(O)OR^(a22),NR^(c22)C(O)NR^(c22)R^(d22), NR^(c22)S(O)₂R^(b22),NR^(c22)S(O)₂NR^(c22)R^(d22), S(O)R^(b22), and S(O)NR^(c22)R^(d22);

each R^(a22), R^(c22), and R^(d22) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl; each R^(b22) is independently selectedfrom C₁₋₆ alkyl and C₁₋₆ haloalkyl;

n is 0, 1, or 2;

R⁴ is selected from 6-10 membered aryl, 4-10 membered heterocycloalkyl,5-10 membered heteroaryl, OR^(a4), and NR^(c4)R^(d4), wherein said 6-10membered aryl, 4-10 membered heterocycloalkyl, and 5-10 memberedheteroaryl are each optionally substituted with 1, 2, 3, or 4independently selected R^(4A) substituents;

each R^(a4), R^(c4), and R^(d4) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl,6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 memberedheteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl,4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 memberedheteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4A) substituents;

or, any R^(c4) and R^(d4) attached to the same N atom, together with theN atom to which they are attached, form a 4-10 membered heterocycloalkylgroup, wherein the 4-10 membered heterocycloalkyl group is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(4A)substituents;

each R^(4A) is independently selected from halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, 5-10 membered heteroaryl-C₁₋₄ alkyl, OR^(a41), SR^(a41),C(O)R^(b41), C(O)NR^(c41)R^(d41), C(O)OR^(a41), OC(O)R^(b41),OC(O)NR^(c41)R^(d41), NR^(c41)R^(d41), NR^(c41)C(O)R^(b41),NR^(c41)C(O)OR^(a41), NR^(c41)C(O)NR^(c41)R^(d41),NR^(c41)S(O)NR^(c41)R^(d41), NR^(c41)S(O)R^(b41), NR^(c41)S(O)₂R^(b41),NR^(c41)S(O)₂NR^(c41)R^(d41), S(O)₂R^(b41), and S(O)₂NR^(c41)R^(d41),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 memberedaryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents;

each R^(a41), R^(c41), and R^(d41) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents;

each R^(b41) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4B) substituents;

each R^(4B) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl,OR^(a42), SR^(a42), C(O)R^(b42), C(O)NR^(c42)R^(d42), C(O)OR^(a42),OC(O)R^(b42), OC(O)NR^(c42)R^(d42), NR^(c42)R^(d42),NR^(c42)C(O)R^(b42), NR^(c42)C(O)OR^(a42), NR^(c42)C(O)NR^(c42)R^(d42),NR^(c42)S(O)₂R^(b42), NR^(c42)S(O)₂NR^(c42)R^(d42), S(O)₂R^(b42), andS(O)₂NR^(c42)R^(d42), wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1,2, 3, or 4 independently selected R^(4C) substituents;

each R^(a42), R^(c42), and R^(d42) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4C) substituents;

each R^(b42) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(4C) substituents;

each R^(4C) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl,OR^(a43), SR^(a43), C(O)R^(b43), C(O)NR^(c43)R^(d43), C(O)OR^(a43),OC(O)R^(b43), OC(O)NR^(c43)R^(d43), NR^(c43)R^(d43) NR^(c43)C(O)R^(b43)NR^(c43)C(O)OR^(a43), NR^(c43)C(O)NR^(c43)R^(d43) NR^(c43)S(O)₂R⁴³,NR^(c43)S(O)(═NR^(e43))R^(b43), NR^(c43)S(O)₂NR^(c43)R^(d43), S(O)₂R⁴³,and S(O)₂NR^(c43)R^(d43), wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1,2, 3, or 4 independently selected R^(G) substituents;

each R^(a43), R^(c43), and R^(d43) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents;

each R^(b43) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(G) substituents;

Z is CR⁵ or N;

R⁵ is independently selected from H, D, halo, CN, OH, NO₂, C₁₋₄ alkyl,C₁₋₄ haloalkyl, C₂-4 alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, C₁₋₄haloalkoxy, amino, C₁₋₄ alkylamino, di(C₁₋₄ alkyl)amino, cyano-C₁₋₄alkyl, HO—C₁₋₄ alkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, C₃₋₄ cycloalkyl, thio,C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, carbamyl, C₁₋₄alkylcarbamyl, di(C₁₋₄ alkyl)carbamyl, carboxy, C₁₋₄ alkylcarbonyl, C₁₋₄alkoxycarbonyl, C₁₋₄ alkylcarbonyloxy, C₁₋₄ alkylcarbonylamino, C₁₋₄alkoxycarbonylamino, C₁₋₄ alkylaminocarbonyloxy, C₁₋₄alkylsulfonylamino, aminosulfonyl, C₁₋₄ alkylaminosulfonyl, di(C₁₋₄alkyl)aminosulfonyl, aminosulfonylamino, C₁₋₄ alkylaminosulfonylamino,di(C₁₋₄ alkyl)aminosulfonylamino, aminocarbonylamino, C₁₋₄alkylaminocarbonylamino, and di(C₁₋₄ alkyl)aminocarbonylamino; and

each R^(G) is independently selected from OH, NO₂, CN, halo, C₁₋₃ alkyl,C₂₋₃ alkenyl, C₂₋₃, alkynyl, C₁₋₃ haloalkyl, cyano-C₁₋₃ alkyl, HO—C₁₋₃alkyl, C₁₋₃ alkoxy-C₁₋₃ alkyl, C₃₋₇ cycloalkyl, C₁₋₃ alkoxy, C₁₋₃haloalkoxy, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino, thio, C₁₋₃alkylthio, C₁₋₃, alkylsulfinyl, C₁₋₃ alkylsulfonyl, carbamyl, C₁₋₃alkylcarbamyl, di(C₁₋₃ alkyl)carbamyl, carboxy, C₁₋₃ alkylcarbonyl, C₁₋₃alkoxycarbonyl, C₁₋₃ alkylcarbonyloxy, C₁₋₃ alkylcarbonylamino, C₁₋₃,alkoxycarbonylamino, C₁₋₃ alkylaminocarbonyloxy, C₁₋₃alkylsulfonylamino, aminosulfonyl, C₁₋₃, alkylaminosulfonyl, di(C₁₋₃alkyl)aminosulfonyl, aminosulfonylamino, C₁₋₃, alkylaminosulfonylamino,di(C₁₋₃ alkyl)aminosulfonylamino, aminocarbonylamino, C₁₋₃,alkylaminocarbonylamino, and di(C₁₋₃ alkyl)aminocarbonylamino.

In Some Embodiments:

is a double bond;

n is 0, 1, 2, 3, or 4;

Ring moiety A is selected from phenyl and 5-10 membered heteroaryl,wherein Ring moiety A is attached to the —NH— in Formula (I) through acarbon atom;

Y is CR^(1a);

R^(1a) is selected from halo, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₃₋₆cycloalkyl, 4-6 membered heterocycloalkyl, OR^(a1), and NR^(c1)R^(d1),wherein said C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, and 4-6membered heterocycloalkyl are optionally substituted by 1, 2, 3, or 4independently selected R^(G) substituents;

or, alternatively, R^(1a) and an R² on an adjacent ring member of Ringmoiety A, together with the ring atoms to which they are attached, formRing moiety B;

Ring moiety B is selected from phenyl or 5-6 membered heteroaryl, eachof which is optionally substituted by 1, 2, 3, or 4 independentlyselected R³ substituents;

each R^(a1), R^(c1), and R^(d1) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, and 5-6 membered heteroaryl, wherein said C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl,and 5-6 membered heteroaryl are each optionally substituted with 1, 2,3, or 4 independently selected R^(G) substituents;

each R² and R³ is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl,6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 memberedheteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl,4-10 membered heterocycloalkyl-C₁₋₄ alkyl, 5-10 membered heteroaryl-C₁₋₄alkyl, OR^(a2), SR^(a2), NHOR^(a2), C(O)R^(b2), C(O)NR^(c2)R^(d2),C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2),NR^(c2)C(O)R^(b2), NR^(c2)C(O)OR^(a2), NR^(c2)C(O)NR^(c2)R^(d2),S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2), wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 memberedaryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2A) substituents;

each R^(a2), R^(c2), and R^(d2) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2A) substituents;

each R^(b2) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2A) substituents;

each R^(2A) is independently selected from H, halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₇ cycloalkyl, OR^(a21), SR^(a21), NHOR^(a21), C(O)R^(b21),C(O)NR^(c21)R^(d21), C(O)OR^(a21), OC(O)R^(b21), OC(O)NR^(c21)R^(d21),NR^(c21)R^(d21), NR^(c21)C(O)R^(b21), NR^(c21)C(O)OR^(a21),NR^(c21)C(O)NR^(c21)R^(d21), NR^(c21)S(O)₂R^(b21),NR^(c21)S(O)₂NR^(c21)R^(d21), S(O)₂R^(b21), and S(O)₂NR^(c21)R^(d21);

each R^(a21), R^(c21), and R^(d21) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

each R^(b21) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl;

n is 0, 1, or 2;

R⁴ is independently selected from phenyl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, OR^(a4), and NR^(c4)R^(d4),wherein said phenyl, 4-10 membered heterocycloalkyl, and 5-10 memberedheteroaryl are each optionally substituted with 1, 2, 3, or 4independently selected R^(4A) substituents;

each R^(a4), R^(c4), and R^(d4) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl,6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10 memberedheteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl,4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 memberedheteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4A) substituents;

or, any R^(c4) and R^(d4) attached to the same N atom, together with theN atom to which they are attached, form a 4-10 membered heterocycloalkylgroup, wherein the 4-10 membered heterocycloalkyl group is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(4A)substituents;

each R^(4A) is independently selected from halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6membered heterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄alkyl, OR^(a41), SR^(a41), C(O)R^(b41), C(O)NR^(c41)R^(d41),C(O)OR^(a41), OC(O)R^(b41), OC(O)NR^(c41)R^(d41), NR^(c41)R^(d41),NR^(c41)C(O)R^(b41), NR^(c41)C(O)OR^(a41), NR^(c41)C(O)NR^(c41)R^(d41),NR^(c41)S(O)NR^(c41)R^(d41), NR^(c41)S(O)R^(b41), NR^(c41)S(O)₂R^(b41),NR^(c41)S(O)₂NR^(c41)R^(d41), S(O)₂R^(b41), and S(O)₂NR^(c41)R^(d41),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(4B) substituents;

each R^(a41), R^(c41), and R^(d41) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 memberedaryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents;

each R^(b41) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl,5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(4B) substituents;

each R^(4B) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a42), SR^(a42), C(O)R^(b42),C(O)NR^(c42)R^(d42), C(O)OR^(a42), OC(O)R^(b42), OC(O)NR^(c42)R^(d42),NR^(c42)R^(d42), NR^(c42)C(O)R^(b42), NR^(c42)C(O)OR^(a42),NR^(c42)C(O)NR^(c42)R^(d42), NR^(c42)S(O)₂R^(b42),NR^(c42)S(O)₂NR^(c42)R^(d42), S(O)₂R^(b42), and S(O)₂NR^(c42)R^(d42),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(4C) substituents;

each R^(a42), R^(c42), and R^(d42) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4C) substituents;

each R^(b42) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4C) substituents;

each R^(4C) is independently selected from H, D, halo, CN, C₁₋₆ alkyl,C₁₋₆ haloalkyl, and C₃₋₄ cycloalkyl, OR^(a43), NR^(c43)R^(d43) andS(O)₂R⁴³;

each R^(a43), R^(c43), and R^(d43) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

each R^(b43) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl;

Z is CR⁵ or N;

R⁵ is selected from H, halo, CN, C₁₋₃ alkyl, and C₁₋₃ haloalkyl; and

each R^(G) is independently selected from OH, NO₂, CN, halo, C₁₋₃ alkyl,C₂₋₃ alkenyl, C₂₋₃, alkynyl, C₁₋₃ haloalkyl, cyano-C₁₋₃ alkyl, HO—C₁₋₃alkyl, C₁₋₃ alkoxy-C₁₋₃ alkyl, C₃₋₇ cycloalkyl, C₁₋₃ alkoxy, C₁₋₃haloalkoxy, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino, thio, C₁₋₃alkylthio, C₁₋₃, alkylsulfinyl, C₁₋₃ alkylsulfonyl, carbamyl, C₁₋₃alkylcarbamyl, di(C₁₋₃ alkyl)carbamyl, carboxy, C₁₋₃ alkylcarbonyl, C₁₋₃alkoxycarbonyl, C₁₋₃ alkylcarbonyloxy, C₁₋₃ alkylcarbonylamino, C₁₋₃,alkoxycarbonylamino, C₁₋₃ alkylaminocarbonyloxy, C₁₋₃alkylsulfonylamino, aminosulfonyl, C₁₋₃, alkylaminosulfonyl, di(C₁₋₃alkyl)aminosulfonyl, aminosulfonylamino, C₁₋₃, alkylaminosulfonylamino,di(C₁₋₃ alkyl)aminosulfonylamino, aminocarbonylamino, C₁₋₃,alkylaminocarbonylamino, and di(C₁₋₃ alkyl)aminocarbonylamino.

In Some Embodiments:

is a double bond;

n is 0, 1, 2, 3, or 4;

Ring moiety A is selected from phenyl and 5-10 membered heteroaryl,wherein Ring moiety A is attached to the —NH— in Formula (I) through acarbon atom;

Y is CR^(1a);

R^(1a) is selected from halo, CN, C₁₋₄ alkyl, and C₁₋₄ haloalkyl;

or, alternatively, R^(1a) and an R² on an adjacent ring member of Ringmoiety A, together with the ring atoms to which they are attached, formRing moiety B;

Ring moiety B is selected from phenyl or 5-6 membered heteroaryl;

each R^(a1), R^(c1), and R^(d1) is independently selected from H andC₁₋₆ alkyl, wherein said C₁₋₆, alkyl is optionally substituted with 1,2, 3, or 4 independently selected R^(G) substituents;

each R² and R³ is independently selected from halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, OR^(a2), SR^(a2), NR^(c2)R^(d2), S(O)₂R^(b2), andS(O)₂NR^(c2)R^(d2), wherein said C₁₋₆ alkyl and C₁₋₆ haloalkyl are eachoptionally substituted with 1 or 2 independently selected R^(2A)substituents;

each R^(a2), R², and R^(d2) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, and 5-6 membered heteroaryl, wherein said C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl,and 5-6 membered heteroaryl are each optionally substituted with 1, 2,3, or 4 independently selected R^(2A) substituents;

each R^(b2) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, and 5-6 memberedheteroaryl, which are each optionally substituted with 1, 2, 3, or 4independently selected R^(2A) substituents;

each R^(2A) is independently selected from H, halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₇ cycloalkyl, OR^(a21), and NR^(c21)R^(d21);

each R^(a21), R^(c21), and R^(d21) is independently selected from H andC₁₋₆ alkyl;

each R^(b21) is independently C₁₋₆ alkyl;

n is 0, 1, or 2;

R⁴ is independently selected from phenyl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, and OR^(a4), wherein saidphenyl, 4-10 membered heterocycloalkyl, and 5-10 membered heteroaryl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4A) substituents;

each R^(4A) is independently selected from halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, C₃₋₆cycloalkyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl,OR^(a41), NR^(c4)R^(d41), and S(O)₂R^(b41), wherein said C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, C₃₋₆cycloalkyl-C₁₋₄ alkyl, and 4-6 membered heterocycloalkyl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents;

each R^(a41), R^(c41), and R^(d41) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents;

each R^(b41) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4B) substituents;

each R^(4B) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a42), SR^(a42), C(O)R^(b42),C(O)NR^(c42)R^(d42), C(O)OR^(a42), OC(O)R^(b42), OC(O)NR^(c42)R^(d42),NR^(c42)R^(d42), NR^(c42)C(O)R^(b42), NR^(c42)C(O)OR^(a42),NR^(c42)C(O)NR^(c42)R^(d42), NR^(c42)S(O)₂R^(b42),NR^(c42)S(O)₂NR^(c42)R^(d42), S(O)₂R^(b42), and S(O)₂NR^(c42)R^(d42),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(4C) substituents;

each R^(a42), R^(c42), and R^(d42) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4C) substituents;

each R^(b42) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4C) substituents;

each R^(4C) is independently selected from H, D, halo, CN, C₁₋₆ alkyl,C₁₋₆ haloalkyl, and C₃₋₄ cycloalkyl, OR^(a43), NR^(c43)R^(d43), andS(O)₂R^(b43);

each R^(a43), R^(c43), and R^(d43) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

each R^(b43) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl;

Z is CR⁵ or N; and

R⁵ is selected from H, halo, CN, C₁₋₃ alkyl, and C₁₋₃ haloalkyl.

In Some Embodiments:

is a double bond;

0, 1, 2, 3, or 4;

Ring moiety A is phenyl, pyridin-4-yl, or imidazo[1,2-a]pyridin-6-yl;

Y is CR^(1a);

R^(1a) is selected from halo and C₁₋₄ alkyl;

or, alternatively, R^(1a) and an R² on an adjacent ring member of Ringmoiety A, together with the ring atoms to which they are attached, formRing moiety B;

Ring moiety B is selected from phenyl or 5-6 membered heteroaryl;

each R² and R³ is independently selected from halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, OR^(a2), S(O)₂R^(b2), and NR^(c2)R^(d2), wherein said C₁₋₆alkyl and C₁₋₆ haloalkyl are each optionally substituted with 1 or 2independently selected R^(2A) substituents;

each R^(a2), R^(c2), and R^(d2) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, and 5-6 membered heteroaryl, wherein said C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl,and 5-6 membered heteroaryl are each optionally substituted with 1, 2,3, or 4 independently selected R^(2A) substituents;

each R^(b2) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, and 5-6 memberedheteroaryl, which are each optionally substituted with 1, 2, 3, or 4independently selected R^(2A) substituents;

each R^(2A) is independently selected from H, halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₇ cycloalkyl, OR^(a21), and NR^(c21)R^(d21).

each R^(a21), R^(c21), and R^(d21) is independently selected from H andC₁₋₆ alkyl;

each R^(b21) is independently C₁₋₆ alkyl;

n is 0, 1, or 2;

R⁴ is independently selected from phenyl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, and OR^(a4), wherein saidphenyl, 4-10 membered heterocycloalkyl, and 5-10 membered heteroaryl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4A) substituents;

each R^(4A) is independently selected from halo, CN, C₁₋₆ alkyl, and 4-6membered heterocycloalkyl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl and 4-6membered heterocycloalkyl-C₁₋₄ alkyl are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(4B) substituents;

each R^(a41), R^(c41), and R^(d41) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents;

each R^(b41) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4B) substituents;

each R^(4B) is independently selected from H, D, halo, CN, C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₄, cycloalkyl, OR^(a42), NR^(c42)R^(d42), andS(O)₂R^(b42);

each R^(a42), R^(c42), and R^(d42) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

each R^(b42) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl;

Z is CR⁵ or N; and

R⁵ is selected from H, halo, CN, C₁₋₃ alkyl, and C₁₋₃ haloalkyl.

In Some Embodiments:

Ring moiety A is phenyl, pyridin-4-yl, or imidazo[1,2-a]pyridin-6-yl;

Y is CR^(1a);

R^(1a) is selected from F and CH₃;

or, alternatively, R^(1a) and an R² on an adjacent ring member of Ringmoiety A, together with the ring atoms to which they are attached, formRing moiety B;

Ring moiety B is phenyl;

each R² and R³ is independently selected from H, F, CH₃, HO—CH₂—,(CH₃)₂N—CH₂—, or CH₃S(O)₂-;

n is 0, 1, or 2;

R⁴ is selected from isopropoxy, phenyl, pyridin-4-yl,2-oxy-benzo[d]oxazol-(3H)-7-yl, and 1H-indazol-5-yl, wherein saidphenyl, pyridin-4-yl, 2-oxy-benzo[d]oxazol-(3H)-7-yl, and1H-indazol-5-yl are each optionally substituted with 1, 2, 3, or 4independently selected R^(4A) substituents; and

Z is CH or N.

In Some Embodiments:

is a double bond;

n is 0, 1, 2, 3, or 4;

Y is CR^(1a), wherein Y is adjacent to the carbon ring member attachingRing moiety A to the —NH— in Formula (I);

Ring moiety A is selected from phenyl and 5-10 membered heteroaryl,wherein Ring moiety A is attached to the —NH— in Formula (I) through acarbon atom;

R^(1a) is selected from halo, CN, C₁₋₄ alkyl, and C₁₋₄ haloalkyl;

or R^(1a) and an R² on an adjacent ring member of Ring moiety A,together with the ring atoms to which they are attached, form Ringmoiety B;

Ring moiety B is selected from phenyl or 5-6 membered heteroaryl, eachof which is optionally substituted by 1, 2, 3, or 4 independentlyselected R³ substituents;

each R² and R³ is independently selected from H, D, halo, CN, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a2), SR^(a2), C(O)R^(b2),C(O)NR^(c2)R^(d2), C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2),NR^(c2)R^(d2), NR^(c2)C(O)R^(b2), NR^(c2)C(O)OR^(a2),NR^(c2)C(O)NR^(c2)R^(d2), NR²S(O)₂R^(b2), NR^(c2)S(O)₂NR^(c2)R^(d2),S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2), wherein said C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄alkyl are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2A) substituents;

each R^(a2), R^(c2), and R^(d2) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2A) substituents;

each R^(b2) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(2A) substituents;

each R^(2A) is independently selected from halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7membered heterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄alkyl, OR^(a21), SR^(a21), C(O)R^(b21), C(O)NR^(c21)R^(d21),C(O)OR^(a21), OC(O)R^(b21), OC(O)NR²¹R²¹, NR^(c21)R^(d21),NR^(c21)C(O)R^(b21), NR^(c21)C(O)OR^(a21), NR^(c21)C(O)NR^(c21)R^(d21),NR^(c21)S(O)NR^(c21)R^(d21), NR^(c21)S(O)R^(b21), NR^(c21)S(O)₂R^(b21),NR^(c21)S(O)₂NR^(c21)R^(d21), S(O)₂R^(b21), and S(O)₂NR^(c21)R^(d21),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(2B) substituents;

each R^(a21), R^(c21), and R^(d21) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2B) substituents;

each R^(b21) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2B) substituents;

each R^(2B) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a22), SR^(a22), C(O)R^(b22),C(O)NR^(c22)R^(d22), C(O)OR^(a22), OC(O)R^(b22), OC(O)NR^(c22)R^(d22),NR^(c22)R^(d22) NR^(c22)C(O)R^(b22) NR^(c22)C(O)OR^(a22),NR^(c22)C(O)NR^(c22)R^(d22) NR^(e22)S(O)₂R^(b22),NR^(c22)S(O)₂NR^(c22)R^(d22), S(O)₂R^(b22), and S(O)₂NR^(c22)R^(d22),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(G) substituents;

each R^(a22), R^(c22), and R^(d22) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents;

each R^(b22) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(G) substituents;

R⁴ is independently selected from phenyl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, OR^(a4), and NR^(c4)R^(d4),wherein said phenyl, 4-10 membered heterocycloalkyl, and 5-10 memberedheteroaryl are each optionally substituted with 1, 2, 3, or 4independently selected R^(4A) substituents;

each R^(a4), R^(c4), and R^(d4) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4A) substituents;

or, any R^(c4) and R^(d4) attached to the same N atom, together with theN atom to which they are attached, form a 4-10 membered heterocycloalkylgroup, wherein the 4-10 membered heterocycloalkyl group is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(4A)substituents;

each R^(4A) is independently selected from halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6membered heterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄alkyl, OR^(a41), SR^(a41), C(O)R^(b41), C(O)NR^(c41)R^(d41),C(O)OR^(a41), OC(O)R^(b41), OC(O)NR^(c41)R^(d41), NR^(c41)R^(d41),NR^(c41)C(O)R^(b41), NR^(c41)C(O)OR^(a41) NR^(c41)C(O)NR^(c41)R^(d41),NR^(c41)S(O)NR^(c41)R^(d41), NR^(c41)S(O)R^(b41), NR^(c41)S(O)₂R^(b41),NR^(c41)S(O)₂NR^(c41)R^(d41), S(O)₂R^(b41), and S(O)₂NR^(c41)R^(d41),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(4B) substituents;

each R^(a41), R^(c41), and R^(d41) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents;

each R^(b41) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4B) substituents;

each R^(4B) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl,OR^(a42), SR^(a42), C(O)R^(b42), C(O)NR^(c42)R^(d42), C(O)OR^(a42),OC(O)R^(b42), OC(O)NR^(c42)R^(d42), NR^(c42)R^(d42),NR^(c42)C(O)R^(b42), NR^(c42)C(O)OR^(a42), NR^(c42)C(O)NR^(c42)R^(d42),NR^(c42)S(O)₂R^(b42), NR^(c42)S(O)₂NR^(c42)R^(d42), S(O)₂R^(b42), andS(O)₂NR^(c42)R^(d42), wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1,2, 3, or 4 independently selected R^(4C) substituents;

each R^(a42), R^(c42), and R^(d42) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4C) substituents;

each R^(b42) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(4C) substituents;

each R^(4C) is independently selected from H, D, halo, CN, NO₂, C₁₋₆alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl,OR^(a43), SR^(a43), C(O)R^(b43), C(O)NR^(c43)R^(d43), C(O)OR^(a43),OC(O)R^(b43), OC(O)NR^(c43)R^(d43), NR^(c43)R^(d43), NR^(c43)C(O)R^(b43)NR^(c43)C(O)OR^(a43), NR^(c43)C(O)NR^(c43)R^(d43), NR^(c43)S(O)₂R^(b43),NR^(c43)S(O)(═NR^(e43))R^(b43), NR^(c43)S(O)₂NR^(c43)R^(d43),S(O)₂R^(b43), and S(O)₂NR^(c43)R^(d43), wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(G) substituents;

each R^(a43), R^(c43), and R^(d43) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents;

each R^(b43) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6,membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(G) substituents;

Z is CR⁵ or N;

R⁵ is independently selected from H, halo, CN, C₁₋₄ alkyl, C₁₋₄haloalkyl, OH, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, amino, C₁₋₃ alkylamino,di(C₁₋₃ alkyl)amino, cyano-C₁₋₄ alkyl, HO—C₁₋₄ alkyl, C₁. 3 alkoxy-C₁₋₄alkyl, and C₃₋₄ cycloalkyl; and

each R^(G) is independently selected from OH, NO₂, CN, halo, C₁₋₃ alkyl,C₂₋₃ alkenyl, C₂₋₃, alkynyl, C₁₋₃ haloalkyl, cyano-C₁₋₃ alkyl, HO—C₁₋₃alkyl, C₁₋₃ alkoxy-C₁₋₃ alkyl, C₃₋₇ cycloalkyl, C₁₋₃ alkoxy, C₁₋₃haloalkoxy, amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino, thio, C₁₋₃alkylthio, C₁₋₃, alkylsulfinyl, C₁₋₃ alkylsulfonyl, carbamyl, C₁₋₃alkylcarbamyl, di(C₁₋₃ alkyl)carbamyl, carboxy, C₁₋₃ alkylcarbonyl, C₁₋₃alkoxycarbonyl, C₁₋₃ alkylcarbonyloxy, C₁₋₃ alkylcarbonylamino, C₁₋₃,alkoxycarbonylamino, C₁₋₃ alkylaminocarbonyloxy, C₁₋₃alkylsulfonylamino, aminosulfonyl, C₁₋₃, alkylaminosulfonyl, di(C₁₋₃alkyl)aminosulfonyl, aminosulfonylamino, C₁₋₃, alkylaminosulfonylamino,di(C₁₋₃ alkyl)aminosulfonylamino, aminocarbonylamino, C₁₋₃,alkylaminocarbonylamino, and di(C₁₋₃ alkyl)aminocarbonylamino.

In Some Embodiments:

is a double bond;

n is 0, 1, 2, 3, or 4;

Y is CR^(1a), wherein Y is adjacent to the carbon ring member attachingRing moiety A to the —NH— in Formula (I);

Ring moiety A is selected from phenyl and 5-10 membered heteroaryl,wherein Ring moiety A is attached to the —NH— in Formula (I) through acarbon atom;

R^(1a) is selected from halo, CN, C₁₋₄ alkyl, and C₁₋₄ haloalkyl;

or R^(1a) and an R² on an adjacent ring member of Ring moiety A,together with the ring atoms to which they are attached, form Ringmoiety B;

Ring moiety B is selected from phenyl or 5-6 membered heteroaryl, eachof which is optionally substituted by 1, 2, 3, or 4 independentlyselected R³ substituents;

each R² and R³ is independently selected from H, D, halo, CN, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₄ cycloalkyl, OR^(a2), SR^(a2), C(O)R^(b2),C(O)NR^(c2)R^(d2), C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2),NR^(c2)R^(d2), NR^(c2)C(O)R^(b2), NR²C(O)OR^(a2),NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)S(O)₂R^(b2), NR^(c2)S(O)₂NR^(c2)R^(d2),S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2), wherein said C₁₋₆ alkyl, C₁₋₆haloalkyl, and C₃₋₄ cycloalkyl are each optionally substituted with 1,2, 3, or 4 independently selected R^(2A) substituents;

each R^(a2), R², and R^(d2) is independently selected from H, C₁₋₆alkyl, and C₁₋₆ haloalkyl, wherein said C₁₋₆ alkyl and C₁₋₆ haloalkylare each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2A) substituents;

each R^(b2) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl, which are each optionally substituted with 1, 2, 3, or 4independently selected R^(2A) substituents;

each R^(2A) is independently selected from halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₄, cycloalkyl, OR^(a21), SR^(a21), C(O)R^(b21),C(O)NR^(c21)R^(d21), C(O)OR^(a21), OC(O)R^(b21), OC(O)NR^(c21)R^(d21),NR^(c21)R^(d21), NR^(c21)C(O)R^(b21), NR^(e21)C(O)OR^(a21),NR^(c21)C(O)NR^(c21)R^(d21), NR^(c21)S(O)NR^(c21)R^(d21),NR^(c21)S(O)R^(b21), NR^(c21)S(O)₂R^(b21), NR^(c21)S(O)₂NR^(c21)R^(d21),S(O)₂R^(b21), and S(O)₂NR^(c21)R^(d21), wherein said C₁₋₆ alkyl, C₁₋₆haloalkyl, and C₃₋₄ cycloalkyl are each optionally substituted with 1,2, 3, or 4 independently selected R^(2B) substituents;

each R^(a21), R^(c21), and R^(d21) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl, wherein said C₁₋₆ alkyl and C₁₋₆haloalkyl are each optionally substituted with 1, 2, 3, or 4independently selected R^(2B) substituents;

each R^(b21) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2B) substituents;

each R^(2B) is independently selected from H, halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, OR^(a22), SR^(a22), C(O)R^(b22), C(O)NR^(c22)R^(d22),C(O)OR^(a22), OC(O)R^(b22), OC(O)NR^(c22)R^(d22), NR^(c22)R^(d22),NR^(c22)C(O)R^(b22), NR^(c22)C(O)OR^(a22) NR^(c22)C(O)NR^(c22)R^(d22),NR^(c22)S(O)₂R^(b22), NR^(c22)S(O)₂NR^(c22)R^(d22), S(O)₂R^(b22), andS(O)₂NR^(c22)R^(d22);

each R^(a22), R^(c22), and R^(d22) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

each R^(b22) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl;

R⁴ is independently selected from phenyl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, and OR^(a4), wherein saidphenyl, 4-10 membered heterocycloalkyl, and 5-10 membered heteroaryl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4A) substituents;

each R^(a4), R^(c4), and R^(d4) is independently selected from H, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4A) substituents;

or, any R^(c4) and R^(d4) attached to the same N atom, together with theN atom to which they are attached, form a 4-10 membered heterocycloalkylgroup, wherein the 4-10 membered heterocycloalkyl group is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(4A)substituents;

each R^(4A) is independently selected from halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, C₃₋₆cycloalkyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl,OR^(a41), NR^(c41)R^(d41) and S(O)₂R^(b41), wherein said C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, C₃₋₆cycloalkyl-C₁₋₄ alkyl, and 4-6 membered heterocycloalkyl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents;

each R^(a41), R^(c41), and R^(d41) is independently selected from H,C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents;

each R^(b41) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4B) substituents;

each R^(4B) is independently selected from H, D, halo, CN, C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₄, cycloalkyl, OR^(a42), NR^(c42)R^(d42) andS(O)₂R^(b42);

each R^(a42), R^(c42), and R^(d42) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl;

each R^(b42) is independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl;

Z is CR⁵ or N; and

R⁵ is selected from H, halo, CN, C₁₋₃ alkyl, and C₁₋₃ haloalkyl.

In some embodiments, the compound is a compound of Formula (II):

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound is a compound of Formula (IIa):

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound is a compound of Formula (IIb):

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound is a compound of Formula (III):

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound is a compound of Formula (IIIa):

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound is a compound of Formula (IIIb):

or a pharmaceutically acceptable salt thereof.

In some embodiments, 1, 2, 3, 4, 5, 6, 7, or 8 hydrogen atoms, attachedto carbon atoms of “alkyl”, “alkenyl”, “alkynyl”, “aryl”, “phenyl”,“cycloalkyl”, “heterocycloalkyl”, or “heteroaryl” substituents or “—C₁₋₄alkyl-” and “alkylene” linking groups, as described herein, areoptionally replaced by deuterium atoms.

It is further appreciated that certain features of the invention, whichare, for clarity, described in the context of separate embodiments, canalso be provided in combination in a single embodiment as if theembodiments were claims written in multiple dependent form. Conversely,various features of the invention which are, for brevity, described inthe context of a single embodiment, can also be provided separately orin any suitable subcombination.

At various places in the present specification, divalent linkingsubstituents are described. Unless otherwise specified, it isspecifically intended that each divalent linking substituent includeboth the forward and backward forms of the linking substituent. Forexample, —NR(CR′R″)_(n)- includes both —NR(CR′R″)_(n)- and—(CR′R″)_(n)NR—. Where the structure clearly requires a linking group,the Markush variables listed for that group are understood to be linkinggroups.

The term “n-membered” where n is an integer typically describes thenumber of ring-forming atoms in a moiety where the number ofring-forming atoms is n. For example, piperidinyl is an example of a6-membered heterocycloalkyl ring, pyrazolyl is an example of a5-membered heteroaryl ring, pyridyl is an example of a 6-memberedheteroaryl ring, and 1,2,3,4-tetrahydro-naphthalene is an example of a10-membered cycloalkyl group.

As used herein, the phrase “optionally substituted” means unsubstitutedor substituted. The substituents are independently selected, andsubstitution may be at any chemically accessible position. As usedherein, the term “substituted” means that a hydrogen atom is removed andreplaced by a substituent. A single divalent substituent, e.g., oxo, canreplace two hydrogen atoms. It is to be understood that substitution ata given atom is limited by valency, that the designated atom's normalvalency is not exceeded, and that the substitution results in a stablecompound.

As used herein, the term “independently selected from” means that eachoccurrence of a variable or substituent are independently selected ateach occurrence from the applicable list.

As used herein, the phrase “each ‘variable’ is independently selectedfrom” means substantially the same as wherein “at each occurrence‘variable’ is selected from.”

When any variable (e.g., R^(G)) occurs more than one time in anyconstituent or formula for a compound, its definition at each occurrenceis independent of its definition at every other occurrence. Thus, forexample, if a group is shown to be substituted with 1, 2, 3, or 4independently selected R^(G) substituents, then said group mayoptionally be substituted with up to four R^(G) groups and R^(G) at eachoccurrence is selected independently from the definition of R^(G).

In some embodiments, substituents are indicated as floatingsubstituents—e.g., (R²)_(n) in Formula (I):

It is understood that substituent R² can occur n number of times on thering, and R² can be a different moiety at each occurrence. It is to beunderstood that each R group may replace any hydrogen atom attached to aring atom, except that R² may not replace R^(1a) or R^(1b) in thevariable Y.

Throughout the definitions, the term “C_(n-m)” indicates a range whichincludes the endpoints, wherein n and m are integers and indicate thenumber of carbons. Examples include C₁₋₃, C₁₋₄, C₁₋₆, and the like.

As used herein, the term “C_(n-m) alkyl”, employed alone or incombination with other terms, refers to a saturated hydrocarbon groupthat may be straight-chain or branched, having n to m carbons. Examplesof alkyl moieties include, but are not limited to, chemical groups suchas methyl (Me), ethyl (Et), n-propyl (n-Pr), isopropyl (i-Pr), n-butyl,tert-butyl, isobutyl, sec-butyl; higher homologs such as2-methyl-1-butyl, n-pentyl, 3-pentyl, n-hexyl, 1,2,2-trimethylpropyl,and the like. In some embodiments, the alkyl group contains from 1 to 6carbon atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or 1to 2 carbon atoms.

As used herein, “C_(n-m) alkenyl” refers to an alkyl group having one ormore double carbon-carbon bonds and having n to m carbons. Examplealkenyl groups include, but are not limited to, ethenyl, n-propenyl,isopropenyl, n-butenyl, sec-butenyl, and the like. In some embodiments,the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.

As used herein, “C_(n-m) alkynyl” refers to an alkyl group having one ormore triple carbon-carbon bonds and having n to m carbons. Examplealkynyl groups include, but are not limited to, ethynyl, propyn-1-yl,propyn-2-yl, and the like. In some embodiments, the alkynyl moietycontains 2 to 6, 2 to 4, or 2 to 3 carbon atoms. As used herein, theterm “C_(n-m) alkoxy”, employed alone or in combination with otherterms, refers to a group of formula-O-alkyl, wherein the alkyl group hasn to m carbons. Example alkoxy groups include, but are not limited to,methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), butoxy (e.g.,n-butoxy and tert-butoxy), and the like. In some embodiments, the alkylgroup has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “amino” refers to a group of formula —NH₂.

As used herein, the term “aryl,” employed alone or in combination withother terms, refers to an aromatic hydrocarbon group, which may bemonocyclic or polycyclic (e.g., having 2, fused rings). The term“C_(n-m) aryl” refers to an aryl group having from n to m ring carbonatoms.

In some embodiments, the aryl group has 6 to 10 carbon atoms. In someembodiments, the aryl group is phenyl or naphthyl. In some embodiments,the aryl is phenyl.

As used herein, “halo” refers to F, Cl, Br, or I. In some embodiments,halo is F, Cl, or Br. In some embodiments, halo is F or Cl. In someembodiments, halo is F. In some embodiments, halo is Cl.

As used herein, “C_(n-m) haloalkoxy” refers to a group of formula—O-haloalkyl having n to m carbon atoms. Example haloalkoxy groupsinclude OCF₃ and OCHF₂. In some embodiments, the haloalkoxy group isfluorinated only. In some embodiments, the alkyl group has 1 to 6, 1 to4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) haloalkyl,” employed alone or incombination with other terms, refers to an alkyl group having from onehalogen atom to 2s+1 halogen atoms which may be the same or different,where “s” is the number of carbon atoms in the alkyl group, wherein thealkyl group has n to m carbon atoms. In some embodiments, the haloalkylgroup is fluorinated only. In some embodiments, the alkyl group of thehaloalkyl has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Example haloalkylgroups include CF₃, C₂F₅, CHF₂, CH₂F, CCl₃, CHCl₂, C₂Cl₅ and the like.

As used herein, the term “thio” refers to a group of formula —SH.

As used herein, the term “C_(n-m) alkylamino” refers to a group offormula —NH(alkyl), wherein the alkyl group has n to m carbon atoms. Insome embodiments, the alkyl group of the alkylamino has 1 to 6, 1 to 4,or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkoxycarbonyl” refers to a group offormula —C(O)O— alkyl, wherein the alkyl group has n to m carbon atoms.In some embodiments, the alkyl group of the alkoxycarbonyl has 1 to 6, 1to 4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkylcarbonyl” refers to a group offormula —C(O)-alkyl, wherein the alkyl group has n to m carbon atoms. Insome embodiments, the alkyl group of the alkylcarbonyl has 1 to 6, 1 to4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkylcarbonylamino” refers to a groupof formula —NHC(O)-alkyl, wherein the alkyl group has n to m carbonatoms. In some embodiments, the alkyl group of the alkylcarbonylaminohas 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkoxycarbonylamino” refers to a groupof formula —NHC(O)O(C_(n-m) alkyl), wherein the alkyl group has n to mcarbon atoms. In some embodiments, the alkyl group of thealkoxycarbonylamino has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkylsulfonylamino” refers to a groupof formula —NHS(O)₂-alkyl, wherein the alkyl group has n to m carbonatoms. In some embodiments, the alkyl group of the alkylsulfonylaminohas 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “aminosulfonyl” refers to a group of formula—S(O)₂NH₂.

As used herein, the term “C_(n-m) alkylaminosulfonyl” refers to a groupof formula —S(O)₂NH (alkyl), wherein the alkyl group has n to m carbonatoms. In some embodiments, the alkyl group of the alkylaminosulfonylhas 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “di(C_(n-m) alkyl)aminosulfonyl” refers to agroup of formula —S(O)₂N(alkyl)₂, wherein each alkyl group independentlyhas n to m carbon atoms. In some embodiments, each alkyl group of thedialkylaminosulfonyl has, independently, 1 to 6, 1 to 4, or 1 to 3carbon atoms.

As used herein, the term “aminosulfonylamino” refers to a group offormula —NHS(O)₂NH₂.

As used herein, the term “C_(n-m) alkylaminosulfonylamino” refers to agroup of formula —NHS(O)₂NH (alkyl), wherein the alkyl group has n to mcarbon atoms. In some embodiments, the alkyl group of thealkylaminosulfonylamino has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “di(C_(n-m) alkyl)aminosulfonylamino” refers toa group of formula —NHS(O)₂N(alkyl)₂, wherein each alkyl groupindependently has n to m carbon atoms. In some embodiments, each alkylgroup of the dialkylaminosulfonylamino has, independently, 1 to 6, 1 to4, or 1 to 3 carbon atoms.

As used herein, the term “aminocarbonylamino,” employed alone or incombination with other terms, refers to a group of formula —NHC(O)NH₂.

As used herein, the term “C_(n-m) alkylaminocarbonylamino” refers to agroup of formula —NHC(O)NH (alkyl), wherein the alkyl group has n to mcarbon atoms. In some embodiments, the alkyl group of thealkylaminocarbonylamino has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “di(C_(n-m) alkyl)aminocarbonylamino” refers toa group of formula —NHC(O)N(alkyl)₂, wherein each alkyl groupindependently has n to m carbon atoms.

In some embodiments, each alkyl group of the dialkylaminocarbonylaminohas, independently, 1, to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkylcarbamyl” refers to a group offormula —C(O)—NH(alkyl), wherein the alkyl group has n to m carbonatoms. In some embodiments, the alkyl group of the alkylcarbamyl has 1to 6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkylthio” refers to a group offormula —S-alkyl, wherein the alkyl group has n to m carbon atoms. Insome embodiments, the alkyl group of the alkylthio has 1 to 6, 1 to 4,or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkylsulfinyl” refers to a group offormula —S(O)-alkyl, wherein the alkyl group has n to m carbon atoms. Insome embodiments, the alkyl group of the alkylsulfinyl has 1 to 6, 1 to4, or 1 to 3 carbon atoms.

As used herein, the term “C_(n-m) alkylsulfonyl” refers to a group offormula —S(O)₂-alkyl, wherein the alkyl group has n to m carbon atoms.In some embodiments, the alkyl group of the alkylsulfonyl has 1 to 6, 1to 4, or 1 to 3 carbon atoms.

As used herein, the term “cyano-C_(n-m) alkyl” refers to a group offormula —(C_(n-m) alkylene)-CN, wherein the alkylene group has n to mcarbon atoms. As used herein, the term “cyano-C₁₋₆, alkyl” refers to agroup of formula —(C₁₋₆ alkylene)-CN. As used herein, the term“cyano-C₁₋₃, alkyl” refers to a group of formula —(C₁₋₃ alkylene)-CN.

As used herein, the term “HO—C_(n-m) alkyl” refers to a group of formula—(C_(n-m) alkylene)-OH, wherein the alkylene group has n to m carbonatoms. As used herein, the term “HO—C₁₋₃, alkyl” refers to a group offormula —(C₁₋₃ alkylene)-OH.

As used herein, the term “C_(n-m) alkoxy-C_(o-p) alkyl” refers to agroup of formula —(C_(n-m) alkylene)-O(C_(o-p) alkyl), wherein thealkylene group has n to m carbon atoms and the alkyl group has o to pcarbon atoms. As used herein, the term “C₁₋₆ alkoxy-C₁₋₆ alkyl” refersto a group of formula —(C₁₋₆ alkylene)-O(C₁₋₆ alkyl). As used herein,the term “C₁₋₃ alkoxy-C₁₋₃ alkyl” refers to a group of formula —(C₁₋₃alkylene)-O(C₁₋₃ alkyl).

As used herein, the term “carboxy” refers to a group of formula —C(O)OH.

As used herein, the term “di(C_(n-m)-alkyl)amino” refers to a group offormula —N(alkyl)₂, wherein the two alkyl groups each has,independently, n to m carbon atoms. In some embodiments, each alkylgroup of the dialkylamino independently has 1 to 6, 1 to 4, or 1 to 3,carbon atoms.

As used herein, the term “di(C_(n-m)-alkyl)carbamyl” refers to a groupof formula —C(O)N(alkyl)₂, wherein the two alkyl groups each has,independently, n to m carbon atoms. In some embodiments, each alkylgroup of the dialkylcarbamoyl independently has 1 to 6, 1 to 4, or 1 to3 carbon atoms.

As used herein, the term “C_(n-m) alkylcarbonyloxy” is a group offormula —OC(O)-alkyl, wherein the alkyl group has n to m carbon atoms.In some embodiments, the alkyl group of the alkylcarbonyloxy has 1 to 6,1 to 4, or 1 to 3 carbon atoms.

As used herein, “aminocarbonyloxy” is a group of formula —OC(O)—NH₂.

As used herein, “C_(n-m) alkylaminocarbonyloxy” is a group of formula—OC(O)—NH-alkyl, wherein the alkyl group has n to m carbon atoms. Insome embodiments, the alkyl group of the alkylaminocarbonyloxy has 1 to6, 1 to 4, or 1 to 3 carbon atoms.

As used herein, “di(C_(n-m) alkyl)aminocarbonyloxy” is a group offormula —OC(O)—N(alkyl)₂, wherein each alkyl group has, independently, nto m carbon atoms. In some embodiments, each alkyl group of thedialkylaminocarbonyloxy independently has 1 to 6, 1 to 4, or 1 to 3carbon atoms.

As used herein “C_(n-m) alkoxycarbonylamino” refers to a group offormula —NHC(O)—O— alkyl, wherein the alkyl group has n to m carbonatoms.

As used herein, the term “carbamyl” to a group of formula —C(O)NH₂.

As used herein, the term “carbonyl,” employed alone or in combinationwith other terms, refers to a —C(O)— group.

As used herein, “cycloalkyl” refers to non-aromatic cyclic hydrocarbonsincluding cyclized alkyl and alkenyl groups. Cycloalkyl groups caninclude mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) groups,spirocycles, and bridged rings (e.g., a bridged bicycloalkyl group).Ring-forming carbon atoms of a cycloalkyl group can be optionallysubstituted by oxo or sulfido (e.g., C(O) or C(S)). Also included in thedefinition of cycloalkyl are moieties that have one or more aromaticrings fused (i.e., having a bond in common with) to the cycloalkyl ring,for example, benzo or thienyl derivatives of cyclopentane, cyclohexane,and the like. A cycloalkyl group containing a fused aromatic ring can beattached through any ring-forming atom including a ring-forming atom ofthe fused aromatic ring. Cycloalkyl groups can have 3, 4, 5, 6, 7, 8, 9,or 10 ring-forming carbons (i.e., C₃₋₁₀). In some embodiments, thecycloalkyl is a C₃₋₁₀ monocyclic or bicyclic cycloalkyl. In someembodiments, the cycloalkyl is a C₃₋₇ monocyclic cycloalkyl. In someembodiments, the cycloalkyl is a C₄₋₇ monocyclic cycloalkyl. In someembodiments, the cycloalkyl is a C₄₋₁₀ spirocycle or bridged cycloalkyl(e.g., a bridged bicycloalkyl group). Example cycloalkyl groups includecyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl,norbornyl, norpinyl, norcaranyl, cubane, adamantane,bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptanyl,bicyclo[3.1.1]heptanyl, bicyclo[2.2.2]octanyl, spiro[3.3]heptanyl, andthe like. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl,cyclopentyl, or cyclohexyl.

As used herein, “heteroaryl” refers to a monocyclic or polycyclic (e.g.,having 2, 3, or 4, fused rings) aromatic heterocycle having at least oneheteroatom ring member selected from N, O, or S. In some embodiments,any ring-forming N in a heteroaryl moiety can be an N-oxide. In someembodiments, the heteroaryl is a 5-10 membered monocyclic or bicyclicheteroaryl having 1, 2, 3, or 4 heteroatom ring members independentlyselected from N, O, and S. In some embodiments, the heteroaryl is a 5-6monocyclic heteroaryl having 1 or 2 heteroatom ring membersindependently selected from N, O, and S. In some embodiments, theheteroaryl group contains 5 to 10 or 5 to 6 ring-forming atoms. In someembodiments, the heteroaryl group has 1, to 4 ring-forming heteroatoms,1 to 3 ring-forming heteroatoms, 1 to 2 ring-forming heteroatoms or 1ring-forming heteroatom. When the heteroaryl group contains more thanone heteroatom ring member, the heteroatoms may be the same ordifferent. Example heteroaryl groups include, but are not limited to,pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl,azolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl,furyl, thienyl, triazolyl (e.g., 1,2,3-triazolyl, 1,2,4-triazolyl,1,3,4-triazolyl), tetrazolyl, thiadiazolyl (e.g., 1,2,3-thiadiazolyl,1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl), quinolinyl, isoquinolinyl,indolyl, benzothienyl, benzofuranyl, benzisoxazolyl,imidazo[1,2-b]thiazolyl, purinyl, triazinyl, thieno[3,2-b]pyridinyl,imidazo[1,2-a]pyridinyl, 1,5-naphthyridinyl,1H-pyrazolo[4,3-b]pyridinyl, oxadiazolyl (e.g., 1,2,3-oxadiazolyl,1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl), 1,2-dihydro-1,2-azoborinyl, andthe like.

As used herein, “heterocycloalkyl” refers to monocyclic or polycyclicheterocycles having at least one non-aromatic ring (saturated orpartially unsaturated ring), wherein one or more of the ring-formingcarbon atoms of the heterocycloalkyl is replaced by a heteroatomselected from N, O, or S, and wherein the ring-forming carbon atoms andheteroatoms of the heterocycloalkyl group can be optionally substitutedby one or more oxo or sulfido (e.g., C(O), S(O), C(S), or S(O)₂, etc.).Heterocycloalkyl groups include monocyclic and polycyclic (e.g., having2 fused rings) systems. Included in heterocycloalkyl are monocyclic andpolycyclic 4-10-, 4-7-, and 5-6-membered heterocycloalkyl groups.Heterocycloalkyl groups can also include spirocycles and bridged rings.The heterocycloalkyl group can be attached through a ring-forming carbonatom or a ring-forming heteroatom. In some embodiments, theheterocycloalkyl group contains 0 to 3 double bonds. In someembodiments, the heterocycloalkyl group contains 0, to 2 double bonds.

Also included in the definition of heterocycloalkyl are moieties thathave one or more aromatic rings fused (i.e., having a bond in commonwith) to the non-aromatic heterocyclic ring, for example, benzo orthienyl derivatives of piperidine, morpholine, azepine, etc. Aheterocycloalkyl group containing a fused aromatic ring can be attachedthrough any ring-forming atom including a ring-forming atom of the fusedaromatic ring. In some embodiments, the heterocycloalkyl group contains4 to 10 ring-forming atoms, 4 to 7 ring-forming atoms, 4 to 6,ring-forming atoms or 5 to 6 ring-forming atoms. In some embodiments,the heterocycloalkyl group has 1 to 4 heteroatoms, 1 to 3 heteroatoms, 1to 2 heteroatoms or 1 heteroatom.

In some embodiments, the heterocycloalkyl is a 4-10 membered monocyclic,bicyclic, or tricyclic heterocycloalkyl having 1, 2, 3, or 4ring-forming heteroatoms independently selected from N, O, and S,wherein 1, 2, 3, or 4 ring-forming carbon or heteroatoms can beoptionally substituted by one or more oxo or sulfido. In someembodiments, the heterocycloalkyl is a 4-10 membered bicyclicheterocycloalkyl having 1, 2, 3, or 4 ring-forming heteroatomsindependently selected from N, O, and S, wherein 1, 2, 3, or 4ring-forming carbon or heteroatoms can be optionally substituted by oneor more oxo or sulfido. In some embodiments, the heterocycloalkyl is a4-7 membered monocyclic heterocycloalkyl having 1 or 2 ring-formingheteroatoms independently selected from N, O, and S, and wherein 1, 2 or3 ring-forming carbon or heteroatoms can be optionally substituted byone or more oxo or sulfido. In some embodiments, the heterocycloalkyl isa monocyclic 4-6 membered heterocycloalkyl having 1 or 2 heteroatomsindependently selected from N, O, S, and B and having one or moreoxidized ring members.

Examples of heterocycloalkyl groups include pyrrolidin-2-one,1,3-isoxazolidin-2-one, pyranyl, tetrahydropyran, oxetanyl, azetidinyl,morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl,tetrahydrothienyl, piperidinyl, pyrrolidinyl, isoxazolidinyl,isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl,imidazolidinyl, azepanyl, benzazapene, 1,2,3,4-tetrahydroisoquinoline,azabicyclo[3.1.0]hexanyl, diazabicyclo[3.1.0]hexanyl,oxabicyclo[2.1.1]hexanyl, azabicyclo[2.2.1]heptanyl,azabicyclo[2.2.1]heptan-7-yl, azabicyclo[2.2.1]heptan-2-yl,diazabicyclo[2.2.1]heptanyl, azabicyclo[3.1.1]heptanyl,diazabicyclo[3.1.1]heptanyl, azabicyclo[3.2.1]octanyl,diazabicyclo[3.2.1]octanyl, oxabicyclo[2.2.2]octanyl,azabicyclo[2.2.2]octanyl, azaadamantanyl, diazaadamantanyl,oxa-adamantanyl, azaspiro[3.3]heptanyl, diazaspiro[3.3]heptanyl,oxa-azaspiro[3.3]heptanyl, azaspiro[3.4]octanyl, diazaspiro[3.4]octanyl,oxa-azaspiro[3.4]octanyl, azaspiro[2.5]octanyl, diazaspiro[2.5]octanyl,azaspiro[4.4]nonanyl, diazaspiro[4.4]nonanyl, oxa-azaspiro[4.4]nonanyl,azaspiro[4.5]decanyl, diazaspiro[4.5]decanyl, diazaspiro[4.4]nonanyl,oxa-diazaspiro[4.4]nonanyl, and the like.

As used herein, “C_(o-p) cycloalkyl-C_(n-m) alkyl-” refers to a group offormula cycloalkyl-alkylene-, wherein the cycloalkyl has o to p carbonatoms and the alkylene linking group has n to m carbon atoms.

As used herein “C_(o-p) aryl-C_(n-m) alkyl-” refers to a group offormula aryl-alkylene-, wherein the aryl has o to p carbon ring membersand the alkylene linking group has n to m carbon atoms.

As used herein, “heteroaryl-C_(n-m) alkyl-” refers to a group of formulaheteroaryl-alkylene-, wherein alkylene linking group has n to m carbonatoms.

As used herein “heterocycloalkyl-C_(n-m) alkyl-” refers to a group offormula heterocycloalkyl-alkylene-, wherein alkylene linking group has nto m carbon atoms.

As used herein, the term “alkylene” refers a divalent straight chain orbranched alkyl linking group. Examples of “alkylene groups” includemethylene, ethan-1,1-diyl, ethan-1,2-diyl, propan-1,3-dilyl,propan-1,2-diyl, propan-1,1-diyl and the like.

As used herein, the term “alkenylene” refers a divalent straight chainor branched alkenyl linking group. Examples of “alkenylene groups”include ethen-1,1-diyl, ethen-1,2-diyl, propen-1,3-diyl,2-buten-1,4-diyl, 3-penten-1,5-diyl, 3-hexen-1,6-diyl, 3-hexen-1,5-diyl,and the like.

As used herein, the term “alkynylene” refers a divalent straight chainor branched alkynyl linking group. Examples of “alkynylene groups”include propyn-1,3-diyl, 2-butyn-1,4-diyl, 3-pentyn-1,5-diyl,3-hexyn-1,6-diyl, 3-hexyn-1,5-diyl, and the like.

As used herein, an “alkyl linking group” is a bivalent straight chain orbranched alkyl linking group (“alkylene group”). For example, “C_(o-p)cycloalkyl-C_(n-m) alkyl-”, “C_(o-p) aryl-C_(n-m) alkyl-”,“phenyl-C_(n-m) alkyl-”, “heteroaryl-C_(n-m) alkyl-”, and“heterocycloalkyl-C_(n-m) alkyl-” contain alkyl linking groups. Examplesof “alkyl linking groups” or “alkylene groups” include methylene,ethan-1,1-diyl, ethan-1,2-diyl, propan-1,3-dilyl, propan-1,2-diyl,propan-1,1-diyl and the like.

As used herein, the term “oxo” refers to an oxygen atom (i.e., ═O) as adivalent substituent, forming a carbonyl group when attached to a carbon(e.g., C═O or C(O)), or attached to a nitrogen or sulfur heteroatomforming a nitroso, sulfinyl or sulfonyl group.

As used herein, the term “independently selected from” means that eachoccurrence of a variable or substituent are independently selected ateach occurrence from the applicable list.

At certain places, the definitions or embodiments refer to specificrings (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwiseindicated, these rings can be attached to any ring member provided thatthe valency of the atom is not exceeded. For example, an azetidine ringmay be attached at any position of the ring, whereas a pyridin-3-yl ringis attached at the 3-position.

The compounds described herein can be asymmetric (e.g., having one ormore stereocenters). All stereoisomers, such as enantiomers anddiastereomers, are intended unless otherwise indicated. Compounds of thepresent disclosure that contain asymmetrically substituted carbon atomscan be isolated in optically active or racemic forms. Methods on how toprepare optically active forms from optically inactive startingmaterials are known in the art, such as by resolution of racemicmixtures or by stereoselective synthesis. Many geometric isomers ofolefins, C═N double bonds, and the like can also be present in thecompounds described herein, and all such stable isomers are contemplatedin the present invention. Cis and trans geometric isomers of thecompounds of the present disclosure are described and may be isolated asa mixture of isomers or as separated isomeric forms. In someembodiments, the compound has the (R)-configuration. In someembodiments, the compound has the (S)-configuration. The Formulas (e.g.,Formula (I), (II), etc.) provided herein include stereoisomers of thecompounds.

Resolution of racemic mixtures of compounds can be carried out by any ofnumerous methods known in the art. An example method includes fractionalrecrystallization using a chiral resolving acid which is an opticallyactive, salt-forming organic acid. Suitable resolving agents forfractional recrystallization methods are, for example, optically activeacids, such as the D and L forms of tartaric acid, diacetyltartaricacid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid orthe various optically active camphorsulfonic acids such as0-camphorsulfonic acid.

Other resolving agents suitable for fractional crystallization methodsinclude stereoisomerically pure forms of α-methylbenzylamine (e.g., Sand R forms, or diastereomerically pure forms), 2-phenylglycinol,norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine,1,2-diaminocyclohexane, and the like.

Resolution of racemic mixtures can also be carried out by elution on acolumn packed with an optically active resolving agent (e.g.,dinitrobenzoylphenylglycine). Suitable elution solvent composition canbe determined by one skilled in the art.

Compounds provided herein also include tautomeric forms. Tautomericforms result from the swapping of a single bond with an adjacent doublebond together with the concomitant migration of a proton. Tautomericforms include prototropic tautomers which are isomeric protonationstates having the same empirical formula and total charge. Exampleprototropic tautomers include ketone-enol pairs, amide-imidic acidpairs, lactam-lactim pairs, enamine-imine pairs, and annular forms wherea proton can occupy two or more positions of a heterocyclic system, forexample, 1H- and 3H-imidazole, 1H-, 2H- and 4H-1,2,4-triazole, 1H- and2H-isoindole, 2-hydroxypyridine and 2-pyridone, and 1H- and 2H-pyrazole.Tautomeric forms can be in equilibrium or sterically locked into oneform by appropriate substitution.

All compounds, and pharmaceutically acceptable salts thereof, can befound together with other substances such as water and solvents (e.g.,hydrates and solvates) or can be isolated.

In some embodiments, preparation of compounds can involve the additionof acids or bases to affect, for example, catalysis of a desiredreaction or formation of salt forms such as acid addition salts.

In some embodiments, the compounds provided herein, or salts thereof,are substantially isolated. By “substantially isolated” is meant thatthe compound is at least partially or substantially separated from theenvironment in which it was formed or detected. Partial separation caninclude, for example, a composition enriched in the compounds providedherein. Substantial separation can include compositions containing atleast about 50%, at least about 60%, at least about 70%, at least about80%, at least about 90%, at least about 95%, at least about 97%, or atleast about 99% by weight of the compounds provided herein, or saltthereof. Methods for isolating compounds and their salts are routine inthe art.

The term “compound” as used herein is meant to include allstereoisomers, geometric isomers, tautomers, and isotopes of thestructures depicted. Compounds herein identified by name or structure asone particular tautomeric form are intended to include other tautomericforms unless otherwise specified.

The phrase “pharmaceutically acceptable” is employed herein to refer tothose compounds, materials, compositions, and/or dosage forms which are,within the scope of sound medical judgment, suitable for use in contactwith the tissues of human beings and animals without excessive toxicity,irritation, allergic response, or other problem or complication,commensurate with a reasonable benefit/risk ratio.

The present application also includes pharmaceutically acceptable saltsof the compounds described herein. As used herein, “pharmaceuticallyacceptable salts” refers to derivatives of the disclosed compoundswherein the parent compound is modified by converting an existing acidor base moiety to its salt form. Examples of pharmaceutically acceptablesalts include, but are not limited to, mineral or organic acid salts ofbasic residues such as amines; alkali or organic salts of acidicresidues such as carboxylic acids; and the like. The pharmaceuticallyacceptable salts of the present disclosure include the conventionalnon-toxic salts of the parent compound formed, for example, fromnon-toxic inorganic or organic acids. The pharmaceutically acceptablesalts of the present disclosure can be synthesized from the parentcompound which contains a basic or acidic moiety by conventionalchemical methods. Generally, such salts can be prepared by reacting thefree acid or base forms of these compounds with a stoichiometric amountof the appropriate base or acid in water or in an organic solvent, or ina mixture of the two; generally, non-aqueous media like ether, ethylacetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) oracetonitrile (ACN) are preferred. Lists of suitable salts are found inRemington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company,Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2(1977), each of which is incorporated herein by reference in itsentirety.

Synthesis

As will be appreciated by those skilled in the art, the compoundsprovided herein, including salts and stereoisomers thereof, can beprepared using known organic synthesis techniques and can be synthesizedaccording to any of numerous possible synthetic routes, such as thoseprovided in the Schemes below.

The reactions for preparing compounds described herein can be carriedout in suitable solvents which can be readily selected by one of skillin the art of organic synthesis. Suitable solvents can be substantiallynon-reactive with the starting materials (reactants), the intermediatesor products at the temperatures at which the reactions are carried out,e.g., temperatures which can range from the solvent's freezingtemperature to the solvent's boiling temperature. A given reaction canbe carried out in one solvent or a mixture of more than one solvent.Depending on the particular reaction step, suitable solvents for aparticular reaction step can be selected by the skilled artisan.

The expressions, “ambient temperature” or “room temperature” or “r.t.”as used herein, are understood in the art, and refer generally to atemperature, e.g., a reaction temperature, that is about the temperatureof the room in which the reaction is carried out, for example, atemperature from about 20° C. to about 30° C.

Preparation of compounds of the invention can involve the protection anddeprotection of various chemical groups. The need for protection anddeprotection, and the selection of appropriate protecting groups, can bereadily determined by one skilled in the art. The chemistry ofprotecting groups is described, e.g., in Kocienski, Protecting Groups,(Thieme, 2007); Robertson, Protecting Group Chemistry, (OxfordUniversity Press, 2000); Smith et al., March's Advanced OrganicChemistry: Reactions, Mechanisms, and Structure, 6^(th) Ed. (Wiley,2007); Peturssion et al., “Protecting Groups in Carbohydrate Chemistry,”J. Chem. Educ., 1997, 74(11), 1297; and Wuts et al., Protective Groupsin Organic Synthesis, 4th Ed., (Wiley, 2006).

Reactions can be monitored according to any suitable method known in theart. For example, product formation can be monitored by spectroscopicmeans, such as nuclear magnetic resonance spectroscopy (e.g., ¹H or¹³C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), massspectrometry or by chromatographic methods such as high performanceliquid chromatography (HPLC), liquid chromatography-mass spectroscopy(LCMS), or thin layer chromatography (TLC). Compounds can be purified bythose skilled in the art by a variety of methods, including highperformance liquid chromatography (HPLC) and normal phase silicachromatography.

The Schemes below provide general guidance in connection with preparingthe compounds of the invention. One skilled in the art would understandthat the preparations shown in the Schemes can be modified or optimizedusing general knowledge of organic chemistry to prepare variouscompounds of the invention.

Compounds of formulas 1-10, 1-11, and 1-15 can be synthesized using theprocesses shown in Scheme 1. Palladium-catalyzed cross-couplingreactions of aryl halides 1-1 and appropriately protected pyrazoleboronic acids/esters 1-2 afford compounds of formula 1-3. Nucleophilicaddition of compounds 1-3 to O-ethyl carbonisothiocyanatidate 1-4affords intermediate compounds 1-5. Cyclization of 1-5 withhydroxylamine hydrochloride/DIPEA provides aminobicyclic cores 1-6.Halogenation of 1-6 with an appropriate reagent (including, but notlimited to, N-bromosuccinimide or N-chlorosuccinimide) in an appropriatesolvent (e.g., CH₂Cl₂, CH₃CN, DMF) gives compounds of formula 1-7. C—Nbond forming reactions (e.g., transition metal catalyzed or nucleophilicaromatic substitution) between the amino compounds 1-7 and appropriatelysubstituted aryl or heteroaryl halides 1-8 affords 1-9. Transition metal(e.g., Pd) catalyzed (including, but not limited to, Suzuki, Stille,Negishi couplings) C—C bond forming reactions of compounds 1-9 andappropriate coupling partners (e.g., aryl or heteroaryl boronicacids/esters, trialkyl tin, or zinc reagents), followed by pyrazoledeprotection furnishes compounds of formula 1-10. Alternatively,transition metal (including, but not limited to, Pd and Cu) catalyzedC—N bond forming reactions between compounds 1-9 and appropriatelysubstituted amino compounds, followed by pyrazole deprotection affordscompounds 1-11. Compounds of formula 1-7 can also undergo Sandmeyerhalogenation under appropriate conditions (e.g., CuBr₂/t-BuONO in CH₃CN,or CH₂Cl₂/NaNO₂/AcOH in CH₂Cl₂/H₂O) to give compounds of formula 1-12.Transition metal (e.g., Pd) catalyzed C—N bond forming reactions betweencompounds 1-12 and appropriately substituted amino compounds 1-13 affordcompounds 1-14. Transition metal catalyzed C—C or C—N bond formingreactions of compounds 1-14 and an appropriate coupling partner (e.g.,aryl or heteroaryl boronic acids/esters, trialkyl tin, or zinc reagentsfor C—C couplings, or primary or secondary amines for C—N couplings,respectively), followed by pyrazole deprotection afford compounds 1-15.

Compounds of formulas 2-10 can be synthesized using the processes shownin Scheme 2. Palladium-catalyzed cross-coupling reactions of arylhalides 2-1 and appropriately protected pyrazole boronic acids/esters2-2 afford compounds of formula 2-3. Nucleophilic addition of compounds2-3 to O-ethyl carbonisothiocyanatidate 2-4 affords intermediatecompounds 2-5. Cyclization of 2-5 with hydroxylamine hydrochloride/DIPEAprovides the aminobicyclic cores 2-6. Sandmeyer halogenation ofcompounds 2-6 under appropriate conditions (e.g., CuBr₂/t-BuONO inCH₃CN, or CH₂Cl₂/NaNO₂/AcOH in CH₂Cl₂/H₂O) generates compounds offormula 2-7. Transition metal (e.g., Pd) catalyzed C—N bond formingreactions between compounds 2-7 and appropriately substituted aminocompounds 2-8 afford compounds 2-9. Transition metal (e.g., Pd)catalyzed C—C or C—N bond forming reactions of compounds 2-9 and anappropriate coupling partner (e.g., aryl or heteroaryl boronicacids/esters, trialkyl tin, or zinc reagents for C—C couplings, orprimary or secondary amines for C—N couplings, respectively), followedby pyrazole deprotection afford compounds 2-10.

Compounds of formula 3-12 can be synthesized using a process shown inScheme 3. Demethylation of appropriately substituted halides 3-1 withBBr₃ in an appropriate solvent (e.g., CH₂Cl₂) affords compounds offormula 3-2. Nucleophilic substitution reactions with appropriateelectrophiles 3-3 afford compounds of formula 3-4. Palladium-catalyzedcross-coupling reactions of aryl halides 3-4 and appropriately protectedpyrazole boronic acids/esters 3-5 afford compounds of formula 3-6.Nucleophilic addition of compounds 3-6 to O-ethylcarbonisothiocyanatidate 3-7 affords intermediate compounds 3-8.Cyclization of 3-8 with hydroxylamine hydrochloride/DIPEA provides theaminobicyclic cores 3-9. Sandmeyer bromination of compounds 3-9 withcopper(II) bromide and tert-butyl nitrite in an appropriate solvent(e.g., CH₃CN) generates aryl bromides 3-10. Transition metal (including,but not limited to, Pd and Cu) catalyzed C—N bond forming reactionsbetween compounds 3-10 and amino compounds 3-11, followed by pyrazoledeprotection afford compounds 3-12. Alternatively, transition metalcatalyzed C—N bond forming reactions between compounds 3-9 andappropriately substituted aryl halides 3-13, followed by pyrazoledeprotection afford compounds 3-12.

Methods of Use

Compounds of the present disclosure can inhibit CDK2 and therefore areuseful for treating diseases wherein the underlying pathology is, whollyor partially, mediated by CDK2. Such diseases include cancer and otherdiseases with proliferation disorder. In some embodiments, the presentdisclosure provides treatment of an individual or a patient in vivousing a compound of Formula (I) or a salt thereof such that growth ofcancerous tumors is inhibited. A compound of Formula (I) or of any ofthe formulas as described herein, or a compound as recited in any of theclaims and described herein, or a salt thereof, can be used to inhibitthe growth of cancerous tumors with aberrations that activate the CDK2kinase activity. These include, but are not limited to, disease (e.g.,cancers) that are characterized by amplification or overexpression ofCCNE1 such as ovarian cancer, uterine carcinosarcoma and breast cancerand p27 inactivation such as breast cancer and melanomas. Accordingly,in some embodiments of the methods, the patient has been previouslydetermined to have an amplification of the cyclin E1 (CCNE1) gene and/oran expression level of CCNE1 in a biological sample obtained from thehuman subject that is higher than a control expression level of CCNE1.Alternatively, a compound of Formula (I) or of any of the formulas asdescribed herein, or a compound as recited in any of the claims anddescribed herein, or a salt thereof, can be used in conjunction withother agents or standard cancer treatments, as described below. In oneembodiment, the present disclosure provides a method for inhibitinggrowth of tumor cells in vitro. The method includes contacting the tumorcells in vitro with a compound of Formula (I) or of any of the formulasas described herein, or of a compound as recited in any of the claimsand described herein, or of a salt thereof. In another embodiment, thepresent disclosure provides a method for inhibiting growth of tumorcells with CCNE1 amplification and overexpression in an individual or apatient. The method includes administering to the individual or patientin need thereof a therapeutically effective amount of a compound ofFormula (I) or of any of the formulas as described herein, or of acompound as recited in any of the claims and described herein, or a saltor a stereoisomer thereof.

In some embodiments, provided herein is a method of inhibiting CDK2,comprising contacting the CDK2 with a compound of Formula (I) or any ofthe formulas as described herein, a compound as recited in any of theclaims and described herein, or a salt thereof. In some embodiments,provided herein is a method of inhibiting CDK2 in a patient, comprisingadministering to the patient a compound of Formula (I) or any of theformulas as described herein, a compound as recited in any of the claimsand described herein, or a salt thereof.

In some embodiments, provided herein is a method for treating cancer.The method includes administering to a patient (in need thereof), atherapeutically effective amount of a compound of Formula (I) or any ofthe formulas as described herein, a compound as recited in any of theclaims and described herein, or a salt thereof. In another embodiment,the cancer is characterized by amplification or overexpression of CCNE1.In some embodiments, the cancer is ovarian cancer or breast cancer,characterized by amplification or overexpression of CCNE1.

In some embodiments, provided herein is a method of treating a diseaseor disorder associated with CDK2 in a patient, comprising administeringto the patient a therapeutically effective amount of a compound ofFormula (I) or any of the formulas as described herein, a compound asrecited in any of the claims and described herein, or a salt thereof. Insome embodiments, the disease or disorder associated with CDK2 isassociated with an amplification of the cyclin E1 (CCNE1) gene and/oroverexpression of CCNE1.

In some embodiments, the disease or disorder associated with CDK2 isN-myc amplified neuroblastoma cells (see Molenaar, et al., Proc NatlAcad Sci USA 106(31): 12968-12973) K-Ras mutant lung cancers (see Hu,S., et al., Mol Cancer Ther, 2015. 14(11): 2576-85, and cancers withFBW7 mutation and CCNE1 overexpression (see Takada et al., Cancer Res,2017. 77(18): 4881-4893).

In some embodiments, the disease or disorder associated with CDK2 islung squamous cell carcinoma, lung adenocarcinoma, pancreaticadenocarcinoma, breast invasive carcinoma, uterine carcinosarcoma,ovarian serous cystadenocarcinoma, stomach adenocarcinoma, esophagealcarcinoma, bladder urothelial carcinoma, mesothelioma, or sarcoma.

In some embodiments, the disease or disorder associated with CDK2 islung adenocarcinoma, breast invasive carcinoma, uterine carcinosarcoma,ovarian serous cystadenocarcinoma, or stomach adenocarcinoma.

In some embodiments, the disease or disorder associated with CDK2 is anadenocarcinoma, carcinoma, or cystadenocarcinoma.

In some embodiments, the disease or disorder associated with CDK2 isuterine cancer, ovarian cancer, stomach cancer, esophageal cancer, lungcancer, bladder cancer, pancreatic cancer, or breast cancer.

In some embodiments, the disease or disorder associated with CDK2 is acancer.

In some embodiments, the cancer is characterized by amplification oroverexpression of CCNE1. In some embodiments, the cancer is ovariancancer or breast cancer, characterized by amplification oroverexpression of CCNE1.

In some embodiments, the breast cancer is chemotherapy or radiotherapyresistant breast cancer, endocrine resistant breast cancer, trastuzumabresistant breast cancer, or breast cancer demonstrating primary oracquired resistance to CDK4/6 inhibition. In some embodiments, thebreast cancer is advanced or metastatic breast cancer.

Examples of cancers that are treatable using the compounds of thepresent disclosure include, but are not limited to, bone cancer,pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous orintraocular malignant melanoma, uterine cancer, ovarian cancer, rectalcancer, cancer of the anal region, stomach cancer, testicular cancer,uterine cancer, carcinoma of the fallopian tubes, carcinoma of theendometrium, endometrial cancer, carcinoma of the cervix, carcinoma ofthe vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin'slymphoma, cancer of the esophagus, cancer of the small intestine, cancerof the endocrine system, cancer of the thyroid gland, cancer of theparathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue,cancer of the urethra, cancer of the penis, chronic or acute leukemiasincluding acute myeloid leukemia, chronic myeloid leukemia, acutelymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors ofchildhood, lymphocytic lymphoma, cancer of the bladder, cancer of thekidney or urethra, carcinoma of the renal pelvis, neoplasm of thecentral nervous system (CNS), primary CNS lymphoma, tumor angiogenesis,spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi'ssarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma,environmentally induced cancers including those induced by asbestos, andcombinations of said cancers. The compounds of the present disclosureare also useful for the treatment of metastatic cancers.

In some embodiments, cancers treatable with compounds of the presentdisclosure include melanoma (e.g., metastatic malignant melanoma, BRAFand HSP90 inhibition-resistant melanoma), renal cancer (e.g., clear cellcarcinoma), prostate cancer (e.g., hormone refractory prostateadenocarcinoma), breast cancer, colon cancer, lung cancer (e.g.,non-small cell lung cancer and small cell lung cancer), squamous cellhead and neck cancer, urothelial cancer (e.g., bladder) and cancers withhigh microsatellite instability (MSI^(high)). Additionally, thedisclosure includes refractory or recurrent malignancies whose growthmay be inhibited using the compounds of the disclosure.

In some embodiments, cancers that are treatable using the compounds ofthe present disclosure include, but are not limited to, solid tumors(e.g., prostate cancer, colon cancer, esophageal cancer, endometrialcancer, ovarian cancer, uterine cancer, renal cancer, hepatic cancer,pancreatic cancer, gastric cancer, breast cancer, lung cancer, cancersof the head and neck, thyroid cancer, glioblastoma, sarcoma, bladdercancer, etc.), hematological cancers (e.g., lymphoma, leukemia such asacute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML),chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML),DLBCL, mantle cell lymphoma, Non-Hodgkin lymphoma (including follicularlymphoma, including relapsed or refractory NHL and recurrentfollicular), Hodgkin lymphoma or multiple myeloma) and combinations ofsaid cancers.

In some embodiments, cancers that are treatable using the compounds ofthe present disclosure include, but are not limited to,cholangiocarcinoma, bile duct cancer, triple negative breast cancer,rhabdomyosarcoma, small cell lung cancer, leiomyosarcoma, hepatocellularcarcinoma, Ewing's sarcoma, brain cancer, brain tumor, astrocytoma,neuroblastoma, neurofibroma, basal cell carcinoma, chondrosarcoma,epithelioid sarcoma, eye cancer, Fallopian tube cancer, gastrointestinalcancer, gastrointestinal stromal tumors, hairy cell leukemia, intestinalcancer, islet cell cancer, oral cancer, mouth cancer, throat cancer,laryngeal cancer, lip cancer, mesothelioma, neck cancer, nasal cavitycancer, ocular cancer, ocular melanoma, pelvic cancer, rectal cancer,renal cell carcinoma, salivary gland cancer, sinus cancer, spinalcancer, tongue cancer, tubular carcinoma, urethral cancer, and ureteralcancer.

In some embodiments, the compounds of the present disclosure can be usedto treat sickle cell disease and sickle cell anemia.

In some embodiments, diseases and indications that are treatable usingthe compounds of the present disclosure include, but are not limited tohematological cancers, sarcomas, lung cancers, gastrointestinal cancers,genitourinary tract cancers, liver cancers, bone cancers, nervous systemcancers, gynecological cancers, and skin cancers.

Exemplary hematological cancers include lymphomas and leukemias such asacute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML),acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL),chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma(DLBCL), mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsedor refractory NHL and recurrent follicular), Hodgkin lymphoma,myeloproliferative diseases (e.g., primary myelofibrosis (PMF),polycythemia vera (PV), and essential thrombocytosis (ET)),myelodysplasia syndrome (MDS), T-cell acute lymphoblastic lymphoma(T-ALL) and multiple myeloma (MM).

Exemplary sarcomas include chondrosarcoma, Ewing's sarcoma,osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma,myxoma, rhabdomyoma, rhapdosarcoma, fibroma, lipoma, harmatoma, andteratoma.

Exemplary lung cancers include non-small cell lung cancer (NSCLC), smallcell lung cancer (SCLC), bronchogenic carcinoma, squamous cell,undifferentiated small cell, undifferentiated large cell,adenocarcinoma, alveolar (bronchiolar) carcinoma, bronchial adenoma,chondromatous hamartoma, and mesothelioma.

Exemplary gastrointestinal cancers include cancers of the esophagus(squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma),stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductaladenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors,vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors,Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma),large bowel (adenocarcinoma, tubular adenoma, villous adenoma,hamartoma, leiomyoma), and colorectal cancer.

Exemplary genitourinary tract cancers include cancers of the kidney(adenocarcinoma, Wilm's tumor [nephroblastoma]), bladder and urethra(squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma),prostate (adenocarcinoma, sarcoma), and testis (seminoma, teratoma,embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma,interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors,lipoma).

Exemplary liver cancers include hepatoma (hepatocellular carcinoma),cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellularadenoma, and hemangioma.

Exemplary bone cancers include, for example, osteogenic sarcoma(osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma,chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cellsarcoma), multiple myeloma, malignant giant cell tumor chordoma,osteochrondroma (osteocartilaginous exostoses), benign chondroma,chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant celltumors Exemplary nervous system cancers include cancers of the skull(osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges(meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma,medulloblastoma, glioma, ependymoma, germinoma (pinealoma),glioblastoma, glioblastoma multiform, oligodendroglioma, schwannoma,retinoblastoma, congenital tumors), and spinal cord (neurofibroma,meningioma, glioma, sarcoma), as well as neuroblastoma andLhermitte-Duclos disease.

Exemplary gynecological cancers include cancers of the uterus(endometrial carcinoma), cervix (cervical carcinoma, pre-tumor cervicaldysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma,mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecalcell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignantteratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma,adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma,squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma),and fallopian tubes (carcinoma).

Exemplary skin cancers include melanoma, basal cell carcinoma, Merkelcell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, molesdysplastic nevi, lipoma, angioma, dermatofibroma, and keloids. In someembodiments, diseases and indications that are treatable using thecompounds of the present disclosure include, but are not limited to,sickle cell disease (e.g., sickle cell anemia), triple-negative breastcancer (TNBC), myelodysplastic syndromes, testicular cancer, bile ductcancer, esophageal cancer, and urothelial carcinoma.

It is believed that compounds of Formula (I), or any of the embodimentsthereof, may possess satisfactory pharmacological profile and promisingbiopharmaceutical properties, such as toxicological profile, metabolismand pharmacokinetic properties, solubility, and permeability. It will beunderstood that determination of appropriate biopharmaceuticalproperties is within the knowledge of a person skilled in the art, e.g.,determination of cytotoxicity in cells or inhibition of certain targetsor channels to determine potential toxicity.

The terms “individual”, “patient,” and “subject” used interchangeably,refer to any animal, including mammals, preferably mice, rats, otherrodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates,and most preferably humans.

The phrase “therapeutically effective amount” refers to the amount ofactive compound or pharmaceutical agent that elicits the biological ormedicinal response in a tissue, system, animal, individual or human thatis being sought by a researcher, veterinarian, medical doctor or otherclinician.

As used herein, the term “treating” or “treatment” refers to one or moreof (1) inhibiting the disease; e.g., inhibiting a disease, condition ordisorder in an individual who is experiencing or displaying thepathology or symptomatology of the disease, condition or disorder (i.e.,arresting further development of the pathology and/or symptomatology);and (2) ameliorating the disease; e.g., ameliorating a disease,condition or disorder in an individual who is experiencing or displayingthe pathology or symptomatology of the disease, condition or disorder(i.e., reversing the pathology and/or symptomatology) such as decreasingthe severity of disease.

In some embodiments, the compounds of the invention are useful inpreventing or reducing the risk of developing any of the diseasesreferred to herein; e.g., preventing or reducing the risk of developinga disease, condition or disorder in an individual who may be predisposedto the disease, condition or disorder but does not yet experience ordisplay the pathology or symptomatology of the disease.

Combination Therapies I. Cancer Therapies

Cancer cell growth and survival can be impacted by dysfunction inmultiple signaling pathways. Thus, it is useful to combine differentenzyme/protein/receptor inhibitors, exhibiting different preferences inthe targets which they modulate the activities of, to treat suchconditions. Targeting more than one signaling pathway (or more than onebiological molecule involved in a given signaling pathway) may reducethe likelihood of drug-resistance arising in a cell population, and/orreduce the toxicity of treatment.

One or more additional pharmaceutical agents such as, for example,chemotherapeutics, anti-inflammatory agents, steroids,immunosuppressants, immune-oncology agents, metabolic enzyme inhibitors,chemokine receptor inhibitors, and phosphatase inhibitors, as well astargeted therapies such as Bcr-Abl, Flt-3, EGFR, HER2, JAK, c-MET,VEGFR, PDGFR, c-Kit, IGF-1R, RAF, FAK, and CDK4/6 kinase inhibitors suchas, for example, those described in WO 2006/056399 can be used incombination with the compounds of the present disclosure for treatmentof CDK2-associated diseases, disorders or conditions. Other agents suchas therapeutic antibodies can be used in combination with the compoundsof the present disclosure for treatment of CDK2-associated diseases,disorders or conditions. The one or more additional pharmaceuticalagents can be administered to a patient simultaneously or sequentially.

In some embodiments, the CDK2 inhibitor is administered or used incombination with a BCL2 inhibitor or a CDK4/6 inhibitor.

The compounds as disclosed herein can be used in combination with one ormore other enzyme/protein/receptor inhibitors therapies for thetreatment of diseases, such as cancer and other diseases or disordersdescribed herein. Examples of diseases and indications treatable withcombination therapies include those as described herein. Examples ofcancers include solid tumors and non-solid tumors, such as liquidtumors, and blood cancers. Examples of infections include viralinfections, bacterial infections, fungus infections or parasiteinfections. For example, the compounds of the present disclosure can becombined with one or more inhibitors of the following kinases for thetreatment of cancer: Akt1, Akt2, Akt3, BCL2, CDK4/6, TGF-βR, PKA, PKG,PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR,HER2, HER3, HER4, INS-R, IDH2, IGF-1R, IR-R, PDGFαR, PDGFβR, PI3K(alpha, beta, gamma, delta, and multiple or selective), CSF1R, KIT,FLK-II, KDR/FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met,PARP, Ron, Sea, TRKA, TRKB, TRKC, TAM kinases (Axl, Mer, Tyro3), FLT3,VEGFR/Flt2, Flt4, EphA1, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn,Lck, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. In someembodiments, the compounds of the present disclosure can be combinedwith one or more of the following inhibitors for the treatment of canceror infections. Non-limiting examples of inhibitors that can be combinedwith the compounds of the present disclosure for treatment of cancer andinfections include an FGFR inhibitor (FGFR1, FGFR2, FGFR3 or FGFR4,e.g., pemigatinib (INCB54828), INCB62079), an EGFR inhibitor (also knownas ErB-1 or HER-1; e.g., erlotinib, gefitinib, vandetanib, orsimertinib,cetuximab, necitumumab, or panitumumab), a VEGFR inhibitor or pathwayblocker (e.g. bevacizumab, pazopanib, sunitinib, sorafenib, axitinib,regorafenib, ponatinib, cabozantinib, vandetanib, ramucirumab,lenvatinib, ziv-aflibercept), a PARP inhibitor (e.g., olaparib,rucaparib, veliparib or niraparib), a JAK inhibitor (JAK1 and/or JAK2,e.g., ruxolitinib or baricitinib; JAK1, e.g., itacitinib (INCB39110),INCB052793, or INCB054707), an IDO inhibitor (e.g., epacadostat, NLG919,or BMS-986205, MK7162), an LSD1 inhibitor (e.g., GSK2979552, INCB59872and INCB60003), a TDO inhibitor, a PI3K-delta inhibitor (e.g.,parsaclisib (INCB50465) or INCB50797), a PI3K-gamma inhibitor such asPI3K-gamma selective inhibitor, a Pim inhibitor (e.g., INCB53914), aCSF1R inhibitor, a TAM receptor tyrosine kinases (Tyro-3, Axl, and Mer;e.g., INCB081776), an adenosine receptor antagonist (e.g., A2a/A2breceptor antagonist), an HIPK1 inhibitor, a chemokine receptor inhibitor(e.g., CCR2 or CCR5 inhibitor), a SHP1/2 phosphatase inhibitor, ahistone deacetylase inhibitor (HDAC) such as an HDAC8 inhibitor, anangiogenesis inhibitor, an interleukin receptor inhibitor, bromo andextra terminal family members inhibitors (for example, bromodomaininhibitors or BET inhibitors such as INCB54329 and INCB57643), c-METinhibitors (e.g., capmatinib), an anti-CD19 antibody (e.g.,tafasitamab), an ALK2 inhibitor (e.g., INCB00928); or combinationsthereof.

In some embodiments, the compound or salt described herein isadministered with a PI3Kδ inhibitor. In some embodiments, the compoundor salt described herein is administered with a JAK inhibitor. In someembodiments, the compound or salt described herein is administered witha JAK1 or JAK2 inhibitor (e.g., baricitinib or ruxolitinib). In someembodiments, the compound or salt described herein is administered witha JAK1 inhibitor. In some embodiments, the compound or salt describedherein is administered with a JAK1, inhibitor, which is selective overJAK2.

Example antibodies for use in combination therapy include, but are notlimited to, trastuzumab (e.g., anti-HER2), ranibizumab (e.g.,anti-VEGF-A), bevacizumab (AVASTIN™ e.g., anti-VEGF), panitumumab (e.g.,anti-EGFR), cetuximab (e.g., anti-EGFR), rituxan (e.g., anti-CD20), andantibodies directed to c-MET.

One or more of the following agents may be used in combination with thecompounds of the present disclosure and are presented as a non-limitinglist: a cytostatic agent, cisplatin, doxorubicin, taxotere, taxol,etoposide, irinotecan, camptosar, topotecan, paclitaxel, docetaxel,epothilones, tamoxifen, 5-fluorouracil, methotrexate, temozolomide,cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, IRESSA™(gefitinib), TARCEVA™ (erlotinib), antibodies to EGFR, intron, ara-C,adriamycin, cytoxan, gemcitabine, uracil mustard, chlormethine,ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine,triethylenethiophosphoramine, busulfan, carmustine, lomustine,streptozocin, dacarbazine, floxuridine, cytarabine, 6-mercaptopurine,6-thioguanine, fludarabine phosphate, oxaliplatin, leucovirin, ELOXATIN™(oxaliplatin), pentostatine, vinblastine, vincristine, vindesine,bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin,idarubicin, mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase,teniposide, 17-alpha-ethinylestradiol, diethylstilbestrol, testosterone,prednisone, fluoxymesterone, dromostanolone propionate, testolactone,megestrolacetate, methylprednisolone, methyltestosterone, prednisolone,triamcinolone, chlorotrianisene, hydroxyprogesterone, aminoglutethimide,estramustine, medroxyprogesterone acetate, leuprolide, flutamide,toremifene, goserelin, carboplatin, hydroxyurea, amsacrine,procarbazine, mitotane, mitoxantrone, levamisole, navelbene,anastrazole, letrazole, capecitabine, reloxafine, droloxafine,hexamethylmelamine, avastin, HERCEPTIN™ (trastuzumab), BEXXAR™(tositumomab), VELCADE™ (bortezomib), ZEVALIN™ (ibritumomab tiuxetan),TRISENOX™ (arsenic trioxide), XELODA™ (capecitabine), vinorelbine,porfimer, ERBITUX™ (cetuximab), thiotepa, altretamine, melphalan,trastuzumab, lerozole, fulvestrant, exemestane, ifosfomide, rituximab,C225 (cetuximab), Campath (alemtuzumab), clofarabine, cladribine,aphidicolon, rituxan, sunitinib, dasatinib, tezacitabine, Sml1,fludarabine, pentostatin, triapine, didox, trimidox, amidox, 3-AP, andMDL-101,731.

The compounds of the present disclosure can further be used incombination with other methods of treating cancers, for example bychemotherapy, irradiation therapy, tumor-targeted therapy, adjuvanttherapy, immunotherapy or surgery. Examples of immunotherapy includecytokine treatment (e.g., interferons, GM-CSF, G-CSF, IL-2), CRS-207immunotherapy, cancer vaccine, monoclonal antibody, bispecific ormulti-specific antibody, antibody drug conjugate, adoptive T celltransfer, Toll receptor agonists, RIG-I agonists, oncolytic virotherapyand immunomodulating small molecules, including thalidomide or JAK1/2inhibitor, PI3Kδ inhibitor and the like. The compounds can beadministered in combination with one or more anti-cancer drugs, such asa chemotherapeutic agent. Examples of chemotherapeutics include any ofabarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol,altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine,bevacizumab, bexarotene, baricitinib, bleomycin, bortezomib, busulfanintravenous, busulfan oral, calusterone, capecitabine, carboplatin,carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine,cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparinsodium, dasatinib, daunorubicin, decitabine, denileukin, denileukindiftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolonepropionate, eculizumab, epirubicin, erlotinib, estramustine, etoposidephosphate, etoposide, exemestane, fentanyl citrate, filgrastim,floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib,gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelinacetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinibmesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate,lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole,lomustine, mechlorethamine, megestrol acetate, melphalan,mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane,mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab,oxaliplatin, paclitaxel, pamidronate, panitumumab, pegaspargase,pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin,procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib,sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen,temozolomide, teniposide, testolactone, thalidomide, thioguanine,thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin,uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine,vorinostat, and zoledronate.

Additional examples of chemotherapeutics include proteasome inhibitors(e.g., bortezomib), thalidomide, revlimid, and DNA-damaging agents suchas melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide,carmustine, and the like.

Example steroids include corticosteroids such as dexamethasone orprednisone.

Example Bcr-Abl inhibitors include imatinib mesylate (GLEEVAC™),nilotinib, dasatinib, bosutinib, and ponatinib, and pharmaceuticallyacceptable salts. Other example suitable Bcr-Abl inhibitors include thecompounds, and pharmaceutically acceptable salts thereof, of the generaand species disclosed in U.S. Pat. No. 5,521,184, WO 04/005281, and U.S.Ser. No. 60/578,491.

Example suitable Flt-3 inhibitors include midostaurin, lestaurtinib,linifanib, sunitinib, sunitinib, maleate, sorafenib, quizartinib,crenolanib, pacritinib, tandutinib, PLX3397 and ASP2215, and theirpharmaceutically acceptable salts. Other example suitable Flt-3inhibitors include compounds, and their pharmaceutically acceptablesalts, as disclosed in WO 03/037347, WO 03/099771, and WO 04/046120.

Example suitable RAF inhibitors include dabrafenib, sorafenib, andvemurafenib, and their pharmaceutically acceptable salts. Other examplesuitable RAF inhibitors include compounds, and their pharmaceuticallyacceptable salts, as disclosed in WO 00/09495 and WO 05/028444.

Example suitable FAK inhibitors include VS-4718, VS-5095, VS-6062,VS-6063, BI853520, and GSK2256098, and their pharmaceutically acceptablesalts. Other example suitable FAK inhibitors include compounds, andtheir pharmaceutically acceptable salts, as disclosed in WO 04/080980,WO 04/056786, WO 03/024967, WO 01/064655, WO 00/053595, and WO01/014402.

Example suitable CDK4/6 inhibitors include palbociclib, ribociclib,trilaciclib, lerociclib, and abemaciclib, and their pharmaceuticallyacceptable salts. Other example suitable CDK4/6, inhibitors includecompounds, and their pharmaceutically acceptable salts, as disclosed inWO 09/085185, WO 12/129344, WO 11/101409, WO 03/062236, WO 10/075074,and WO 12/061156.

In some embodiments, the compounds of the disclosure can be used incombination with one or more other kinase inhibitors including imatinib,particularly for treating patients resistant to imatinib or other kinaseinhibitors.

In some embodiments, the compounds of the disclosure can be used incombination with a chemotherapeutic in the treatment of cancer, and mayimprove the treatment response as compared to the response to thechemotherapeutic agent alone, without exacerbation of its toxic effects.In some embodiments, the compounds of the disclosure can be used incombination with a chemotherapeutic provided herein. For example,additional pharmaceutical agents used in the treatment of multiplemyeloma, can include, without limitation, melphalan, melphalan plusprednisone [MP], doxorubicin, dexamethasone, and Velcade (bortezomib).Further additional agents used in the treatment of multiple myelomainclude Bcr-Abl, Flt-3, RAF and FAK kinase inhibitors. In someembodiments, the agent is an alkylating agent, a proteasome inhibitor, acorticosteroid, or an immunomodulatory agent. Examples of an alkylatingagent include cyclophosphamide (CY), melphalan (MEL), and bendamustine.In some embodiments, the proteasome inhibitor is carfilzomib. In someembodiments, the corticosteroid is dexamethasone (DEX). In someembodiments, the immunomodulatory agent is lenalidomide (LEN) orpomalidomide (POM). Additive or synergistic effects are desirableoutcomes of combining a CDK2 inhibitor of the present disclosure with anadditional agent.

The agents can be combined with the present compound in a single orcontinuous dosage form, or the agents can be administered simultaneouslyor sequentially as separate dosage forms.

The compounds of the present disclosure can be used in combination withone or more other inhibitors or one or more therapies for the treatmentof infections. Examples of infections include viral infections,bacterial infections, fungus infections or parasite infections.

In some embodiments, a corticosteroid such as dexamethasone isadministered to a patient in combination with the compounds of thedisclosure where the dexamethasone is administered intermittently asopposed to continuously.

The compounds of Formula (I) or any of the formulas as described herein,a compound as recited in any of the claims and described herein, orsalts thereof can be combined with another immunogenic agent, such ascancerous cells, purified tumor antigens (including recombinantproteins, peptides, and carbohydrate molecules), cells, and cellstransfected with genes encoding immune stimulating cytokines.Non-limiting examples of tumor vaccines that can be used includepeptides of melanoma antigens, such as peptides of gp100, MAGE antigens,Trp-2, MARTI and/or tyrosinase, or tumor cells transfected to expressthe cytokine GM-CSF.

The compounds of Formula (I) or any of the formulas as described herein,a compound as recited in any of the claims and described herein, orsalts thereof can be used in combination with a vaccination protocol forthe treatment of cancer. In some embodiments, the tumor cells aretransduced to express GM-CSF. In some embodiments, tumor vaccinesinclude the proteins from viruses implicated in human cancers such asHuman Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) andKaposi's Herpes Sarcoma Virus (KHSV). In some embodiments, the compoundsof the present disclosure can be used in combination with tumor specificantigen such as heat shock proteins isolated from tumor tissue itself.In some embodiments, the compounds of Formula (I) or any of the formulasas described herein, a compound as recited in any of the claims anddescribed herein, or salts thereof can be combined with dendritic cellsimmunization to activate potent anti-tumor responses.

The compounds of the present disclosure can be used in combination withbispecific macrocyclic peptides that target Fe alpha or Fe gammareceptor-expressing effectors cells to tumor cells. The compounds of thepresent disclosure can also be combined with macrocyclic peptides thatactivate host immune responsiveness.

In some further embodiments, combinations of the compounds of thedisclosure with other therapeutic agents can be administered to apatient prior to, during, and/or after a bone marrow transplant or stemcell transplant. The compounds of the present disclosure can be used incombination with bone marrow transplant for the treatment of a varietyof tumors of hematopoietic origin.

The compounds of Formula (I) or any of the formulas as described herein,a compound as recited in any of the claims and described herein, orsalts thereof can be used in combination with vaccines, to stimulate theimmune response to pathogens, toxins, and self-antigens. Examples ofpathogens for which this therapeutic approach may be particularly usefulinclude pathogens for which there is currently no effective vaccine, orpathogens for which conventional vaccines are less than completelyeffective. These include, but are not limited to, HIV, Hepatitis (A, B,& C), Influenza, Herpes, Giardia, Malaria, Leishmania, Staphylococcusaureus, Pseudomonas Aeruginosa.

Viruses causing infections treatable by methods of the presentdisclosure include, but are not limited to human papillomavirus,influenza, hepatitis A, B, C or D viruses, adenovirus, poxvirus, herpessimplex viruses, human cytomegalovirus, severe acute respiratorysyndrome virus, Ebola virus, measles virus, herpes virus (e.g., VZV,HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus), flaviviruses,echovirus, rhinovirus, coxsackie virus, cornavirus, respiratorysyncytial virus, mumps virus, rotavirus, measles virus, rubella virus,parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus,molluscum virus, poliovirus, rabies virus, JC virus and arboviralencephalitis virus.

Pathogenic bacteria causing infections treatable by methods of thedisclosure include, but are not limited to, chlamydia, rickettsialbacteria, mycobacteria, staphylococci, streptococci, pneumococci,meningococci and conococci, klebsiella, proteus, serratia, pseudomonas,legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism,anthrax, plague, leptospirosis, and Lyme's disease bacteria.

Pathogenic fungi causing infections treatable by methods of thedisclosure include, but are not limited to, Candida (albicans, krusei,glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus(fumigatus, niger, etc.), Genus Mucorales (mucor, absidia, rhizophus),Sporothrix schenkii, Blastomyces dermatitidis, Paracoccidioidesbrasiliensis, Coccidioides immitis and Histoplasma capsulatum.

Pathogenic parasites causing infections treatable by methods of thedisclosure include, but are not limited to, Entamoeba histolytica,Balantidium coli, Naegleriafowleri, Acanthamoeba, sp., Giardia lambia,Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesiamicroti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani,Toxoplasma gondi, and Nippostrongylus brasiliensis.

When more than one pharmaceutical agent is administered to a patient,they can be administered simultaneously, separately, sequentially, or incombination (e.g., for more than two agents).

Methods for the safe and effective administration of most of thesechemotherapeutic agents are known to those skilled in the art. Inaddition, their administration is described in the standard literature.For example, the administration of many of the chemotherapeutic agentsis described in the “Physicians' Desk Reference” (PDR, e.g., 1996edition, Medical Economics Company, Montvale, N.J.), the disclosure ofwhich is incorporated herein by reference as if set forth in itsentirety.

II. Immune-Checkpoint Therapies

Compounds of the present disclosure can be used in combination with oneor more immune checkpoint inhibitors for the treatment of diseases, suchas cancer or infections. Exemplary immune checkpoint inhibitors includeinhibitors against immune checkpoint molecules such as CBL-B, CD20,CD28, CD40, CD70, CD122, CD96, CD73, CD47, CDK2 GITR, CSF1R, JAK, PI3Kdelta, PI3K gamma, TAM, arginase, HPK1, CD137 (also known as 4-1BB),ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, TLR (TLR7/8), TIGIT,CD112R, VISTA, PD-1, PD-L1 and PD-L2. In some embodiments, the immunecheckpoint molecule is a stimulatory checkpoint molecule selected fromCD27, CD28, CD40, ICOS, OX40, GITR and CD137. In some embodiments, theimmune checkpoint molecule is an inhibitory checkpoint molecule selectedfrom A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3,TIGIT, and VISTA. In some embodiments, the compounds provided herein canbe used in combination with one or more agents selected from KIRinhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4inhibitors and TGFR beta inhibitors.

In some embodiments, the compounds provided herein can be used incombination with one or more agonists of immune checkpoint molecules,e.g., OX40, CD27, GITR, and CD137 (also known as 4-1BB).

In some embodiments, the inhibitor of an immune checkpoint molecule isanti-PD1 antibody, anti-PD-L1 antibody, or anti-CTLA-4 antibody.

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of PD-1 or PD-L1, e.g., an anti-PD-1 or anti-PD-L1monoclonal antibody. In some embodiments, the anti-PD-1 or anti-PD-L1antibody is nivolumab, pembrolizumab, atezolizumab, durvalumab,avelumab, cemiplimab, atezolizumab, avelumab, tislelizumab,spartalizumab (PDR001), cetrelimab (JNJ-63723283), toripalimab (JS001),camrelizumab (SHR-1210), sintilimab (IBI308), AB122 (GLS-010), AMP-224,AMP-514/MEDI-0680, BMS936559, JTX-4014, BGB-108, SHR-1210, MEDI4736,FAZ053, BCD-100, KN035, CS1001, BAT1306, LZM009, AK105, HLX10, SHR-1316,CBT-502 (TQB2450), A167 (KL-A167), STI-A101 (ZKAB001), CK-301, BGB-A333,MSB-2311, HLX20, TSR-042, or LY3300054. In some embodiments, theinhibitor of PD-1 or PD-L1 is one disclosed in U.S. Pat. Nos. 7,488,802,7,943,743, 8,008,449, 8,168,757, 8,217, 149, WO 03042402, WO 2008156712,WO 2010089411, WO 2010036959, WO 2011066342, WO 2011159877, WO2011082400, or WO 2011161699, which are each incorporated herein byreference in its entirety.

In some embodiments, the antibody is an anti-PD-1 antibody, e.g., ananti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1antibody is nivolumab, pembrolizumab, cemiplimab, spartalizumab,camrelizumab, cetrelimab, toripalimab, sintilimab, AB122, AMP-224,JTX-4014, BGB-108, BCD-100, BAT1306, LZM009, AK105, HLX10, or TSR-042.In some embodiments, the anti-PD-1 antibody is nivolumab, pembrolizumab,cemiplimab, spartalizumab, camrelizumab, cetrelimab, toripalimab, orsintilimab. In some embodiments, the anti-PD-1 antibody ispembrolizumab. In some embodiments, the anti-PD-1, antibody isnivolumab. In some embodiments, the anti-PD-1 antibody is cemiplimab. Insome embodiments, the anti-PD-1 antibody is spartalizumab. In someembodiments, the anti-PD-1, antibody is camrelizumab. In someembodiments, the anti-PD-1 antibody is cetrelimab. In some embodiments,the anti-PD-1 antibody is toripalimab. In some embodiments, theanti-PD-1, antibody is sintilimab. In some embodiments, the anti-PD-1antibody is AB122. In some embodiments, the anti-PD-1 antibody isAMP-224. In some embodiments, the anti-PD-1, antibody is JTX-4014. Insome embodiments, the anti-PD-1 antibody is BGB-108. In someembodiments, the anti-PD-1 antibody is BCD-100. In some embodiments, theanti-PD-1, antibody is BAT1306. In some embodiments, the anti-PD-1antibody is LZM009. In some embodiments, the anti-PD-1 antibody isAK105. In some embodiments, the anti-PD-1 antibody is HLX10. In someembodiments, the anti-PD-1 antibody is TSR-042. In some embodiments, theanti-PD-1 monoclonal antibody is nivolumab or pembrolizumab. In someembodiments, the anti-PD-1 monoclonal antibody is MGA012. In someembodiments, the anti-PD1 antibody is SHR-1210. Other anti-canceragent(s) include antibody therapeutics such as 4-1BB (e.g., urelumab,utomilumab). In some embodiments, the inhibitor of an immune checkpointmolecule is an inhibitor of PD-L1, e.g., an anti-PD-L1 monoclonalantibody. In some embodiments, the anti-PD-L1 monoclonal antibody isatezolizumab, avelumab, durvalumab, tislelizumab, BMS-935559, MEDI4736,atezolizumab (MPDL3280A; also known as RG7446), avelumab (MSB0010718C),FAZ053, KN035, CS1001, SHR-1316, CBT-502, A167, STI-A101, CK-301,BGB-A333, MSB-2311, HLX20, or LY3300054. In some embodiments, theanti-PD-L1, antibody is atezolizumab, avelumab, durvalumab, ortislelizumab. In some embodiments, the anti-PD-L1 antibody isatezolizumab. In some embodiments, the anti-PD-L1 antibody is avelumab.In some embodiments, the anti-PD-L1 antibody is durvalumab. In someembodiments, the anti-PD-L1 antibody is tislelizumab. In someembodiments, the anti-PD-L1, antibody is BMS-935559. In someembodiments, the anti-PD-L1 antibody is MEDI4736. In some embodiments,the anti-PD-L1 antibody is FAZ053. In some embodiments, the anti-PD-L1,antibody is KN035. In some embodiments, the anti-PD-L1 antibody isCS1001. In some embodiments, the anti-PD-L1 antibody is SHR-1316. Insome embodiments, the anti-PD-L1, antibody is CBT-502. In someembodiments, the anti-PD-L1 antibody is A167. In some embodiments, theanti-PD-L1 antibody is STI-A101. In some embodiments, the anti-PD-L1,antibody is CK-301. In some embodiments, the anti-PD-L1 antibody isBGB-A333. In some embodiments, the anti-PD-L1 antibody is MSB-2311. Insome embodiments, the anti-PD-L1, antibody is HLX20. In someembodiments, the anti-PD-L1 antibody is LY3300054.

In some embodiments, the inhibitor of an immune checkpoint molecule is asmall molecule that binds to PD-L1, or a pharmaceutically acceptablesalt thereof. In some embodiments, the inhibitor of an immune checkpointmolecule is a small molecule that binds to and internalizes PD-L1, or apharmaceutically acceptable salt thereof. In some embodiments, theinhibitor of an immune checkpoint molecule is a compound selected fromthose in US 2018/0179201, US 2018/0179197, US 2018/0179179, US2018/0179202, US 2018/0177784, US 2018/0177870, U.S. Ser. No. 16/369,654(filed Mar. 29, 2019), and U.S. Ser. No. 62/688,164, or apharmaceutically acceptable salt thereof, each of which is incorporatedherein by reference in its entirety.

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of KIR, TIGIT, LAIR1, CD160, 2B4 and TGFR beta.

In some embodiments, the inhibitor is MCLA-145.

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In someembodiments, the anti-CTLA-4 antibody is ipilimumab, tremelimumab,AGEN1884, or CP-675,206.

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of LAG3, e.g., an anti-LAG3 antibody. In some embodiments,the anti-LAG3 antibody is BMS-986016, LAG525, INCAGN2385, or eftilagimodalpha (IMP321).

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of CD73. In some embodiments, the inhibitor of CD73 isoleclumab.

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of TIGIT. In some embodiments, the inhibitor of TIGIT isOMP-31M32.

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of VISTA. In some embodiments, the inhibitor of VISTA isJNJ-61610588 or CA-170.

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of B7-H3. In some embodiments, the inhibitor of B7-H3 isenoblituzumab, MGD009, or 8H9.

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of KIR. In some embodiments, the inhibitor of KIR islirilumab or IPH4102.

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of A2aR. In some embodiments, the inhibitor of A2aR isCPI-444.

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of TGF-beta. In some embodiments, the inhibitor of TGF-betais trabedersen, galusertinib, or M7824.

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of PI3K-gamma. In some embodiments, the inhibitor ofPI3K-gamma is IPI-549.

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of CD47. In some embodiments, the inhibitor of CD47 isHu5F9-G4 or TTI-621.

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of CD73. In some embodiments, the inhibitor of CD73 isMEDI9447.

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of CD70. In some embodiments, the inhibitor of CD70 iscusatuzumab or BMS-936561.

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of TIM3, e.g., an anti-TIM3 antibody. In some embodiments,the anti-TIM3 antibody is INCAGN2390, MBG453, or TSR-022.

In some embodiments, the inhibitor of an immune checkpoint molecule isan inhibitor of CD20, e.g., an anti-CD20 antibody. In some embodiments,the anti-CD20 antibody is obinutuzumab or rituximab.

In some embodiments, the agonist of an immune checkpoint molecule is anagonist of OX40, CD27, CD28, GITR, ICOS, CD40, TLR7/8, and CD137 (alsoknown as 4-1BB).

In some embodiments, the agonist of CD137 is urelumab. In someembodiments, the agonist of CD137 is utomilumab.

In some embodiments, the agonist of an immune checkpoint molecule is aninhibitor of GITR. In some embodiments, the agonist of GITR is TRX518,MK-4166, INCAGN1876, MK-1248, AMG228, BMS-986156, GWN323, MEDI1873, orMEDI6469. In some embodiments, the agonist of an immune checkpointmolecule is an agonist of OX40, e.g., OX40 agonist antibody or OX40Lfusion protein. In some embodiments, the anti-OX40 antibody isINCAGN01949, MEDI0562 (tavolimab), MOXR-0916, PF-04518600, GSK3174998,BMS-986178, or 9B12. In some embodiments, the OX40L fusion protein isMEDI6383.

In some embodiments, the agonist of an immune checkpoint molecule is anagonist of CD40. In some embodiments, the agonist of CD40 is CP-870893,ADC-1013, CDX-1140, SEA-CD40, RO7009789, JNJ-64457107, APX-005M, or ChiLob 7/4.

In some embodiments, the agonist of an immune checkpoint molecule is anagonist of ICOS. In some embodiments, the agonist of ICOS isGSK-3359609, JTX-2011, or MEDI-570.

In some embodiments, the agonist of an immune checkpoint molecule is anagonist of CD28. In some embodiments, the agonist of CD28 istheralizumab.

In some embodiments, the agonist of an immune checkpoint molecule is anagonist of CD27. In some embodiments, the agonist of CD27 is varlilumab.

In some embodiments, the agonist of an immune checkpoint molecule is anagonist of TLR7/8. In some embodiments, the agonist of TLR7/8 isMEDI9197.

The compounds of the present disclosure can be used in combination withbispecific antibodies. In some embodiments, one of the domains of thebispecific antibody targets PD-1, PD-L1, CTLA-4, GITR, OX40, TIM3, LAG3,CD137, ICOS, CD3 or TGFβ receptor. In some embodiments, the bispecificantibody binds to PD-1 and PD-L1. In some embodiments, the bispecificantibody that binds to PD-1 and PD-L1 is MCLA-136. In some embodiments,the bispecific antibody binds to PD-L1 and CTLA-4. In some embodiments,the bispecific antibody that binds to PD-L1 and CTLA-4 is AK104.

In some embodiments, the compounds of the disclosure can be used incombination with one or more metabolic enzyme inhibitors. In someembodiments, the metabolic enzyme inhibitor is an inhibitor of IDO1,TDO, or arginase. Examples of IDO1 inhibitors include epacadostat,NLG919, BMS-986205, PF-06840003, IOM2983, RG-70099 and LY338196.

As provided throughout, the additional compounds, inhibitors, agents,etc. can be combined with the present compound in a single or continuousdosage form, or they can be administered simultaneously or sequentiallyas separate dosage forms.

Pharmaceutical Formulations and Dosage Forms

When employed as pharmaceuticals, the compounds of the disclosure can beadministered in the form of pharmaceutical compositions. Thesecompositions can be prepared in a manner well known in thepharmaceutical art, and can be administered by a variety of routes,depending upon whether local or systemic treatment is desired and uponthe area to be treated. Administration may be topical (includingtransdermal, epidermal, ophthalmic and to mucous membranes includingintranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalationor insufflation of powders or aerosols, including by nebulizer;intratracheal or intranasal), oral, or parenteral. Parenteraladministration includes intravenous, intraarterial, subcutaneous,intraperitoneal intramuscular or injection or infusion; or intracranial,e.g., intrathecal or intraventricular, administration. Parenteraladministration can be in the form of a single bolus dose, or may be, forexample, by a continuous perfusion pump. Pharmaceutical compositions andformulations for topical administration may include transdermal patches,ointments, lotions, creams, gels, drops, suppositories, sprays, liquidsand powders. Conventional pharmaceutical carriers, aqueous, powder oroily bases, thickeners and the like may be necessary or desirable.

This disclosure also includes pharmaceutical compositions which contain,as the active ingredient, the compound of the disclosure or apharmaceutically acceptable salt thereof, in combination with one ormore pharmaceutically acceptable carriers (excipients). In someembodiments, the composition is suitable for topical administration. Inmaking the compositions of the disclosure, the active ingredient istypically mixed with an excipient, diluted by an excipient or enclosedwithin such a carrier in the form of, for example, a capsule, sachet,paper, or other container. When the excipient serves as a diluent, itcan be a solid, semi-solid, or liquid material, which acts as a vehicle,carrier or medium for the active ingredient. Thus, the compositions canbe in the form of tablets, pills, powders, lozenges, sachets, cachets,elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solidor in a liquid medium), ointments containing, for example, up to 10% byweight of the active compound, soft and hard gelatin capsules,suppositories, sterile injectable solutions, and sterile packagedpowders.

In preparing a formulation, the active compound can be milled to providethe appropriate particle size prior to combining with the otheringredients. If the active compound is substantially insoluble, it canbe milled to a particle size of less than 200 mesh. If the activecompound is substantially water soluble, the particle size can beadjusted by milling to provide a substantially uniform distribution inthe formulation, e.g., about 40 mesh.

The compounds of the disclosure may be milled using known millingprocedures such as wet milling to obtain a particle size appropriate fortablet formation and for other formulation types. Finely divided(nanoparticulate) preparations of the compounds of the disclosure can beprepared by processes known in the art, e.g., see International App. No.WO 2002/000196.

Some examples of suitable excipients include lactose, dextrose, sucrose,sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates,tragacanth, gelatin, calcium silicate, microcrystalline cellulose,polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. Theformulations can additionally include: lubricating agents such as talc,magnesium stearate, and mineral oil; wetting agents; emulsifying andsuspending agents; preserving agents such as methyl- andpropylhydroxy-benzoates; sweetening agents; and flavoring agents. Thecompositions of the disclosure can be formulated so as to provide quick,sustained or delayed release of the active ingredient afteradministration to the patient by employing procedures known in the art.

The compositions can be formulated in a unit dosage form, each dosagecontaining from about 5 to about 1000 mg (1 g), or more, such as about100 to about 500 mg, of the active ingredient. The term “unit dosageforms” refers to physically discrete units suitable as unitary dosagesfor human subjects and other mammals, each unit containing apredetermined quantity of active material calculated to produce thedesired therapeutic effect, in association with a suitablepharmaceutical excipient.

In some embodiments, the compositions of the disclosure contain fromabout 5 to about 50 mg of the active ingredient. One having ordinaryskill in the art will appreciate that this embodies compositionscontaining about 5 to about 10, about 10 to about 15, about 15 to about20, about 20 to about 25, about 25 to about 30, about 30 to about 35,about 35 to about 40, about 40 to about 45, or about 45 to about 50 mgof the active ingredient.

In some embodiments, the compositions of the disclosure contain fromabout 50 to about 500 mg of the active ingredient. One having ordinaryskill in the art will appreciate that this embodies compositionscontaining about 50 to about 100, about 100 to about 150, about 150 toabout 200, about 200 to about 250, about 250 to about 300, about 350 toabout 400, or about 450 to about 500 mg of the active ingredient.

In some embodiments, the compositions of the disclosure contain fromabout 500 to about 1000 mg of the active ingredient. One having ordinaryskill in the art will appreciate that this embodies compositionscontaining about 500 to about 550, about 550 to about 600, about 600 toabout 650, about 650 to about 700, about 700 to about 750, about 750 toabout 800, about 800 to about 850, about 850 to about 900, about 900 toabout 950, or about 950 to about 1000 mg of the active ingredient.

Similar dosages may be used of the compounds described herein in themethods and uses of the disclosure.

The active compound can be effective over a wide dosage range and isgenerally administered in a pharmaceutically effective amount. It willbe understood, however, that the amount of the compound actuallyadministered will usually be determined by a physician, according to therelevant circumstances, including the condition to be treated, thechosen route of administration, the actual compound administered, theage, weight, and response of the individual patient, the severity of thepatient's symptoms, and the like.

For preparing solid compositions such as tablets, the principal activeingredient is mixed with a pharmaceutical excipient to form a solidpreformulation composition containing a homogeneous mixture of acompound of the present disclosure. When referring to thesepreformulation compositions as homogeneous, the active ingredient istypically dispersed evenly throughout the composition so that thecomposition can be readily subdivided into equally effective unit dosageforms such as tablets, pills and capsules. This solid preformulation isthen subdivided into unit dosage forms of the type described abovecontaining from, for example, about 0.1 to about 1000 mg of the activeingredient of the present disclosure.

The tablets or pills of the present disclosure can be coated orotherwise compounded to provide a dosage form affording the advantage ofprolonged action. For example, the tablet or pill can comprise an innerdosage and an outer dosage component, the latter being in the form of anenvelope over the former. The two components can be separated by anenteric layer which serves to resist disintegration in the stomach andpermit the inner component to pass intact into the duodenum or to bedelayed in release. A variety of materials can be used for such entericlayers or coatings, such materials including a number of polymeric acidsand mixtures of polymeric acids with such materials as shellac, cetylalcohol, and cellulose acetate.

The liquid forms in which the compounds and compositions of the presentdisclosure can be incorporated for administration orally or by injectioninclude aqueous solutions, suitably flavored syrups, aqueous or oilsuspensions, and flavored emulsions with edible oils such as cottonseedoil, sesame oil, coconut oil, or peanut oil, as well as elixirs andsimilar pharmaceutical vehicles.

Compositions for inhalation or insufflation include solutions andsuspensions in pharmaceutically acceptable, aqueous or organic solvents,or mixtures thereof, and powders. The liquid or solid compositions maycontain suitable pharmaceutically acceptable excipients as describedsupra. In some embodiments, the compositions are administered by theoral or nasal respiratory route for local or systemic effect.Compositions can be nebulized by use of inert gases. Nebulized solutionsmay be breathed directly from the nebulizing device or the nebulizingdevice can be attached to a face mask, tent, or intermittent positivepressure breathing machine. Solution, suspension, or powder compositionscan be administered orally or nasally from devices which deliver theformulation in an appropriate manner.

Topical formulations can contain one or more conventional carriers. Insome embodiments, ointments can contain water and one or morehydrophobic carriers selected from, for example, liquid paraffin,polyoxyethylene alkyl ether, propylene glycol, white Vaseline, and thelike. Carrier compositions of creams can be based on water incombination with glycerol and one or more other components, e.g.,glycerinemonostearate, PEG-glycerinemonostearate and cetylstearylalcohol. Gels can be formulated using isopropyl alcohol and water,suitably in combination with other components such as, for example,glycerol, hydroxyethyl cellulose, and the like. In some embodiments,topical formulations contain at least about 0.1, at least about 0.25, atleast about 0.5, at least about 1, at least about 2, or at least about 5wt % of the compound of the disclosure. The topical formulations can besuitably packaged in tubes of, for example, 100 g which are optionallyassociated with instructions for the treatment of the select indication,e.g., psoriasis or other skin condition.

The amount of compound or composition administered to a patient willvary depending upon what is being administered, the purpose of theadministration, such as prophylaxis or therapy, the state of thepatient, the manner of administration, and the like. In therapeuticapplications, compositions can be administered to a patient alreadysuffering from a disease in an amount sufficient to cure or at leastpartially arrest the symptoms of the disease and its complications.Effective doses will depend on the disease condition being treated aswell as by the judgment of the attending clinician depending uponfactors such as the severity of the disease, the age, weight and generalcondition of the patient, and the like.

The compositions administered to a patient can be in the form ofpharmaceutical compositions described above. These compositions can besterilized by conventional sterilization techniques, or may be sterilefiltered. Aqueous solutions can be packaged for use as is, orlyophilized, the lyophilized preparation being combined with a sterileaqueous carrier prior to administration. The pH of the compoundpreparations typically will be between 3 and 11, more preferably from 5to 9 and most preferably from 7 to 8. It will be understood that use ofcertain of the foregoing excipients, carriers, or stabilizers willresult in the formation of pharmaceutical salts.

The therapeutic dosage of a compound of the present disclosure can varyaccording to, for example, the particular use for which the treatment ismade, the manner of administration of the compound, the health andcondition of the patient, and the judgment of the prescribing physician.The proportion or concentration of a compound of the disclosure in apharmaceutical composition can vary depending upon a number of factorsincluding dosage, chemical characteristics (e.g., hydrophobicity), andthe route of administration. For example, the compounds of thedisclosure can be provided in an aqueous physiological buffer solutioncontaining about 0.1 to about 10% w/v of the compound for parenteraladministration. Some typical dose ranges are from about 1 μg/kg to about1 g/kg of body weight per day. In some embodiments, the dose range isfrom about 0.01 mg/kg to about 100 mg/kg of body weight per day. Thedosage is likely to depend on such variables as the type and extent ofprogression of the disease or disorder, the overall health status of theparticular patient, the relative biological efficacy of the compoundselected, formulation of the excipient, and its route of administration.Effective doses can be extrapolated from dose-response curves derivedfrom in vitro or animal model test systems.

The compositions of the disclosure can further include one or moreadditional pharmaceutical agents such as a chemotherapeutic, steroid,anti-inflammatory compound, or immunosuppressant, examples of which arelisted herein.

Labeled Compounds and Assay Methods

Another aspect of the present disclosure relates to labeled compounds ofthe disclosure (radio-labeled, fluorescent-labeled, etc.) that would beuseful not only in imaging techniques but also in assays, both in vitroand in vivo, for localizing and quantitating CDK2 in tissue samples,including human, and for identifying CDK2 activators by inhibitionbinding of a labeled compound. Substitution of one or more of the atomsof the compounds of the present disclosure can also be useful ingenerating differentiated ADME (Adsorption, Distribution, Metabolism andExcretion.) Accordingly, the present disclosure includes CDK2 assaysthat contain such labeled or substituted compounds.

The present disclosure further includes isotopically-labeled compoundsof the disclosure. An “isotopically” or “radio-labeled” compound is acompound of the disclosure where one or more atoms are replaced orsubstituted by an atom having an atomic mass or mass number differentfrom the atomic mass or mass number typically found in nature (i.e.,naturally occurring). Suitable radionuclides that may be incorporated incompounds of the present disclosure include but are not limited to ²H(also written as D for deuterium), ³H (also written as T for tritium),¹¹C, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵O, ¹⁷O, ¹⁸O, ¹⁸F, ³⁵S, ³⁶Cl, ⁸²Br, ⁷⁵Br,⁷⁶Br, ⁷⁷Br, ¹²³I, ¹²⁴I, ¹²⁵I and ¹³¹I. For example, one or more hydrogenatoms in a compound of the present disclosure can be replaced bydeuterium atoms (e.g., one or more hydrogen atoms of a C₁₋₆ alkyl groupof Formula (I) can be optionally substituted with deuterium atoms, suchas —CD₃ being substituted for —CH₃). In some embodiments, alkyl groupsof the disclosed Formulas (e.g., Formula (I)) can be perdeuterated.

One or more constituent atoms of the compounds presented herein can bereplaced or substituted with isotopes of the atoms in natural ornon-natural abundance. In some embodiments, the compound includes atleast one deuterium atom. For example, one or more hydrogen atoms in acompound presented herein can be replaced or substituted by deuterium(e.g., one or more hydrogen atoms of a C₁₋₆ alkyl group can be replacedby deuterium atoms, such as —CD₃ being substituted for —CH₃). In someembodiments, the compound includes two or more deuterium atoms. In someembodiments, the compound includes 1-2, 1-3, 1-4, 1-5, or 1-6 deuteriumatoms. In some embodiments, all of the hydrogen atoms in a compound canbe replaced or substituted by deuterium atoms.

In some embodiments, 1, 2, 3, 4, 5, 6, 7, or 8 hydrogen atoms, attachedto carbon atoms of alkyl, alkenyl, alkynyl, aryl, phenyl, cycloalkyl,heterocycloalkyl, or heteroaryl substituents or —C₁₋₄ alkyl-, alkylene,alkenylene and alkynylene linking groups, as described herein, areoptionally replaced by deuterium atoms.

Synthetic methods for including isotopes into organic compounds areknown in the art (Deuterium Labeling in Organic Chemistry by Alan F.Thomas, New York, N.Y., Appleton-Century-Crofts, 1971; The Renaissanceof H/D Exchange by Jens Atzrodt, Volker Derdau, Thorsten Fey and JochenZimmermann, Angew. Chem. Int. Ed. 2007, 7744-7765; The Organic Chemistryof Isotopic Labelling by James R. Hanson, Royal Society of Chemistry,2011). Isotopically labeled compounds can be used in various studiessuch as NMR spectroscopy, metabolism experiments, and/or assays.

Substitution with heavier isotopes, such as deuterium, may affordcertain therapeutic advantages resulting from greater metabolicstability, for example, increased in vivo half-life or reduced dosagerequirements, and hence may be preferred in some circumstances. (seee.g., A. Kerekes et al. J. Med. Chem. 2011, 54, 201-210; R. Xu et al. J.Label Compd. Radiopharm. 2015, 58, 308-312). In particular, substitutionat one or more metabolism sites may afford one or more of thetherapeutic advantages.

The radionuclide that is incorporated in the instant radio-labeledcompounds will depend on the specific application of that radio-labeledcompound. For example, for in vitro CDK2 labeling and competitionassays, compounds that incorporate ³H, ¹⁴C, ⁸²Br, ¹²⁵I, ¹³¹I, or ³⁵S canbe useful. For radio-imaging applications ¹¹C, ¹⁸F, ¹²⁵I, ¹²³I, ¹²⁴I,¹³¹I, ⁷⁵Br, ⁷⁶Br, or ⁷⁷Br can be useful.

It is understood that a “radio-labeled” or “labeled compound” is acompound that has incorporated at least one radionuclide. In someembodiments, the radionuclide is selected from the group consisting of³H, ¹⁴C, ¹²⁵I, ³⁵S, and ⁸²Br.

The present disclosure can further include synthetic methods forincorporating radio-isotopes into compounds of the disclosure. Syntheticmethods for incorporating radio-isotopes into organic compounds are wellknown in the art, and one of ordinary skill in the art will readilyrecognize the methods applicable for the compounds of disclosure.

A labeled compound of the disclosure can be used in a screening assay toidentify/evaluate compounds. For example, a newly synthesized oridentified compound (i.e., test compound) which is labeled can beevaluated for its ability to bind and activate CDK2 by monitoring itsconcentration variation when contacting with CDK2, through tracking ofthe labeling. For example, a test compound (labeled) can be evaluatedfor its ability to reduce binding of another compound which is known toinhibit CDK2 (i.e., standard compound). Accordingly, the ability of atest compound to compete with the standard compound for binding to CDK2directly correlates to its binding affinity. Conversely, in some otherscreening assays, the standard compound is labeled and test compoundsare unlabeled. Accordingly, the concentration of the labeled standardcompound is monitored in order to evaluate the competition between thestandard compound and the test compound, and the relative bindingaffinity of the test compound is thus ascertained.

Kits

The present disclosure also includes pharmaceutical kits useful, forexample, in the treatment or prevention of CDK2-associated diseases ordisorders (such as, e.g., cancer, an inflammatory disease, acardiovascular disease, or a neurodegenerative disease) which includeone or more containers containing a pharmaceutical compositioncomprising a therapeutically effective amount of a compound of thedisclosure. Such kits can further include, if desired, one or more ofvarious conventional pharmaceutical kit components, such as, forexample, containers with one or more pharmaceutically acceptablecarriers, additional containers, etc., as will be readily apparent tothose skilled in the art. Instructions, either as inserts or as labels,indicating quantities of the components to be administered, guidelinesfor administration, and/or guidelines for mixing the components, canalso be included in the kit.

Biomarkers and Pharmacodynamics Markers

The disclosure further provides predictive markers (e.g., biomarkers andpharmacodynamic markers, e.g., gene copy number, gene sequence,expression levels, or phosphorylation levels) to identify those humansubjects having, suspected of having, or at risk of developing a diseaseor disorder associated with CDK2 for whom administering a CDK2 inhibitor(“a CDK2 inhibitor” as used herein refers to a compound of thedisclosure, or a pharmaceutically acceptable salt thereof) is likely tobe effective. The disclosure also provides pharmacodynamic markers(e.g., phosphorylation levels) to identify those human subjects having,suspected of having, or at risk of developing a disease or disorderassociated with CDK2 whom are responding to a CDK2 inhibitor. The use ofCCNE1, p16, and Rb S780 is further described in U.S. Patent Publ. No.2020/0316064), the figures and disclosure of which is incorporated byreference herein in its entirety.

The methods are based, at least in part, on the discovery that thefunctional status of cyclin dependent kinase inhibitor 2A (“CDKN2A”;also referred to as “p16”) is a biomarker for predicting sensitivity toCDK2-targeting therapies in G1/S-specific cyclin-E1- (“CCNE1-”)amplified cells suitable for use in patient stratification. In addition,the present invention is based, at least in part, on the discovery that,in CCNE1-amplified cell lines, the level of human retinoblastomaassociated protein (“Rb”) phosphorylation at the serine corresponding toamino acid position 780 of SEQ ID NO:3 is a pharmacodynamic marker forCDK2 activity and is suitable for use in measuring CDK2 enzymaticactivity in cellular assay or preclinical and clinical applications,such as, e.g., monitoring the progress of or responsiveness to treatmentwith a CDK2 inhibitor.

CCNE1 and p16

CCNE1 and p16 have been identified in the Examples as genes, incombination, useful in predicting responsiveness (e.g., improvement indisease as evidenced by disease remission/resolution) of a subjecthaving a disease or disorder associated with CDK2 to a CDK2 inhibitor.

p16 (also known as cyclin-dependent kinase inhibitor 2A,cyclin-dependent kinase 4, inhibitor A, multiple tumor suppressor 1, andp16-INK4a) acts as a negative regulator of the proliferation of normalcells by interacting with CDK4 and CDK6. p16 is encoded by the cyclindependent kinase inhibitor 2A (“CDKN2A”) gene (GenBank Accession No.NM_000077). The cytogenic location of the CDKN2A gene is 9p21.3, whichis the short (p) arm of chromosome 9 at position 21.3. The molecularlocation of the CDKN2A gene is base pairs 21,967,752 to 21,995,043 onchromosome 9 (Homo sapiens Annotation Release 109, GRCh38.p12). Geneticand epigenetic abnormalities in the gene encoding p16 are believed tolead to escape from senescence and cancer formation (Okamoto et al.,1994, PNAS 91(23):11045-9). Nonlimiting examples of geneticabnormalities in the gene encoding p16 are described in Table A, below.The amino acid sequence of human p16 is provided below (GenBankAccession No. NP_000068/UniProtKB Accession No. P42771):

(SEQ ID NO: 1) 1 MEPAAGSSME PSADWLATAA ARGRVEEVRA LLEAGALPNAPNSYGRRPIQ VMMMGSARVA 61 ELLLLHGAEP NCADPATLTR PVHDAAREGF LDTLVVLHRAGARLDVRDAW GRLPVDLAEE 121 LGHRDVARYL RAAAGGTRGS NHARIDAAEG PSDIPD.

CCNE1 is a cell cycle factor essential for the control of the cell cycleat the G1/S transition (Ohtsubo et al., 1995, Mol. Cell. Biol.15:2612-2624). CCNE1 acts as a regulatory subunit of CDK2, interactingwith CDK2 to form a serine/threonine kinase holoenzyme complex. TheCCNE1 subunit of this holoenzyme complex provides the substratespecificity of the complex (Honda et al., 2005, EMBO 24:452-463). CCNE1is encoded by the cyclin E1 (“CCNE”) gene (GenBank Accession No.NM_001238). The amino acid sequence of human CCNE1 is provided below(GenBank Accession No. NP_001229/UniProtKB Accession No. P24864):

(SEQ ID NO: 2) 1 mprerrerda kerdtmkedg gaefsarsrk rkanvtvflqdpdeemakid rtardqcgsq 61 pwdnnavcad pcsliptpdk edddrvypns tckpriiapsrgsplpvlsw anreevwkim 121 lnkektylrd qhfleqhpll qpkmrailld wlmevcevyklhretfylaq dffdrymatq 181 envvktllql igisslfiaa kleeiyppkl hqfayvtdgacsgdeiltme lmimkalkwr 241 lspltivswl nvymqvayln dlhevllpqy pqqifiqiaelldlcvldvd clefpygila 301 asalyhfsss elmqkvsgyq wcdiencvkw mvpfamviretgssklkhfr gvadedahni 361 qthrdsldll dkarakkaml seqnrasplp sglltppqsgkkqssgpema.

The Examples demonstrate CDK2-knockdown inhibits proliferation ofCCNE1-amplified cell lines, but not of CCNE1-non-amplified cell lines.Conversely, the Examples show that CDK4/6 inhibition inhibitsproliferation of CCNE1-non-amplified cell lines, but not ofCCNE1-amplified cell lines. The Examples further demonstrate thatpresence of a normal (e.g., non-mutated or non-deleted) p16 gene isrequired for the observed inhibition of cell proliferation inCCNE1-amplified cells treated with a CDK2-inhibitor. Accordingly, CCNE1and p16 are, together, a combination biomarker: cells that respond totreatment with a CDK2 inhibitor display an amplification of the CCNE1gene and/or an expression level of CCNE1 that is higher than a controlexpression level of CCNE1, and have a nucleotide sequence (e.g., a geneor an mRNA) that encodes the p16 protein (e.g., a p16 protein comprisingthe amino acid sequence of SEQ ID NO:1) and/or have p16 protein present,while control cells that do not respond to treatment with a CDK2inhibitor do not have an amplification of the CCNE1 gene and/or anexpression level of CCNE1 that is higher than a control expression levelof CCNE1, and tend to have a mutated or deleted gene that encodes thep16 protein and/or lack expression of p16 protein.

Thus, the disclosure provides a method of treating a human subjecthaving, suspected of having, or at risk of developing a disease ordisorder associated with CDK2, comprising administering to the humansubject a CDK2 inhibitor, wherein the human subject has been previouslydetermined to: (i) (a) have a nucleotide sequence encoding a p16 proteincomprising the amino acid sequence of SEQ ID NO:1, (b) have a CDKN2Agene lacking one or more inactivating nucleic acid substitutions and/ordeletions, and/or (c) express a p16 protein, and (ii) (a) have anamplification of the CCNE1 gene and/or (b) have an expression level ofCCNE1 in a biological sample obtained from the human subject that ishigher than a control expression level of CCNE1. In certain embodiments,the predictive methods described herein predict that the subject willrespond to treatment with the CDK2 inhibitor with at least 50%, at least60%, at least 70%, at least 80%, at least 90%, at least 95%, at least98% or 100% accuracy. For example, in some embodiments, if thepredictive methods described herein are applied to 10 subjects having,suspected of having, or at risk of developing a disease or disorderassociated with CDK2 and 8 of those 10 subjects are predicted to respondto treatment with a CDK2 inhibitor based on a predictive methoddescribed herein, and 7 of those 8 subjects do indeed respond totreatment with a CDK2 inhibitor, then the predictive method has anaccuracy of 87.5% (7 divided by 8). A subject is considered to respondto the CDK2 inhibitor if the subject shows any improvement in diseasestatus as evidenced by, e.g., reduction or alleviation in symptoms,disease remission/resolution, etc.

In some embodiments, the subject has a disease or disorder associatedwith CDK2. In some embodiments, the human subject has been previouslydetermined to: (i) (a) have a nucleotide sequence encoding a p16 proteincomprising the amino acid sequence of SEQ ID NO:1 and/or (b) a CDKN2Agene lacking one or more inactivating nucleic acid substitutions and/ordeletions, and (ii) have an amplification of the CCNE1 gene in abiological sample obtained from the human subject. In some embodiments,the CDKN2A gene encodes a protein comprising the amino acid sequence ofSEQ ID NO: 1. In specific embodiments, the CDKN2A gene encodes a proteincomprising the amino acid sequence of SEQ ID NO: 1.

In specific embodiments, the one or more inactivating nucleic acidsubstitutions and/or deletions in the CDKN2A gene is as described inTable A. In specific embodiments, the one or more inactivating nucleicacid substitutions and/or deletions in the CDKN2A gene is as describedin Yarbrough et al., Journal of the National Cancer Institute, 91(18):1569-1574, 1999; Liggett and Sidransky, Biology of Neoplasia, Journal ofOncology, 16(3):1197-1206, 1998, and Cairns et al., Nature Genetics,11:210-212, 1995, each of which is incorporated by reference herein inits entirety.

TABLE A CDKN2A gene substitutions, deletions, and modificationsDescription Reference(s) C to T transition converting codon 232 of theRefSNP Accession No. rs121913388; CDKN2A gene from an arginine codon toa stop Kamb et al., Science 264: 436-440, codon 1994 19-basepairgermline deletion at nucleotide 225 RefSNP Accession No. rs587776716;causing a reading-frame shift predicted to severely Gruis et al., NatureGenet. 10: 351-353, truncate p16 protein 1995 6-basepair deletion atnucleotides 363-368 of the ClinVar Accession No. CDKN2A geneRCV000010017.2; Liu et al., Oncogene 11: 405-412, 1995 Mutation atchromosome 9: 21971058 predicted to RefSNP Accession No. rs104894094;substitute glycine corresponding to amino acid Ciotti et al., Am. J.Hum. Genet. 67: position 101 of SEQ ID NO: 1 with a tryptophan 311-319,2000 Germline mutation constituting an in-frame 3- ClinVar Accession No.basepair duplication at nucleotide 332 in exon 2 of RCV000010020.3; Borget al., Cancer the CDKN2A gene Res. 56: 2497-2500, 1996 Mutationpredicted to substitute methionine RefSNP Accession No. rs104894095;corresponding to amino acid position 53 of SEQ ID Harland et al., Hum.Molec. Genet. 6: NO: 1 with an isoleucine 2061-2067, 1997 Mutationpredicted to substitute arginine RefSNP Accession No. rs104894097;corresponding to amino acid position 24 of SEQ ID Monzon et al., NewEng. J. Med. 338: NO: 1 with a proline 879-887, 1998 24-basepair repeatinserted at chromosome 9 RefSNP Accession No. rs587780668; between21974795 and 21974796 (forward strand) Pollock et al., Hum. Mutat. 11:424-431, 1998) G-to-T transversion at nucleotide -34 of the ClinVarAccession No. CDKN2A gene RCV000010024.5; Liu et al., Nature Genet. 21:128-132, 1999 Deletion of the p14(ARF)-specific exon 1-beta of ClinVarAccession No. CDKN2A RCV000010026.2; Randerson-Moor et al., Hum. Molec.Genet. 10: 55-62, 2001 Mutation predicted to substitute valine RefSNPAccession No. rsl04894098; corresponding to amino acid position 126 ofSEQ Goldstein et al., Brit. J. Cancer 85: ID NO: 1 with an isoleucine527-530, 2001 Transition (IVS2-105 A-G) in intron 2 of the ClinVarAccession No. CDKN2A gene creating a false GT splice donor siteRCV000010028.3; Harland et al., Hum. 105 bases 5-prime of exon 3resulting in aberrant Molec. Genet. 10: 2679-2686, 2001 splicing of themRNA Mutation predicted to result in substitution of RefSNP AccessionNo. rs113798404; glycine corresponding to amino acid position 122 ofHewitt et al., Hum. Molec. Genet. 11: SEQ ID NO: 1 with an arginine1273-1279, 2002 Mutation predicted to result in substitution of valineRefSNP Accession No. rs113798404; corresponding to amino acid position59 of SEQ ID Yakobson et al., Melanoma Res. 11: NO: 1 with an arginine569-570, 2001 Tandem germline339G-C transversion and a 340C- RefSNPAccession Nos. rs113798404 T transition in the CDKN2A gene resulting inand rs104894104; Kannengiesser et al., substitution of prolinecorresponding to amino acid Genes Chromosomes Cancer 46: position 114 ofSEQ ID NO: 1 with a serine 751-760, 2007 Mutation predicted to result insubstitution of serine RefSNP Accession No. rsl04894109; correspondingto amino acid position 56 of SEQ ID Kannengiesser et al., Genes NO: 1with an isoleucine Chromosomes Cancer 46: 751-760, 2007 Mutationpredicted to result in substitution of RefSNP Accession No. rs137854599;glycine corresponding to amino acid position 89 of Goldstein et al., J.Med. Genet. 45: SEQ ID NO: 1 with an aspartic acid 284-289, 2008Heterozygous A-to-G transition in exon 1B of the ClinVar Accession no.CDKN2A gene, affecting splicing of the p14(ARF) RCV000022943.3; Binni etal., Clin. isoform Genet. 77: 581-586, 2010 Heterozygous 5-bpduplication (19_23dup) in the ClinVar Accession No. CDKN2A gene,resulting in a frameshift and RCV000030680.6; Harinck, F., Kluijt etpremature termination al., J. Med. Genet. 49: 362-365, 2012 Mutationpredicted to result in substitution of Yarbrough et al., Journal of theaspartic acid corresponding to amino acid position National CancerInstitute, 91(18): 84 of SEQ ID NO: 1 with a valine 1569-1574 Mutationpredicted to result in substitution of Yarbrough et al., Journal of theaspartic acid corresponding to amino acid position National CancerInstitute, 91(18): 84 of SEQ ID NO: 1 with a glycine 1569-1574 Mutationpredicted to result in substitution of Yarbrough et al., Journal of thearginine corresponding to amino acid position 87 of National CancerInstitute, 91(18): SEQ ID NO: 1 with a proline 1569-1574 Mutationpredicted to result in substitution of Yarbrough et al., Journal of theproline corresponding to amino acid position 48 of National CancerInstitute, 91(18): SEQ ID NO: 1 with a leucine 1569-1574 Mutationpredicted to result in substitution of Yarbrough et al., Journal of theaspartic acid corresponding to amino acid position National CancerInstitute, 91(18): 74 of SEQ ID NO: 1 with a asparagine 1569-1574Mutation predicted to result in substitution of Yarbrough et al.,Journal of the arginine corresponding to amino acid position 87 ofNational Cancer Institute, 91(18): SEQ ID NO: 1 with a leucine 1569-1574Mutation predicted to result in substitution of Yarbrough et al.,Journal of the asparagine corresponding to amino acid position 71National Cancer Institute, 91(18): of SEQ ID NO: 1 with a serine1569-1574 Mutation predicted to result in substitution of Yarbrough etal., Journal of the arginine corresponding to amino acid position 80 ofNational Cancer Institute, 91(18): SEQ ID NO: 1 with a leucine 1569-1574Mutation predicted to result in substitution of Yarbrough et al.,Journal of the histidine corresponding to amino acid position 83 ofNational Cancer Institute, 91(18): SEQ ID NO: 1 with a tyrosine1569-1574

The disclosure also features a method of treating a human subjecthaving, suspected of having, or at risk of developing a disease ordisorder associated with CDK2, comprising: (i) identifying, in abiological sample obtained from the human subject: (a) a nucleotidesequence encoding a p16 protein comprising the amino acid sequence ofSEQ ID NO:1, (b) a CDKN2A gene lacking one or more inactivating nucleicacid substitutions, and/or (c) the presence of a p16 protein; (ii)identifying, in a biological sample obtained from the human subject: (a)an amplification of the CCNE1 gene and/or (b) an expression level ofCCNE1 that is higher than a control expression level of CCNE1; and (iii)administering a CDK2 inhibitor to the human subject. In someembodiments, the subject has a disease or disorder associated with CDK2.In some embodiments, the subject is suspected of having or is at risk ofdeveloping a disease or disorder associated with CDK2. In someembodiments, the method comprises: (i) identifying, in a biologicalsample obtained from the human subject: (a) a nucleotide sequenceencoding a p16 protein comprising the amino acid sequence of SEQ IDNO:1, (b) a CDKN2A gene lacking one or more inactivating nucleic acidsubstitutions and/or deletions, and/or (c) the presence of a p16protein; (ii) identifying, in a biological sample obtained from thehuman subject: (a) an amplification of the CCNE1 gene; and (iii)administering a CDK2 inhibitor to the human subject.

The disclosure also features a method of predicting the response of ahuman subject having, suspected of having, or at risk of developing adisease or disorder associated with CDK2 to a CDK2 inhibitor,comprising: (i) determining, from a biological sample obtained from thehuman subject: (a) the nucleotide sequence of a CDKN2A gene, (b) thepresence of a CDKN2A gene lacking one or more inactivating nucleic acidsubstitutions and/or deletions, and/or (c) the presence of a p16protein; and (ii) determining, from a biological sample obtained fromthe human subject: (a) the copy number of the CCNE1 gene and/or (b) theexpression level of CCNE1, wherein (1) (a) the presence of a CDKN2A geneencoding a p16 protein comprising the amino acid sequence of SEQ IDNO:1, (b) the presence of a CDKN2A gene lacking one or more inactivatingnucleic acid substitutions and/or deletions, and/or (c) the presence ofa p16 protein, and (2) (a) an amplification of the CCNE1 gene and/or (b)an expression level of CCNE1 that is higher than a control expressionlevel of CCNE1, is predictive that the human subject will respond to theCDK2 inhibitor. In some embodiments, the subject has a disease ordisorder associated with CDK2. In some embodiments, the subject issuspected of having or is at risk of developing a disease or disorderassociated with CDK2. In some embodiments, the method comprises: (i)determining, from a biological sample obtained from the human subject:(a) the nucleotide sequence of a CDKN2A gene and/or (b) the presence ofa CDKN2A gene lacking one or more inactivating nucleic acidsubstitutions and/or deletions; and (ii) determining, from a biologicalsample obtained from the human subject: (a) the copy number of the CCNE1gene, wherein (1) (a) the presence of a CDKN2A gene encoding a p16protein comprising the amino acid sequence of SEQ ID NO:1 and/or (b) thepresence of a CDKN2A gene lacking one or more inactivating nucleic acidsubstitutions and/or deletions, and (2) (a) an amplification of theCCNE1 gene, is predictive that the human subject will respond to theCDK2 inhibitor.

In specific embodiments, the (i) determining of (a) the nucleotidesequence of a CDKN2A gene, (b) the presence of a CDKN2A gene lacking oneor more inactivating nucleic acid substitutions and/or deletions, and/or(c) the presence of a p16 protein is performed before (e.g., at least 1day, at least 2 days, at least 3 days, at least 4 days, at least 5 days,at least 6 days, at least 7 days, at least 2 weeks, at least 3 weeks, orat least 4 weeks, or from 6 hours to 16 hours, from 6 hours to 20 hours,or from 6 hours to 24 hours, from 2 days to 3 days, from 2 days to 4,days, from 2 days to 5 days, from 2 days to 6 days, from 2 days to 7days, from 1 week to 2, weeks, from 1 week to 3 weeks, or from 1 week to4 weeks before) administering to the human subject the CDK2 inhibitor.In specific embodiments, the (ii) determining of (a) the copy number ofthe CCNE1 gene and/or (b) the expression level of CCNE1 in thebiological sample obtained from the human subject is performed before(e.g., at least 1 day, at least 2 days, at least 3 days, at least 4days, at least 5 days, at least 6 days, at least 7 days, at least 2weeks, at least 3 weeks, or at least 4 weeks, or from 6 hours to 16hours, from 6 hours to 20 hours, or from 6 hours to 24 hours, from 2days to 3 days, from 2 days to 4 days, from 2 days to 5 days, from 2days to 6 days, from 2 days to 7 days, from 1 week to 2 weeks, from 1week to 3 weeks, or from 1 week to 4 weeks before) administering to thehuman subject the CDK2 inhibitor.

An amplification of the CCNE1 gene and/or an expression level of CCNE1that is higher than a control expression level of CCNE1, combined withthe presence of a CDKN2A gene encoding a p16 protein comprising theamino acid sequence of SEQ ID NO:1, the presence of a CDKN2A genelacking one or more inactivating nucleic acid substitutions and/ordeletions, and/or the presence of a p16 protein (e.g., a p16 proteincomprising the amino acid sequence of SEQ ID NO:1), isindicative/predictive that a human subject having, suspected of having,or at risk of developing a disease or disorder associated with CDK2 willrespond to a CDK2 inhibitor.

In some embodiments, the CCNE1 gene is amplified to a gene copy numberfrom 3 to 25. In specific embodiments, the CCNE1 gene is amplified to agene copy number of at least 3. In specific embodiments, the CCNE1 geneis amplified to a gene copy number of at least 5. In specificembodiments, the CCNE1 gene is amplified to a gene copy number of atleast 7. In specific embodiments, the CCNE1 gene is amplified to a genecopy number of at least 10. In specific embodiments, the CCNE1 gene isamplified to a gene copy number of at least 12. In specific embodiments,the CCNE1 gene is amplified to a gene copy number of at least 14. Inspecific embodiments, the CCNE1 gene is amplified to a gene copy numberof at least 21.

In specific embodiments, the expression level of CCNE1 is the level ofCCNE1 mRNA. In specific embodiments, the expression level of CCNE1 isthe level of CCNE1 protein.

In some embodiments of the foregoing methods, the control expressionlevel of CCNE1, is a pre-established cut-off value. In some embodimentsof the foregoing methods, the control expression level of CCNE1 is theexpression level of CCNE1 in a sample or samples obtained from one ormore subjects that have not responded to treatment with the CDK2inhibitor.

In some embodiments of the foregoing methods, the expression level ofCCNE1 is the expression level of CCNE1 mRNA. In some embodiments of theforegoing methods, the expression level of CCNE1 is the expression levelof CCNE1 protein. In some embodiments in which the expression level ofCCNE1 is the expression level of CCNE1 mRNA, the expression level ofCCNE1 is measured by RNA sequencing, quantitative polymerase chainreaction (PCR), in situ hybridization, nucleic acid array or RNAsequencing. In some embodiments in which the expression level of CCNE1is the expression level of CCNE1 protein, the expression level of CCNE1is measured by western blot, enzyme-linked immunosorbent assay, orimmunohistochemistry staining.

Rb S780

The disclosure also features a method for assessing the CDKN2A gene andthe CCNE1, gene, comprising determining, from a biological sample orbiological samples obtained from a human subject having a disease ordisorder associated with CDK2, (i) (a) the nucleotide sequence of aCDKN2A gene or (b) the presence of a CDKN2A gene lacking one or moreinactivating nucleic acid substitutions and/or deletions, and (ii) thecopy number of the CCNE1, gene.

The disclosure also features a method of evaluating the response of ahuman subject having, suspected of having, or at risk of developing adisease or disorder associated with CDK2 to a CDK2 inhibitor,comprising: (a) administering a CDK2 inhibitor to the human subject,wherein the human subject has been previously determined to have anamplification of the CCNE1 gene and/or an expression level of CCNE1 thatis higher than a control expression level of CCNE1; (b) measuring, in abiological sample of obtained from the subject subsequent to theadministering of step (a), the level of retinoblastoma (Rb) proteinphosphorylation at the serine corresponding to amino acid position 780of SEQ ID NO:3, wherein a reduced level of Rb phosphorylation at theserine corresponding to amino acid position 780 of SEQ ID NO:3, ascompared to a control level of Rb phosphorylation at the serinecorresponding to amino acid position 780 of SEQ ID NO:3, is indicativethat the human subject responds to the CDK2 inhibitor. In someembodiments, the subject has a disease or disorder associated with CDK2.In some embodiments, the subject is suspected of having or is at risk ofdeveloping a disease or disorder associated with CDK2. In someembodiments, the biological sample comprises a blood sample or a tumorbiopsy sample.

Phosphorylation of Rb at the serine corresponding to amino acid position780 of SEQ ID NO:3 (referred to herein as “Ser780” or “S780”) has beenidentified in the Examples as a pharmacodynamic marker useful inassessing responsiveness (e.g., inhibition by CDK2) of a human subjecthaving a disease or disorder having CCNE1 amplification to a CDK2inhibitor.

Rb is a regulator of the cell cycle and acts as a tumor suppressor. Rbis activated upon phosphorylation by cyclin D-CDK4/6 at Ser780 andSer795 and by cyclin E/CDK2 at Ser807 and Ser811. Rb is encoded by theRB transcriptional corepressor 1 (“RB1”) gene (GenBank Accession No.NM_000321). The amino acid sequence of human Rb is provided below(GenBank Accession No. NP_000312/UniProtKB Accession No. P06400) (5780is in bold and underlined):

(SEQ ID NO: 3) 1 MPPKTPRKTA ATAAAAAAEP PAPPPPPPPE EDPEQDSGPEDLPLVRLEFE ETEEPDFTAL 61 CQKLKIPDHV RERAWLTWEK VSSVDGVLGG YIQKKKELWGICIFIAAVDL DEMSFTFTEL 121 QKNIEISVHK FFNLLKEIDT STKVDNAMSR LLKKYDVLFALFSKLERTCE LIYLTQPSSS 181 ISTEINSALV LKVSWITFLL AKGEVLQMED DLVISFQLMLCVLDYFIKLS PPMLLKEPYK 241 TAVIPINGSP RTPRRGQNRS ARIAKQLEND TRIIEVLCKEHECNIDEVKN VYFKNFIPFM 301 NSLGLVTSNG LPEVENLSKR YEEIYLKNKD LDARLFLDHDKTLQTDSIDS FETQRTPRKS 361 NLDEEVNVIP PHTPVRTVMN TIQQLMMILN SASDQPSENLISYFNNCTVN PKESILKRVK 421 DIGYIFKEKF AKAVGQGCVE IGSQRYKLGV RLYYRVMESMLKSEEERLSI QNFSKLLNDN 481 IFHMSLLACA LEVVMATYSR STSQNLDSGT DLSFPWILNVLNLKAFDFYK VIESFIKAEG 541 NLTREMIKHL ERCEHRIMES LAWLSDSPLF DLIKQSKDREGPTDHLESAC PLNLPLQNNH 601 TAADMYLSPV RSPKKKGSTT RVNSTANAET QATSAFQTQKPLKSTSLSLF YKKVYRLAYL 661 RLNTLCERLL SEHPELEHII WTLFQHTLQN EYELMRDRHLDQIMMCSMYG ICKVKNIDLK 721 FKIIVTAYKD LPHAVQETFK RVLIKEEEYD SIIVFYNSVFMQRLKTNILQ YASTRPPTL

781 PIPHIPRSPY KFPSSPLRIP GGNIYISPLK SPYKISEGLP TPTKMTPRSR ILVSIGESFG841 TSEKFQKINQ MVCNSDRVLK RSAEGSNPPK PLKKLRFDIE GSDEADGSKH LPGESKFQQK901 LAEMTSTRTR MQKQKMNDSM DTSNKEEK.

As stated above, the Examples demonstrate CDK2-knockdown inhibitsproliferation in CCNE1-amplified cell lines, but not inCCNE1-non-amplified cell lines. The Examples further demonstrateCDK2-knockdown or inhibition blocks Rb phosphorylation at the S780 inCCNE1-amplified cell lines, but not in CCNE1-non-amplified cell lines.Accordingly, Rb phosphorylation at the serine corresponding to aminoacid position 780 of SEQ ID NO:3 is a pharmacodynamic marker forassessing response to CDK2 inhibition in CCNE1 amplified cancer cells orpatients with diseases or disorders having CCNE1 amplification. Thus,provided herein are methods relating to the use of the level of Rbphosphorylation at the serine corresponding to amino acid position 780of SEQ ID NO:3 in a human subject having, suspected of having, or atrisk of developing a disease or disorder associated with CDK2 as amarker for indicating the response of the human subject to a CDK2inhibitor, wherein the human subject has an increased expression levelof CCNE1.

Thus, the disclosure features a method for measuring the amount of aprotein in a sample, comprising: (a) providing a biological sampleobtained from a human subject having a disease or disorder associatedwith CDK2; and (b) measuring the level of Rb protein phosphorylation atthe serine corresponding to amino acid position 780 of SEQ ID NO:3 inthe biological sample. In some embodiments, the biological samplecomprises a blood sample or a tumor biopsy sample. In a specificembodiment, provided herein is a method of evaluating the response of ahuman subject having, suspected of having, or at risk of developing adisease or disorder associated with CDK2 to a CDK2 inhibitor,comprising: (a) administering a CDK2 inhibitor to the human subject,wherein the human subject has been previously determined to have anamplification of the CCNE1 gene and/or an expression level of CCNE1 thatis higher than a control expression level of CCNE1; and (b) measuring,in a biological sample obtained from the human subject subsequent to theadministering of step (a), the level of Rb phosphorylation at the serinecorresponding to amino acid position 780 of SEQ ID NO:3, wherein areduced level of Rb phosphorylation at the serine corresponding to aminoacid position 780 of SEQ ID NO:3, as compared to a control level of Rbphosphorylation at the serine corresponding to amino acid position 780of SEQ ID NO:3, is indicative that the human subject responds to theCDK2 inhibitor. In specific embodiments, the human subject has a diseaseor disorder associated with CDK2.

A reduced level of Rb phosphorylation at the serine corresponding toamino acid position 780 of SEQ ID NO:3, as compared to a control levelof Rb phosphorylation at the serine corresponding to amino acid position780 of SEQ ID NO:3, combined with an amplification of the CCNE1 geneand/or an expression level of CCNE1 that is higher than a controlexpression level of CCNE1, is indicative that a human subject having,suspected of having, or at risk of developing a disease or disorderassociated with CDK2 responds to a CDK2 inhibitor. For example, in asubject having an amplification of the CCNE1 gene and/or an expressionlevel of CCNE1 that is higher than a control expression level of CCNE1,a biological sample, obtained from the subject after treatment with aCDK2 inhibitor, having low (e.g., reduced as compared to a control) orundetectable levels of Rb phosphorylation at serine corresponding toamino acid position 780 of SEQ ID NO:3 is indicative that the subjectresponds to the CDK2 inhibitor.

A biological sample, obtained from a subject after administration of aCDK2 inhibitor to the subject, having a reduced level of Rbphosphorylation at the serine corresponding to amino acid position 780of SEQ ID NO:3, as compared to a control level of Rb phosphorylation atthe serine corresponding to amino acid position 780 of SEQ ID NO:3,combined with: (i) an amplification of the CCNE1 gene and/or anexpression level of CCNE1 that is higher than a control expression levelof CCNE1, and (ii) presence of a CDKN2A gene encoding a p16 proteincomprising the amino acid sequence of SEQ ID NO:1, presence of a CDKN2Agene lacking one or more inactivating nucleic acid substitutions and/ordeletions, and/or presence of a p16 protein (e.g., a p16 proteincomprising the amino acid sequence of SEQ ID NO: 1), is indicative thata human subject having, suspected of having, or at risk of developing adisease or disorder associated with CDK2 responds to a CDK2 inhibitor.For example, in a human subject having (i) an amplification of the CCNE1gene and/or an expression level of CCNE1 that is higher than a controlexpression level of CCNE1, and (ii) the presence of a CDKN2A geneencoding a p16 protein comprising the amino acid sequence of SEQ IDNO:1, the presence of a CDKN2A gene lacking one or more inactivatingnucleic acid substitutions and/or deletions, and/or the presence of ap16 protein (e.g., a p16 protein comprising the amino acid sequence ofSEQ ID NO:1), a biological sample, obtained from the human subject afteradministration of a CDK2 inhibitor to the subject, having low (e.g.,reduced as compared to a control) or undetectable levels of Rbphosphorylation at the serine corresponding to amino acid position 780of SEQ ID NO:3 is indicative that the human subject responds to the CDK2inhibitor

In some embodiments, the CCNE1 gene is amplified to a gene copy numberfrom 3 to 25. In specific embodiments, the CCNE1 gene is amplified to agene copy number of at least 3. In specific embodiments, the CCNE1 geneis amplified to a gene copy number of at least 5. In specificembodiments, the CCNE1 gene is amplified to a gene copy number of atleast 7. In specific embodiments, the CCNE1 gene is amplified to a genecopy number of at least 10. In specific embodiments, the CCNE1 gene isamplified to a gene copy number of at least 12. In specific embodiments,the CCNE1 gene is amplified to a gene copy number of at least 14. Inspecific embodiments, the CCNE1 gene is amplified to a gene copy numberof at least 21. In specific embodiments, the expression level of CCNE1is the level of CCNE1 mRNA. In specific embodiments, the expressionlevel of CCNE1 is the level of CCNE1 protein.

Controls

As described above, the methods related to biomarkers andpharmacodynamic markers can involve, measuring one or more markers(e.g., a biomarker or a pharmacodynamics marker, e.g., the amplificationof the CCNE1 gene, the expression level of CCNE1, the presence of aCDKN2A gene encoding a p16 protein comprising the amino acid sequence ofSEQ ID NO:1, the presence of a CDKN2A gene lacking one or moreinactivating nucleic acid substitutions and/or deletions, the presenceof a p16 protein (e.g., a p16 protein comprising the amino acid sequenceof SEQ ID NO:1), and Rb phosphorylation at the serine corresponding toamino acid position 780 of SEQ ID NO:3) in a biological sample from ahuman subject having, suspected of having or at risk of developing adisease or disorder associated with CDK2. In specific embodiments, thehuman subject has a disease or disorder associated with CDK2. Inspecific embodiments, the human subject is suspected of having or is atrisk of developing a disease or disorder associated with CDK2. Incertain aspects, the level (e.g., amplification (e.g., for the CCNE1gene), expression level (e.g., for CCNE1 or p16 protein), orphosphorylation level (e.g., for Rb)) of one or more biomarkers,compared to a control level of the one or more biomarkers,predicts/indicates the response of a human subject to treatmentcomprising a CDK2 inhibitor. In certain embodiments, when (i) the CCNE1gene is amplified and/or an expression level of CCNE1 that is higherthan a control expression level of CCNE1, and (ii) a CDKN2A geneencoding a p16 protein comprising the amino acid sequence of SEQ ID NO:1is present, a CDKN2A gene lacking one or more inactivating nucleic acidsubstitutions and/or deletions is present, and/or a p16 protein (e.g., ap16 protein comprising the amino acid sequence of SEQ ID NO:1) ispresent, the human subject is identified as likely to respond to a CDK2inhibitor. In other embodiments, when (i) the CCNE1 gene is amplifiedand/or an expression level of CCNE1, that is higher than a controlexpression level of CCNE1, and (ii) in a biological sample from thehuman subject after the human subject has been administered a CDK2inhibitor, the level of Rb phosphorylation at the serine correspondingto amino acid position 780 of SEQ ID NO:3 is less than the control levelof Rb phosphorylation at the serine corresponding to amino acid position780 of SEQ ID NO:3, the human subject is identified as responding to aCDK2 inhibitor. In yet another embodiment, when (i) the CCNE1 gene isamplified and/or an expression level of CCNE1 that is higher than acontrol expression level of CCNE1, (ii) a CDKN2A gene encoding a p16protein comprising the amino acid sequence of SEQ ID NO:1 is present, aCDKN2A gene lacking one or more inactivating nucleic acid substitutionsand/or deletions is present, and/or a p16 protein (e.g., a p16 proteincomprising the amino acid sequence of SEQ ID NO:1) is present, and (iii)in a biological sample from the human subject after the human subjecthas been administered a CDK2 inhibitor, the level of Rb phosphorylationat the serine corresponding to amino acid position 780 of SEQ ID NO:3 isless than the control level of Rb phosphorylation at the serinecorresponding to amino acid position 780 of SEQ ID NO:3, the humansubject is identified as responding to a CDK2 inhibitor. In thiscontext, the term “control” includes a sample (from the same tissuetype) obtained from a human subject who is known to not respond to aCDK2 inhibitor. The term “control” also includes a sample (from the sametissue type) obtained in the past from a human subject who is known tonot respond to a CDK2 inhibitor and used as a reference for futurecomparisons to test samples taken from human subjects for whichtherapeutic responsiveness is to be predicted. The “control” level(e.g., gene copy number, expression level, or phosphorylation level) fora particular biomarker (e.g., CCNE1, p16, or Rb phosphorylation) in aparticular cell type or tissue may be pre-established by an analysis ofbiomarker level (e.g., expression level or phosphorylation level) in oneor more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, or 40 ormore) human subjects that have not responded to treatment with a CDK2inhibitor. This pre-established reference value (which may be an averageor median level (e.g., gene copy number, expression level, orphosphorylation level) taken from multiple human subjects that have notresponded to the therapy) may then be used for the “control” level ofthe biomarker (e.g., CCNE1, p16, or Rb phosphorylation) in thecomparison with the test sample. In such a comparison, the human subjectis predicted to respond to a CDK2 inhibitor if the CCNE1 gene isamplified and/or the expression level of CCNE is higher than thepre-established reference, and a CDKN2A gene encoding a p16 proteincomprising the amino acid sequence of SEQ ID NO:1 is present, a CDKN2Agene lacking one or more inactivating nucleic acid substitutions and/ordeletions is present, and/or a p16 protein (e.g., a p16 proteincomprising the amino acid sequence of SEQ ID NO:1) is present. Inanother such a comparison, the human subject is predicted to respond toa CDK2 inhibitor if (i) CCNE1 gene is amplified and/or the expressionlevel of CCNE is higher than the pre-established reference, and (ii)after administering to the human subject a CDK2 inhibitor, the level ofRb phosphorylation at the serine corresponding to amino acid position780 of SEQ ID NO:3 is lower than the pre-established reference. In yetanother such a comparison, the human subject is indicated to respond toa CDK2 inhibitor if (i) CCNE1 gene is amplified and/or the expressionlevel of CCNE is higher than the pre-established reference, (ii) aCDKN2A gene encoding a p16 protein comprising the amino acid sequence ofSEQ ID NO:1 is present, a CDKN2A gene lacking one or more inactivatingnucleic acid substitutions and/or deletions is present, and/or a p16protein (e.g., a p16 protein comprising the amino acid sequence of SEQID NO:1) is present, and (iii) after administering to the human subjecta CDK2 inhibitor, the level of Rb phosphorylation at the serinecorresponding to amino acid position 780 of SEQ ID NO:3 is lower thanthe pre-established reference.

The “control” level for a particular biomarker in a particular cell typeor tissue may alternatively be pre-established by an analysis ofbiomarker level in one or more human subjects that have responded totreatment with a CDK2 inhibitor. This pre-established reference value(which may be an average or median level (e.g., expression level orphosphorylation level) taken from multiple human subjects that haveresponded to the therapy) may then be used as the “control” level (e.g.,expression level or phosphorylation level) in the comparison with thetest sample. In such a comparison, the human subject is indicated torespond to a CDK2 inhibitor if the level (e.g., copy number of the CCNE1gene, expression level of CCNE1, expression level of p16, orphosphorylation level of Rb at the serine corresponding to amino acidposition 780 of SEQ ID NO:3) of the biomarker being analyzed is equal orcomparable to (e.g., at least 85% but less than 115% of), thepre-established reference.

In certain embodiments, the “control” is a pre-established cut-offvalue. A cut-off value is typically a level (e.g., a copy number, anexpression level, or a phosphorylation level) of a biomarker above orbelow which is considered predictive of responsiveness of a humansubject to a therapy of interest. Thus, in accordance with the methodsand compositions described herein, a reference level (e.g., of CCNE1gene copy number, CCNE1 expression, p16 expression, or Rbphosphorylation at the serine corresponding to amino acid position 780of SEQ ID NO:3) is identified as a cut-off value, above or below ofwhich is predictive of responsiveness to a CDK2 inhibitor. Cut-offvalues determined for use in the methods described herein can becompared with, e.g., published ranges of concentrations but can beindividualized to the methodology used and patient population.

In some embodiments, the expression level of CCNE1 is increased ascompared to the expression level of CCNE1 in a control. For example, theexpression level of CCNE1 analyzed can be at least 1.5, at least 2, atleast 3, at least 4, at least 5, at least 6, at least 7, at least 8, atleast 9, at least 10, at least 20, at least 25, at least 50, at least75, or at least 100 times higher, or at least 10%, at least 20%, atleast 30%, at least 40%, at least 50%, at least 60%, at least 70%, atleast 80%, at least 90%, at least 100%, at least 200%, at least 300%, atleast 400%, at least 500%, at least 600%, at least 700%, at least 800%,at least 900%, at least 1,000%, at least 1,500%, at least 2,000%, atleast 2,500%, at least 3,000%, at least 3,500%, at least 4,000%, atleast 4,500%, or at least 5,000% higher, than the expression level ofCCNE1 in a control.

A p16 protein is present if the protein is detectable by any assay knownin the art or described herein, such as, for example, western blot,immunohistochemistry, fluorescence-activated cell sorting, andenzyme-linked immunoassay. In some embodiments, a p16 protein is presentat an expression level that is within at least 5%, at least 10%, atleast 20%, or at least 30% of the p16 expression level in a healthycontrol.

In some embodiments, the level of Rb phosphorylation at the serinecorresponding to amino acid position 780 of SEQ ID NO:3 being analyzedis reduced as compared to the level of Rb phosphorylation at the serinecorresponding to amino acid position 780 of SEQ ID NO:3 in a control.For example, the level of the Rb phosphorylation at the serinecorresponding to amino acid position 780 of SEQ ID NO:3 being analyzedcan be at least 1.5, at least 2, at least 3, at least 4, at least 5, atleast 6, at least 7, at least 8, at least 9, at least 10, at least 20,at least 25, at least 50, at least 75, or at least 100 times lower, orat least 10%, at least 20%, at least 30%, at least 40%, at least 50%, atleast 60%, at least 70%, at least 80%, at least 90%, or 100% lower, thanthe level of Rb phosphorylation at the serine corresponding to aminoacid position 780 of SEQ ID NO:3 in a control.

Biological Samples

Suitable biological samples for the methods described herein include anysample that contains blood or tumor cells obtained or derived from thehuman subject in need of treatment. For example, a biological sample cancontain tumor cells from biopsy from a patient suffering from a solidtumor. A tumor biopsy can be obtained by a variety of means known in theart. Alternatively, a blood sample can be obtained from a patientssuffering from a hematological cancer.

A biological sample can be obtained from a human subject having,suspected of having, or at risk of developing, a disease or disorderassociated with CDK2. In some embodiments, the disease or disorderassociated with CDK2 is a cancer (such as those described supra).

Methods for obtaining and/or storing samples that preserve the activityor integrity of molecules (e.g., nucleic acids or proteins) in thesample are well known to those skilled in the art. For example, abiological sample can be further contacted with one or more additionalagents such as buffers and/or inhibitors, including one or more ofnuclease, protease, and phosphatase inhibitors, which preserve orminimize changes in the molecules in the sample.

Evaluating Biomarkers and Pharmacodynamic Markers

Expression levels of CCNE1 or p16 can be detected as, e.g., RNAexpression of a target gene (i.e., the genes encoding CCNE1 or p16).That is, the expression level (amount) of CCNE1, or p16 can bedetermined by detecting and/or measuring the level of mRNA expression ofthe gene encoding CCNE1. Alternatively, expression levels of CCNE1 orp16 can be detected as, e.g., protein expression of target gene (i.e.,the genes encoding CCNE1 or p16). That is, the expression level (amount)of CCNE1 or p16 can be determined by detecting and/or measuring thelevel of protein expression of the genes encoding CCNE1 or p16.

In some embodiments, the expression level of CCNE1 or p16 is determinedby measuring RNA levels. A variety of suitable methods can be employedto detect and/or measure the level of mRNA expression of a gene. Forexample, mRNA expression can be determined using Northern blot or dotblot analysis, reverse transcriptase-PCR (RT-PCR; e.g., quantitativeRT-PCR), in situ hybridization (e.g., quantitative in situhybridization), nucleic acid array (e.g., oligonucleotide arrays or genechips) and RNA sequencing analysis. Details of such methods aredescribed below and in, e.g., Sambrook et al., Molecular Cloning: ALaboratory Manual Second Edition vol. 1, 2 and 3. Cold Spring HarborLaboratory Press: Cold Spring Harbor, N.Y., USA, November 1989; Gibsonet al. (1999) Genome Res., 6(10):995-1001; and Zhang et al. (2005)Environ. Sci. Technol., 39(8):2777-2785; U.S. Publication No.2004086915; European Patent No. 0543942; and U.S. Pat. No. 7,101,663;Kukurba et al. (2015) Cold Spring Harbor Protocols, 2015 (11): 951-69;the disclosures of each of which are incorporated herein by reference intheir entirety.

In one example, the presence or amount of one or more discrete mRNApopulations in a biological sample can be determined by isolating totalmRNA from the biological sample (see, e.g., Sambrook et al. (supra) andU.S. Pat. No. 6,812,341) and subjecting the isolated mRNA to agarose gelelectrophoresis to separate the mRNA by size. The size-separated mRNAsare then transferred (e.g., by diffusion) to a solid support such as anitrocellulose membrane. The presence or amount of one or more mRNApopulations in the biological sample can then be determined using one ormore detectably-labeled-polynucleotide probes, complementary to the mRNAsequence of interest, which bind to and thus render detectable theircorresponding mRNA populations. Detectable-labels include, e.g.,fluorescent (e.g., umbelliferone, fluorescein, fluoresceinisothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansylchloride, allophycocyanin, or phycoerythrin), luminescent (e.g.,europium, terbium, Qdot™ nanoparticles supplied by the Quantum DotCorporation, Palo Alto, Calif.), radiological (e.g., 125I, 131I, 35S,32P, 33P, or 3H), and enzymatic (horseradish peroxidase, alkalinephosphatase, beta-galactosidase, or acetylcholinesterase) labels.

In some embodiments, the expression level of CCNE1 or p16 is determinedby measuring protein levels. A variety of suitable methods can beemployed to detect and/or measure the level of protein expression oftarget genes. For example, CCNE1 or p16 protein expression can bedetermined using western blot, enzyme-linked immunosorbent assay(“ELISA”), fluorescence activated cell sorting, or immunohistochemistryanalysis (e.g., using a CCNE1-specific or p16-specific antibody,respectively). Details of such methods are described below and in, e.g.,Sambrook et al., supra.

In one example, the presence or amount of one or more discrete proteinpopulations (e.g., CCNE1 or p16) in a biological sample can bedetermined by western blot analysis, e.g., by isolating total proteinfrom the biological sample (see, e.g., Sambrook et al. (supra)) andsubjecting the isolated protein to agarose gel electrophoresis toseparate the protein by size. The size-separated proteins are thentransferred (e.g., by diffusion) to a solid support such as anitrocellulose membrane. The presence or amount of one or more proteinpopulations in the biological sample can then be determined using one ormore antibody probes, e.g., a first antibody specific for the protein ofinterest (e.g., CCNE1 or p16), and a second antibody, detectablylabeled, specific for the first antibody, which binds to and thusrenders detectable the corresponding protein population.Detectable-labels suitable for use in western blot analysis are known inthe art.

Methods for detecting or measuring gene expression (e.g., mRNA orprotein expression) can optionally be performed in formats that allowfor rapid preparation, processing, and analysis of multiple samples.This can be, for example, in multi-welled assay plates (e.g., 96 wellsor 386 wells) or arrays (e.g., nucleic acid chips or protein chips).Stock solutions for various reagents can be provided manually orrobotically, and subsequent sample preparation (e.g., RT-PCR, labeling,or cell fixation), pipetting, diluting, mixing, distribution, washing,incubating (e.g., hybridization), sample readout, data collection(optical data) and/or analysis (computer aided image analysis) can bedone robotically using commercially available analysis software,robotics, and detection instrumentation capable of detecting the signalgenerated from the assay. Examples of such detectors include, but arenot limited to, spectrophotometers, luminometers, fluorimeters, anddevices that measure radioisotope decay. Exemplary high-throughputcell-based assays (e.g., detecting the presence or level of a targetprotein in a cell) can utilize ArrayScan® VTI HCS Reader or KineticScan®HCS Reader technology (Cellomics Inc., Pittsburgh, Pa.).

In some embodiments, the presence of a CDKN2A gene encoding a p16protein comprising the amino acid sequence of SEQ ID NO:1 and/or thepresence of a CDKN2A gene lacking one or more inactivating nucleic acidsubstitutions and/or deletions is determined by evaluating the DNAsequence of the CDKN2A gene (e.g., genomic DNA or cDNA) or by evaluatingthe RNA sequence of the CDKN2A gene (e.g., RNA, e.g., mRNA). Methods ofperforming nucleic acid sequencing analyses are known in the art anddescribed above. Nonlimiting examples of inactivating nucleic acidsubstitutions and/or deletions preventing the CDKN2A gene from encodinga protein comprising the amino acid sequence of SEQ ID NO:1, aredescribed in Table A, above. In specific embodiments, the one or moreinactivating nucleic acid substitutions and/or deletions in the CDKN2Agene is as described in Yarbrough et al., Journal of the National CancerInstitute, 91(18):1569-1574, 1999; Liggett and Sidransky, Biology ofNeoplasia, Journal of Oncology, 16(3):1197-1206, 1998, and Cairns etal., Nature Genetics, 11:210-212, 1995, each of which is incorporated byreference herein in its entirety.

In some embodiments, the expression level of a gene or the presence of agene lacking one or more inactivating nucleic acid substitutions ordeletions is determined by evaluating the copy number variation (CNV) ofthe gene. The CNV of genes (e.g., the CCNE1 gene and/or the CDKN2A gene)can be determined/identified by a variety of suitable methods. Forexample, CNV can be determined using fluorescent in situ hybridization(FISH), multiplex ligation dependent probe amplification (MLPA), arraycomparative genomic hybridization (aCGH), single-nucleotidepolymorphisms (SNP) array, and next-generation sequencing (NGS)technologies.

In one example, the copy number variation of one or more discrete genesin a biological sample can be determined by MLPA, e.g., by extractingDNA specimens from the biological sample (see, e.g., Sambrook et al.(supra) and U.S. Pat. No. 6,812,341), and amplifying DNA sequence ofinterest (e.g., CCNE1 or CDKN2A) using a mixture of MLPA probes. EachMLPA probe consists of two oligonucleotides that hybridize toimmediately adjacent target DNA sequence (e.g., CCNE1 or CDKN2A) inorder to be ligated into a single probe. Ligated probes are amplifiedthough PCR with one PCR primer fluorescently labeled, enabling theamplification products to be visualized during fragment separation bycapillary electrophoresis. The presence, absence or amplification of oneor more genes of interest in the biological sample is calculated bymeasuring PCR derived fluorescence, quantifying the amount of PCRproduct after normalization and comparing it with control DNA samples.

The level of Rb phosphorylation at the serine corresponding to aminoacid position 780 of SEQ ID NO:3 can be detected by a variety ofsuitable methods. For example, phosphorylation status can be determinedusing western blot, ELISA, fluorescence activated cell sorting, orimmunohistochemistry analysis. Details of such methods are describedbelow and in, e.g., Sambrook et al., supra.

As with the methods for detecting or measuring gene expression (above),methods for detecting or measuring the level of Rb phosphorylation atthe serine corresponding to amino acid position 780 of SEQ ID NO:3 canoptionally be performed in formats that allow for rapid preparation,processing, and analysis of multiple samples.

The invention will be described in greater detail by way of specificexamples. The following examples are offered for illustrative purposes,and are not intended to limit the invention in any manner. Those ofskill in the art will readily recognize a variety of non-criticalparameters which can be changed or modified to yield essentially thesame results.

EXAMPLES

Experimental procedures for compounds of the invention are providedbelow. Preparatory LC-MS purifications of some of the compounds preparedwere performed on Waters mass directed fractionation systems. The basicequipment setup, protocols, and control software for the operation ofthese systems have been described in detail in the literature. See e.g.,“Two-Pump at-Column Dilution Configuration for Preparative LC-MS,” K.Blom, J. Combi. Chem., 4, 295 (2002); “Optimizing Preparative LC-MSConfigurations and Methods for Parallel Synthesis Purification,” K.Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi.Chem., 5, 670 (2003); and “Preparative LC-MS Purification: ImprovedCompound Specific Method Optimization,” K. Blom, B. Glass, R. Sparks, A.Combs, J. Combi. Chem., 6, 874-883 (2004). The separated compounds weretypically subjected to analytical liquid chromatography massspectrometry (LCMS) for purity check under the following conditions:Instrument: Agilent 1100 series, LC/MSD; Column: Waters Sunfire™ C₁₈ 5μm particle size, 2.1×5.0 mm; Buffers: mobile phase A: 0.025% TFA inwater and mobile phase B: acetonitrile; gradient 2% to 80% of B in 3minutes with flow rate 2.0 mL/minute.

Some of the compounds prepared were also separated on a preparativescale by reverse-phase high performance liquid chromatography (RP-HPLC)with MS detector or flash chromatography (silica gel) as indicated inthe Examples. Typical preparative reverse-phase high performance liquidchromatography (RP-HPLC) column conditions are as follows:

pH=2 purifications: Waters Sunfire™ C₁₈ 5 μm particle size, 19×100 mmcolumn, eluting with mobile phase A: 0.1% TFA (trifluoroacetic acid) inwater and mobile phase B: acetonitrile; the flow rate was 30 mL/minute,the separating gradient was optimized for each compound using theCompound Specific Method Optimization protocol as described in theliterature (see “Preparative LCMS Purification: Improved CompoundSpecific Method Optimization,” K. Blom, B. Glass, R. Sparks, A. Combs, JComb. Chem., 6, 874-883 (2004)). Typically, the flow rate used with the30×100 mm column was 60 mL/minute.

pH=10 purifications: Waters XBridge C₁₈ 5 μm particle size, 19×100 mmcolumn, eluting with mobile phase A: 0.15% NH₄OH in water and mobilephase B: acetonitrile; the flow rate was 30 mL/minute, the separatinggradient was optimized for each compound using the Compound SpecificMethod Optimization protocol as described in the literature (See“Preparative LCMS Purification: Improved Compound Specific MethodOptimization,” K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem.,6, 874-883 (2004)). Typically, the flow rate used with 30×100 mm columnwas 60 mL/minute.

Intermediate 1.8-Chloro-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-2-iodo-[1,2,4]triazolo[1,5-a]pyridine

Step 1:7-(1-(1-Ethoxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

A N₂-degassed mixture of 7-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-amine(1.67 g, 7.82 mmol, Ambeed A218977),1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(2.5 g, 9.4 mmol), potassium phosphate (4.98 g, 23.5 mmol), andchloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)(431 mg, 0.548 mmol, Aldrich 741825) in 1,4-dioxane (26.1 mL) and water(5.2 mL) was stirred at 100° C. for 30 min. After cooling to rt, thereaction mixture was diluted with CH₂Cl₂ and washed with water. Theaqueous layer was further extracted with CH₂Cl₂/MeOH (10:1) three times.The combined organic phases were dried over MgSO₄, filtered, andconcentrated to dryness. The residue was dissolved in CH₂Cl₂ (2 mL), andthen hexanes (100 mL) was added to the solution with stirring. Theprecipitate was collected and washed by Et₂O to give the desiredproduct, which was used without further purification. LC-MS calculatedfor C₁₃H₁₇N₆O (M+H)⁺: m/z=273.2; found 273.1.

Step 2:8-Chloro-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

To a solution of7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine(700 mg, 2.57 mmol) in CH₂Cl₂ (12.85 mL) was added N-chlorosuccinimide(378 mg, 2.83 mmol) and the reaction mixture was stirred at 45° C. for 3h. After cooling to rt, the mixture was washed with water. The organicphase was collected and dried over MgSO₄, filtered, and concentrated.The residue was purified by silica gel flash column chromatography(gradient 0-10% MeOH/CH₂Cl₂) to give the desired product. LC-MScalculated for C₁₃H₁₆ClN₆O (M+H)⁺: m/z=307.1; found 307.2.

Step 3:8-Chloro-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-2-iodo-[1,2,4]triazolo[1,5-a]pyridine

A mixture of8-chloro-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine(Step 2), diiodomethane (1.38 g, 5.14 mmol), and sodium nitrite (887 mg,12.85 mmol) in water (6 mL) and CH₂Cl₂ (6 mL) was stirred at rt for 5min. The reaction mixture was equipped with a balloon and then aceticacid (3 mL) was slowly added to the mixture. After stirring at rt for 30min, the organic phase was collected and the aqueous phase was washedwith CH₂Cl₂ three times. The combined organic phases were dried overMgSO₄, filtered, and concentrated. The crude residue was purified bysilica gel flash column chromatography. LC-MS calculated forC₁₃H₁₄ClIN₅O (M+H)⁺: m/z=418.0; found 418.1.

Intermediate 2.8-Chloro-N-(2,3-dimethylpyridin-4-yl)-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

In an oven-dried vial with a stir bar, a mixture of8-chloro-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-2-iodo-[1,2,4]triazolo[1,5-a]pyridine(Intermediate 1, 596 mg, 1.43 mmol), 2,3-dimethylpyridin-4-amine (262mg, 2.14 mmol),[(2-di-cyclohexylphosphino-3,6-dimethoxy-2′,4′,6′-triisopropyl-1,1′-biphenyl)-2-(2′-amino-1,1′-biphenyl)]palladium(II)methanesulfonate (129 mg, 0.143 mmol, Aldrich 745979), and cesiumcarbonate (1396 mg, 4.28 mmol) in 1,4-dioxane (9.5 mL) was sparged withnitrogen and stirred at 120° C. overnight. After cooling to roomtemperature, the reaction mixture was diluted with CH₂Cl₂ and water. Theaqueous layer was washed with CH₂Cl₂ three times. The combined organiclayers were dried over MgSO₄, filtered, and concentrated. The cruderesidue was purified by silica gel flash column chromatography (gradient0-10% MeOH/CH₂Cl₂) to give the desired product. LC-MS calculated forC₂₀H₂₃ClN₇O (M+H)⁺: m/z=412.2; found 412.3.

Intermediate 3.8-Bromo-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

This compound was prepared according to the procedure described forIntermediate 1, with N-bromosuccinimide replacing N-chlorosuccinimide inStep 2. LC-MS calculated for C₁₃H₁₆BrN₆O (M+H)⁺: m/z=351.1; found 351.1.

Intermediate 4.7-(1-(1-Ethoxyethyl)-1H-pyrazol-4-yl)-8-isopropoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-amine

Step 1: 4-Amino-6-chloropyrimidin-5-ol Hydrobromide

To a mixture of 6-chloro-5-methoxypyrimidin-4-amine (26.0 g, 163 mmol,Combi-Blocks QC-2900) in CH₂Cl₂ (500 mL) was slowly added neat borontribromide (17.7 mL, 187 mmol) and the reaction mixture was stirred atrt for 3 days. The reaction mixture was quenched with 2-propanol (43.9mL, 570 mmol) and Et₂O (200 mL) was added. The solid precipitate thatformed was collected via filtration, washed with Et₂O, and dried undervacuum to afford the desired product. The crude material obtained wasused directly without further purification. LC-MS calculated forC₄H5ClN₃O (M+H)⁺: m/z=146.0; found 145.9.

Step 2: 4-Amino-6-chloropyrimidin-5-ol hydrobromide

To a mixture of 4-amino-6-chloropyrimidin-5-ol hydrobromide (Step 1) inCH₃CN (300 mL) was added 2-iodopropane (25.0 mL, 250 mmol) and K₂CO₃(56.3 g, 407 mmol) and the reaction mixture was stirred at 60° C.overnight. After cooling to rt, the reaction mixture was diluted withEtOAc (300 mL) and filtered. The filtrate was concentrated under reducedpressure, and the crude residue was dissolved in EtOAc and the mixturewas concentrated to half volume before hexanes was added. The solidprecipitate that formed was collected via filtration, washed with 10%EtOAc in hexanes, and dried under vacuum to afford the desired product.The crude material obtained was used directly without furtherpurification. LC-MS calculated for C₇H₁₁ClN₃O (M+H)⁺: m/z=188.1; found188.0.

Step 3:6-(1-(1-Ethoxyethyl)-1H-pyrazol-4-yl)-5-isopropoxypyrimidin-4-amine

A mixture of 6-chloro-5-isopropoxypyrimidin-4-amine (7.45 g, 39.7 mmol),1-(1-ethoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(12.7 g, 48 mmol), Pd(dppf)Cl₂CH₂Cl₂ adduct (1.62 g, 1.98 mmol), andpotassium phosphate, tribasic (25.3 g, 119 mmol) in 1,4-dioxane/H₂O(5:1, 200 mL) was purged with nitrogen and stirred at 90° C. overnight.After cooling to rt, the reaction mixture was diluted with water andextracted with CH₂Cl₂. The combined organic phases were dried overMgSO₄, filtered, and concentrated. The crude material obtained was useddirectly without further purification. LC-MS calculated for C₁₄H₂₂N₅O₂(M+H)⁺: m/z=292.2; found 292.1.

Step 4:7-(1-(1-Ethoxyethyl)-1H-pyrazol-4-yl)-8-isopropoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-amine

To a mixture of6-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-5-isopropoxypyrimidin-4-amine(Step 3) in 1,4-dioxane (100 mL) was added O-ethylcarbonisothiocyanatidate (9.37 mL, 79 mmol) and the reaction mixture waspurged with nitrogen and stirred at 90° C. for 8 h. After cooling to rt,the reaction mixture was concentrated in vacuo. To the crude residue wasadded a mixture of hydroxylamine hydrochloride (25.8 g, 371 mmol) andN-ethyl-N-isopropylpropan-2-amine (64.7 mL, 371 mmol) in MeOH/EtOH (1:1,200 mL) and the reaction mixture was stirred at 60° C. for 30 min. Aftercooling to rt, the reaction mixture was concentrated in vacuo and theresidue was diluted with saturated aqueous NH₄Cl and extracted withCH₂Cl₂. The combined organic phases were dried over MgSO₄, filtered, andconcentrated. The residue was purified by silica gel columnchromatography. LC-MS calculated for C₁₅H₂₂N₇O₂ (M+H)⁺: m/z=332.2; found332.1.

Intermediate 5.2-Bromo-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-8-isopropoxy-[1,2,4]triazolo[1,5-c]pyrimidine

To a suspension of7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-8-isopropoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-amine(Intermediate 4, 0.80 g, 2.4 mmol) and copper(II) bromide (0.539 g,2.414 mmol) in CH₃CN (10 mL) was added tert-butyl nitrite (90 wt %, 0.7mL, 5 mmol) and the reaction mixture was stirred at rt for 1 h. Thereaction mixture was treated with a 35% aqueous ammonia solution and themixture was diluted with saturated aqueous NH₄Cl and extracted withEtOAc (3×10 mL). The combined organic phases were washed with brine,dried over MgSO₄, filtered, and concentrated. The crude residue waspurified by flash column chromatography (SiO₂, EtOAc/hexanes). LC-MScalculated for C₁₅H₂₀BrN₆O₂(M+H)⁺: m/z=395.1; found 395.1.

Intermediate 6.1-(4-Chloro-3-methylpyridin-2-yl)-N,N-dimethylmethanamine

A mixture of 4-chloro-3-methylpicolinaldehyde (23.3 mg, 0.15 mmol,Combi-Blocks HC-4471), a 2 M solution of dimethylamine in THF (375 μL,0.75 mmol), and N-ethyl-N-isopropylpropan-2-amine (52 μL, 0.3 mmol) inTHE (0.75 mL) were stirred at rt for 10 min before sodiumtriacetoxyborohydride (63.5 mg, 0.30 mmol) was added and the mixture wasstirred at rt for 2 hours. The reaction mixture was diluted withsaturated aqueous NaHCO₃ and extracted with EtOAc. The combined organicphases were dried over MgSO₄ and concentrated. The crude materialobtained was used directly without further purification. LC-MScalculated for C₉H₁₄ClN₂ (M+H)⁺: m/z=185.1; found 185.2.

Intermediate 7. (4-Chloro-3-methylpyridin-2-yl)methanol

A mixture of 4-chloro-3-methylpicolinaldehyde (23.3 mg, 0.15 mmol,Combi-Blocks HC-4471) in THE (0.75 mL) and sodium triacetoxyborohydride(63.5 mg, 0.30 mmol) stirred at rt for 2 h. The reaction mixture wasdiluted with saturated aqueous NaHCO₃ and extracted with EtOAc. Thecombined organic phases were dried over MgSO₄ and concentrated. Thecrude material obtained was used directly without further purification.LC-MS calculated for C₇H₉ClNO (M+H)⁺: m/z=158.0; found 158.2.

Example 1.6-(2-((2,3-Dimethylpyridin-4-yl)amino)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-3-methylbenzo[d]oxazol-2(3H)-one

A N₂-degassed mixture of8-chloro-N-(2,3-dimethylpyridin-4-yl)-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine(Intermediate 2, 10 mg, 0.024 mmol),3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2(3H)-one(10 mg, 0.036 mmol), potassium phosphate (15.5 mg, 0.073 mmol), andchloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)(1.9 mg, 2.4 μmol, Aldrich 741825) in 1,4-dioxane/water (5:1, 0.16 mL)was stirred at 100° C. for 30 min. After cooling to rt, the reactionmixture was diluted with MeOH (1 mL) and filtered over a SiliaPrep SPEsilica-based thiol cartridge. A 4 M solution of HCl in 1,4-dioxane (0.2mL) was added to the filtrate and the reaction mixture was stirred at rtfor 30 min. The mixture was diluted with MeOH, filtered, and purified byprep-HPLC (Sunfire C18 column, eluting with a gradient ofacetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min) toafford the desired product as its TFA salt. LC-MS calculated forC₂₄H₂₁N₈O₂ (M+H)⁺: m/z=453.2; found 453.2.

Example 2.3-(2-((2,3-Dimethylpyridin-4-yl)amino)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-4-fluorobenzonitrile

This compound was prepared according to the procedure described inExample 1, with4-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrilereplacing3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2(3H)-one.LC-MS calculated for C₂₃H₁₈FN₈ (M+H)⁺: m/z=425.2; found 425.3.

Example 3.N-(2,3-Dimethylpyridin-4-yl)-8-(1-methyl-1H-indazol-5-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

This compound was prepared according to the procedure described inExample 1, with1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazolereplacing3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2(3H)-one.LC-MS calculated for C₂₄H₂₂N₉(M+H)⁺: m/z=436.2; found 436.3.

Example 4.(4-(2-((2,3-Dimethylpyridin-4-yl)amino)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-3-fluorophenyl)methanol

This compound was prepared according to the procedure described inExample 1, with (2-fluoro-4-(hydroxymethyl)phenyl)boronic acid replacing3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2(3H)-one.LC-MS calculated for C₂₃H₂₁FN₇O (M+H)⁺: m/z=430.2; found 430.3.

Example 5.N-(2,3-Dimethylpyridin-4-yl)-8-(3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

This compound was prepared according to the procedure described inExample 1, with1-(2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pyrrolidinereplacing3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2(3H)-one.LC-MS calculated for C₂₇H₂₈FN₈ (M+H)⁺: m/z=483.2; found 483.4.

Example 6.N-(2,3-Dimethylpyridin-4-yl)-8-(5-fluoro-2-methylpyridin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine

This compound was prepared according to the procedure described inExample 1, with (5-fluoro-2-methylpyridin-4-yl)boronic acid replacing3-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]oxazol-2(3H)-one.LC-MS calculated for C₂₂H₂₀FN₈ (M+H)⁺: m/z=415.2; found 415.3.

Example 7.4-(7-(1H-Pyrazol-4-yl)-2-(quinolin-4-ylamino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-5-fluoro-2-methylbenzonitrile

Step 1:N-(8-Bromo-7-(1-(I-ethoxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)quinolin-4-amine

To a mixture of8-bromo-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine(Intermediate 3, 131 mg, 0.373 mmol) and 4-fluoroquinoline (60.4 mg,0.410 mmol) in THF (2.5 mL) was added potassium tert-butoxide (75 μL,0.75 mmol, 1.0 M in THF). The mixture was stirred at 80° C. for 2 h.After cooling to rt, the reaction was quenched with water. The mixturewas extracted with CH₂Cl₂ three times. The organic phase was dried overMgSO₄, filtered, and concentrated. The residue was purified by silicagel flash chromatography to give the desired product. LC-MS calculatedfor C₂₂H₂₁BrN₇O (M+H)⁺: m/z=478.1; found 478.2.

Step 2:4-(7-(1H-Pyrazol-4-yl)-2-(quinolin-4-ylamino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-5-fluoro-2-methylbenzonitrile

A N₂-degassed mixture ofN-(8-bromo-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl)quinolin-4-amine(Step 1, 11 mg, 0.023 mmol),5-fluoro-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile(9.0 mg, 0.034 mmol), potassium phosphate (14.6 mg, 0.069 mmol) andchloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II)(1.8 mg, 2.3 μmol, Aldrich 741825) in 1,4-dioxane/water (5:1, 0.15 mL)was stirred at 100° C. for 30 min. After cooling to room temperature,the reaction mixture was diluted with MeOH (1 mL) and filtered over aSiliaPrep SPE silica-based thiol cartridge. A 4 M solution of HCl in1,4-dioxane (0.2 mL) was added to the filtrate and the reaction mixturewas stirred at rt for 30 min. The mixture was diluted with MeOH,filtered, and purified by prep-HPLC (Sunfire C18 column, eluting with agradient of acetonitrile/water containing 0.1% TFA, at flow rate of 60mL/min) to afford the desired product as its TFA salt. LC-MS calculatedfor C₂₆H₁₈FN₈ (M+H)⁺: m/z=461.2; found 461.1.

Example 8.N-(2-((Dimethylamino)methyl)-3-methylpyridin-4-yl)-8-isopropoxy-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-2-amine

To a mixture of7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-8-isopropoxy-[1,2,4]triazolo[1,5-c]pyrimidin-2-amine(Intermediate 4, 100 mg, 0.30 mmol), Pd(OAc)₂ (6.8 mg, 0.030 mmol),(±)-([1,1′-binaphthalene]-2,2′-diyl)bis(diphenylphosphane) (18.8 mg,0.030 mmol), and Cs₂CO₃ (197 mg, 0.60 mmol) in 1,4-dioxane (5 mL) wasadded 1-(4-chloro-3-methylpyridin-2-yl)-N,N-dimethylmethanamine(Intermediate 6, 66.9 mg, 0.36 mmol) and the reaction mixture was purgedwith nitrogen and stirred at 120° C. overnight. After cooling to rt, a4:1 mixture of TFA/H₂O (4 mL) was added and the reaction mixture wasstirred at 50° C. for 4 h. After cooling to rt, the mixture was dilutedwith MeOH, filtered, and purified by prep-HPLC (Sunfire C18, column,eluting with a gradient of acetonitrile/water containing 0.1% TFA, atflow rate of 60 mL/min) to afford the desired product as its TFA salt.LC-MS calculated for C₂₀H₂₆N₉O (M+H)⁺: m/z=408.2; found 408.3. ¹H NMR(TFA salt, 600 MHz, DMSO-d₆) δ 9.59 (s, 1H), 9.35 (s, 1H), 8.43 (d,J=5.8 Hz, 1H), 8.30 (s, 2H), 8.26 (d, J=5.8 Hz, 1H), 5.64 (hept, J=6.2Hz, 1H), 4.55 (s, 2H), 2.88 (s, 6H), 2.30 (s, 3H), 1.37 (d, J=6.2 Hz,6H).

Example 9.(4-((8-Isopropoxy-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)amino)-3-methylpyridin-2-yl)methanol

This compound was prepared according to the procedure described inExample 8, with (4-chloro-3-methylpyridin-2-yl)methanol (Intermediate 7)replacing 1-(4-chloro-3-methylpyridin-2-yl)-N,N-dimethylmethanamine.LC-MS calculated for C₁₈H₂₁N₈O₂ (M+H)⁺: m/z=381.2; found 381.3. ¹H NMR(TFA salt, 600 MHz, DMSO-d₆) δ 13.84 (brs, 1H), 10.48 (s, 1H), 9.44 (s,1H), 8.62 (d, J=7.0 Hz, 1H), 8.47 (d, J=7.0 Hz, 1H), 8.32 (s, 2H), 6.50(brs, 1H), 5.66 (hept, J=6.2 Hz, 1H), 4.87 (s, 2H), 2.32 (s, 3H), 1.39(d, J=6.2 Hz, 6H).

Example 10.N-(2,3-Dimethylpyridin-4-yl)-8-isopropoxy-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-2-amine

This compound was prepared according to a modification of the proceduredescribed in Example 8, with 4-bromo-2,3-dimethylpyridine (1.5 equiv)replacing 1-(4-chloro-3-methylpyridin-2-yl)-N,N-dimethylmethanamine.LC-MS calculated for C₁₈H₂₁N₈O (M+H)⁺: m/z=365.2; found 365.1. ¹H NMR(TFA salt, 600 MHz, DMSO-d₆) δ 14.40 (brs, 1H), 10.43 (s, 1H), 9.45 (s,1H), 8.56 (d, J=7.0 Hz, 1H), 8.50 (d, J=7.0 Hz, 1H), 8.31 (s, 2H), 5.65(hept, J=6.2 Hz, 1H), 2.62 (s, 3H), 2.39 (s, 3H), 1.39 (d, J=6.2 Hz,6H).

Example 11.8-Isopropoxy-N-(5-methylimidazo[1,2-a]pyridin-6-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-2-amine

To a mixture of2-bromo-7-(1-(1-ethoxyethyl)-1H-pyrazol-4-yl)-8-isopropoxy-[1,2,4]triazolo[1,5-c]pyrimidine(Intermediate 5, 10 mg, 0.025 mmol), Pd(OAc)₂ (0.6 mg, 3 μmol),(±)-([1,1′-binaphthalene]-2,2′-diyl)bis(diphenylphosphane) (1.6 mg, 3μmol), and Cs₂CO₃ (16.49 mg, 0.051 mmol) in 1,4-dioxane (1 mL) was added5-methylimidazo[1,2-a]pyridin-6-amine (5.6 mg, 0.038 mmol) and thereaction mixture was purged with nitrogen and stirred at 120° C.overnight. After cooling to rt, a 4:1 mixture of TFA/H₂O (0.5 mL) wasadded and the reaction mixture was stirred at 50° C. for 4 h. Aftercooling to rt, the mixture was diluted with MeOH, filtered, and purifiedby prep-HPLC (Sunfire C18 column, eluting with a gradient ofacetonitrile/water containing 0.1% TFA, at flow rate of 60 mL/min) toafford the desired product as its TFA salt. LC-MS calculated forC₁₉H₂₀N₉O (M+H)⁺: m/z=390.2; found 390.2.

Example 12.N-(2-Fluoro-4-(methylsulfonyl)phenyl)-8-isopropoxy-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-2-amine

This compound was prepared according to the procedure described inExample 11, with 2-fluoro-4-(methylsulfonyl)aniline replacing5-methylimidazo[1,2-a]pyridin-6-amine. LC-MS calculated for C₁₈H₁₉FN₇O₃S(M+H)⁺: m/z=432.1; found 432.1.

Example A. CDK2/Cyclin E1 HTRF Enzyme Activity Assay

CDK2/Cyclin E1 enzyme activity assays utilize full-length human CDK2co-expressed as N-terminal GST-tagged protein with FLAG-Cyclin E1 in abaculovirus expression system (Carna Product Number 04-165). Assays wereconducted in white 384-well polystyrene plates in a final reactionvolume of 8 μL. CDK2/Cyclin E1 (0.25 nM) was incubated with thecompounds of the Examples (40 nL serially diluted in DMSO) in thepresence of ATP (50 μM or 1 mM) and 50 nM ULight™-labeled eIF4E-bindingprotein 1 (THR37/46) peptide (PerkinElmer) in assay buffer (containing50 mM HEPES pH 7.5, 1 mM EGTA, 10 mM MgCl₂, 2 mM DTT, 0.05 mg/mL BSA,and 0.01% Tween 20) for 60 minutes at room temperature. The reactionswere stopped by the addition of EDTA and Europium-labeledanti-phospho-4E-BP1 antibody (PerkinElmer), for a final concentration of15 mM and 1.5 nM, respectively. HTRF signals were read after 1 hour atroom temperature on a PHERAstar FS plate reader (BMG Labtech). Data wasanalyzed with IDBS XLFit and GraphPad Prism 5.0 software using a threeor four parameter dose response curve to determine IC₅₀ for eachcompound. The IC₅₀ data as measured for the compounds of the Examples at1 mM ATP in the assay of Example A is shown in Table 1.

TABLE 1 Example IC₅₀ (nM) 1 + 2 + 3 + 4 + 5 + 6 + 7 + 8 + 9 + 10 + 11 +12 + + refers to ≤ 10 nM

Various modifications of the invention, in addition to those describedherein, will be apparent to those skilled in the art from the foregoingdescription. Such modifications are also intended to fall within thescope of the appended claims. Each reference, including all patent,patent applications, and publications, cited in the present applicationis incorporated herein by reference in its entirety.

What is claimed is:
 1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

is a single or a double bond; n is 0, 1, 2, 3, or 4; Y is CR^(1a) orNR^(1b), wherein Y is adjacent to the carbon ring member attaching Ringmoiety A to the —NH— in Formula (I); Ring moiety A is selected fromC₆₋₁₀ aryl and 5-10 membered heteroaryl, wherein Ring moiety A isattached to the —NH— in Formula (I) through a carbon atom; R^(1a) isselected from halo, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, 4-6membered heterocycloalkyl, OR^(a1), SR^(a1), SF₅, NR^(c1)R^(d1), C₃₋₆cycloalkyl-C₁₋₃ alkyl, and 4-6 membered heterocycloalkyl-C₁₋₃ alkyl,wherein said C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, 4-6 memberedheterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl, and 4-6 memberedheterocycloalkyl-C₁₋₃ alkyl are optionally substituted by 1, 2, 3, or 4independently selected R^(G) substituents; or, alternatively, R^(1a) andan R² on an adjacent ring member of Ring moiety A, together with thering atoms to which they are attached, form Ring moiety B; R^(1b) isselected from C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₃₋₆ cycloalkyl, 4-6 memberedheterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl, and 4-6 memberedheterocycloalkyl-C₁₋₃ alkyl, wherein said C₁₋₄ alkyl, C₁₋₄ haloalkyl,C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, C₃₋₆ cycloalkyl-C₁₋₃alkyl, and 4-6 membered heterocycloalkyl-C₁₋₃ alkyl are optionallysubstituted by 1, 2, 3, or 4 independently selected R^(G) substituents;or, alternatively, R^(1b) and an R² on an adjacent ring member of Ringmoiety A, together with the ring atoms to which they are attached, formRing moiety B; Ring moiety B is selected from C₃₋₆ cycloalkyl, 4-6membered heterocycloalkyl, phenyl, and 5-6 membered heteroaryl, each ofwhich is optionally substituted by 1, 2, 3, or 4 independently selectedR³ substituents; each R^(a1), R^(c1), and R^(d1) is independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents; or, any R^(c1) and R^(d1) attached to the same Natom, together with the N atom to which they are attached, form a 4-7membered heterocycloalkyl group, wherein the 4-7 memberedheterocycloalkyl group is optionally substituted with 1, 2, 3, or 4independently selected R^(G) substituents; each R² and R³ isindependently selected from H, D, halo, CN, NO₂, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 memberedaryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-10 membered heteroaryl-C₁₋₄ alkyl,OR^(a2), SR^(a2), NHOR^(a2), C(O)R^(b2), C(O)NR^(c2)R^(d2),C(O)NR^(c2)(OR^(a2)), C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2),NR^(c2)R^(d2), NR^(c2)NR^(c2)R^(d2), NR^(c2)C(O)R^(b2),NR^(c2)C(O)OR^(a2), NR^(c2)C(O)NR^(c2)R^(d2), C(═NR^(e2))R^(b2),C(═NR^(e2))NR^(c2)R^(d2), NR^(c2)C(═NR^(e2))NR^(c2)R^(d2),NR^(c2)C(═NR^(e2))R^(b2), NR^(c2)S(O)NR^(c2)R^(d2), NR^(c2)S(O)R^(b2),NR^(c2)S(O)₂R^(b2), NR^(c2)S(O)(═NR^(e2))R^(b2),NR^(c2)S(O)₂NR^(c2)R^(d2), S(O)R^(b2), S(O)NR^(c2)R^(d2), S(O)₂R^(b2),S(O)₂NR^(c2)R^(d2), OS(O)(═NR^(e2))R^(b2), OS(O)₂R^(b2),S(O)(═NR^(e2))R^(b2), SF₅, P(O)R^(f2)R^(g2), OP(O)(OR^(h2))(OR^(i2)),P(O)(OR^(h2))(OR^(i2)), and BR^(j2)R^(k2), wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 memberedaryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2A) substituents; each R^(a2), R^(c2), and R^(d2) is independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl,5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2A) substituents; or, any R^(c2) and R^(d2) attached to the same Natom, together with the N atom to which they are attached, form a 4-10membered heterocycloalkyl group, wherein the 4-10 memberedheterocycloalkyl group is optionally substituted with 1, 2, 3, or 4independently selected R^(2A) substituents; each R^(b2) is independentlyselected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl,5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(2A) substituents; eachR^(e2) is independently selected from H, OH, CN, C₁₋₆ alkyl, C₁₋₆alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₇ cycloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl; each R^(f2) and R^(g2)are independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10membered heteroaryl-C₁₋₄ alkyl; each R^(h2) and R^(i2) is independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl,5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10membered heteroaryl-C₁₋₄ alkyl; each R^(j2) and R^(k2) is independentlyselected from OH, C₁₋₆ alkoxy, and C₁₋₆ haloalkoxy; or any R^(j2) andR^(k2) attached to the same B atom, together with the B atom to whichthey are attached, form a 5- or 10-membered heterocycloalkyl groupoptionally substituted with 1, 2, 3, or 4 substituents independentlyselected from C₁₋₆ alkyl and C₁₋₆ haloalkyl; each R^(2A) isindependently selected from H, D, halo, CN, NO₂, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 memberedaryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-10 membered heteroaryl-C₁₋₄ alkyl,OR^(a21), SR^(a21), NHOR^(a21), C(O)R^(b21), C(O)NR^(c21)R^(d21),C(O)NR^(c21)(OR^(a21)), C(O)OR^(a21), OC(O)R^(b21),OC(O)NR^(c21)R^(d21), NR^(c21)R^(d21), NR^(c21)NR^(c21)R^(d21),NR^(c21)C(O)R^(b21), NR^(c21)C(O)OR^(a21), NR^(c21)C(O)NR^(c21)R^(d21),C(═NR^(e21))R^(b21), C(═NR^(e21))NR^(c21)R^(d21),NR^(c21)C(═NR^(e21))NR^(c21)R^(d21), NR^(c21)C(═NR^(e21))R^(b21),NR^(c21)S(O)NR^(c21)R^(d21), NR^(c21)S(O)R^(b21), NR^(c21)S(O)₂R^(b21),NR^(c21)S(O)(═NR^(e21))R^(b21), NR^(c21)S(O)₂NR^(c21)R^(d21),S(O)R^(b21), S(O)NR^(c21)R^(d21), S(O)₂R^(b21), S(O)₂NR^(c21)R^(d21),OS(O)(═NR^(e21))R^(b21), OS(O)₂R^(b21), S(O)(═NR^(e21))R^(b21), SF₅,P(O)R^(f21)R^(g21), OP(O)(OR^(h21))(OR^(i21)), P(O)(OR^(h21))(OR^(i21)),and BR^(j21)R^(k21), wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2B) substituents; each R^(a21), R^(c21), and R^(d21) is independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl,5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2B) substituents; or, any R^(c21) and R^(d21) attached to the same Natom, together with the N atom to which they are attached, form a 4-10membered heterocycloalkyl group, wherein the 4-10 memberedheterocycloalkyl group is optionally substituted with 1, 2, 3, or 4independently selected R^(2B) substituents; each R^(b21) isindependently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl, which are eachoptionally substituted with 1, 2, 3, or 4 independently selected R^(2B)substituents; each R^(e21) is independently selected from H, OH, CN,C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl,4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;each R^(f21) and R^(g21) are independently selected from H, C₁₋₆ alkyl,C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl; each R^(h21) and R^(i21)is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;each R^(j21) and R^(k21) is independently selected from OH, C₁₋₆ alkoxy,and C₁₋₆ haloalkoxy; or any R^(j21) and R^(k21) attached to the same Batom, together with the B atom to which they are attached, form a 5- or10-membered heterocycloalkyl group optionally substituted with 1, 2, 3,or 4 substituents independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl; each R^(2B) is independently selected from H, D, halo, CN,NO₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl,OR^(a22), SR^(a22), NHOR^(a22), C(O)R^(b22), C(O)NR^(c22)R^(d22),C(O)NR^(c22)(OR^(a22)), C(O)OR^(a22), OC(O)R^(b22),OC(O)NR^(c22)R^(d22), NR^(c22)R^(d22), NR^(c22)NR^(c22)R^(d22),NR^(c22)C(O)R^(b22), NR^(c22)C(O)OR^(a22), NR^(c22)C(O)NR^(c22)R^(d22),C(═NR^(e22))R^(b22), C(═NR^(e22))NR^(c22)R^(d22),NR^(c22)C(═NR^(e22))NR^(c22)R^(d22), NR^(c22)C(═NR^(e22))R^(b22),NR^(c22)S(O)NR^(c22)R^(d22), NR^(c22)S(O)R^(b22), NR^(c22)S(O)₂R^(b22),NR^(c22)S(O)(═NR^(e22))R^(b22), NR^(c22)S(O)₂NR^(c22)R^(d22),S(O)R^(b22), S(O)NR^(c22)R^(d22), S(O)₂R^(b22), S(O)₂NR^(c22)R^(d22),OS(O)(═NR^(e22))R^(b22), OS(O)₂R^(b22), S(O)(═NR^(e22))R^(b22), SF₅,P(O)R^(f22)R^(g22), OP(O)(OR^(h22))(OR^(i22)), P(O)(OR^(h22))(OR^(i22)),and BR^(j22)R^(k22), wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1,2, 3, or 4 independently selected R^(G) substituents; each R^(a22),R^(c22), and R^(d22) is independently selected from H, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(G) substituents; or, any R^(c22)and R^(d22) attached to the same N atom, together with the N atom towhich they are attached, form a 4-7 membered heterocycloalkyl group,wherein the 4-7 membered heterocycloalkyl group is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(G)substituents; each R^(b22) is independently selected from C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl, which are each optionallysubstituted with 1, 2, 3, or 4 independently selected R^(G)substituents; each R^(e22) is independently selected from H, OH, CN,C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl,5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl,4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 memberedheteroaryl-C₁₋₄ alkyl; each R^(f22) and R^(g22) are independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl; each R^(h22) and R^(i22) isindependently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl,5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl,4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 memberedheteroaryl-C₁₋₄ alkyl; each R^(j22) and R^(k22) is independentlyselected from OH, C₁₋₆ alkoxy, and C₁₋₆ haloalkoxy; or any R^(j22) andR^(k22) attached to the same B atom, together with the B atom to whichthey are attached, form a 5- or 6-membered heterocycloalkyl groupoptionally substituted with 1, 2, 3, or 4 substituents independentlyselected from C₁₋₆ alkyl and C₁₋₆ haloalkyl; R⁴ is independentlyselected from 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10membered heteroaryl, OR^(a4), and NR^(c4)R^(d4), wherein said 6-10membered aryl, 4-10 membered heterocycloalkyl, and 5-10 memberedheteroaryl are each optionally substituted with 1, 2, 3, or 4independently selected R^(4A) substituents; each R^(a4), R^(c4), andR^(d4) is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl,5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1,2, 3, or 4 independently selected R^(4A) substituents; or, any R^(c4)and R^(d4) attached to the same N atom, together with the N atom towhich they are attached, form a 4-10 membered heterocycloalkyl group,wherein the 4-10 membered heterocycloalkyl group is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(4A)substituents; each R^(4A) is independently selected from H, D, halo, CN,NO₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, 5-10membered heteroaryl-C₁₋₄ alkyl, OR^(a41), SR^(a41), NHOR^(a41),C(O)R^(b41), C(O)NR^(c41)R^(d41), C(O)NR^(c41)(OR^(a41)), C(O)OR^(a41),OC(O)R^(b41), OC(O)NR^(c41)R^(d41), NR^(c41)R^(d41),NR^(c41)NR^(c41)R^(d41), NR^(c41)C(O)R^(b41), NR^(c41)C(O)OR^(a41),NR^(c41)C(O)NR^(c41)R^(d41), C(═NR^(e41))R^(b41),C(═NR^(e41))NR^(c41)R^(d41), NR^(c41)C(═NR^(e41))NR^(c41)R^(d41),NR^(c41)C(═NR^(e41))R^(b41), NR^(c41)S(O)NR^(c41)R^(d41),NR^(c41)S(O)R^(b41), NR^(c41)S(O)₂R^(b41),NR^(c41)S(O)(═NR^(e41))R^(b41), NR^(c41)S(O)₂NR^(c41)R^(d41),S(O)R^(b41), S(O)NR^(c41)R^(d41), S(O)₂R^(b41), S(O)₂NR^(c41)R^(d41),OS(O)(═NR^(e41))R^(b41), OS(O)₂R^(b41), S(O)(═NR^(e41))R^(b41), SF₅,P(O)R^(f41)R^(g41), OP(O)(OR^(h41))(OR^(i41)), P(O)(OR^(h41))(OR^(i41))and BR^(j41)R^(k41), wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents; each R^(a41), R^(c41), and R^(d41) is independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl,5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents; or, any R^(c41) and R^(d41) attached to the same Natom, together with the N atom to which they are attached, form a 4-10membered heterocycloalkyl group, wherein the 4-10 memberedheterocycloalkyl group is optionally substituted with 1, 2, 3, or 4independently selected R^(4B) substituents; each R^(b41) isindependently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl, which are eachoptionally substituted with 1, 2, 3, or 4 independently selected R^(4B)substituents; each R^(e41) is independently selected from H, OH, CN,C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl,4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;each R^(f41) and R^(g41) are independently selected from H, C₁₋₆ alkyl,C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl; each R^(h41) and R^(i41)is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10membered heterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl;each R^(j41) and R^(k41) is independently selected from OH, C₁₋₆ alkoxy,and C₁₋₆ haloalkoxy; or any R^(j41) and R^(k41) attached to the same Batom, together with the B atom to which they are attached, form a 5- or10-membered heterocycloalkyl group optionally substituted with 1, 2, 3,or 4 substituents independently selected from C₁₋₆ alkyl and C₁₋₆haloalkyl; each R^(4B) is independently selected from H, D, halo, CN,NO₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl,OR^(a42), SR^(a42), NHOR^(a42), C(O)R^(b42), C(O)NR^(c42)R^(d42),C(O)NR^(c42)(OR^(a42)), C(O)OR^(a42), OC(O)R^(b42),OC(O)NR^(c42)R^(d42), NR^(c42)R^(d42), NR^(c42)NR^(c42)R^(d42),NR^(c42)C(O)R^(b42), NR^(c42)C(O)OR^(a42), NR^(c42)C(O)NR^(c42)R^(d42),C(═NR^(e42))R^(b42), C(═NR^(e42))NR^(c42)R^(d42),NR^(c42)C(═NR^(e42))NR^(c42)R^(d42), NR^(c42)C(═NR^(e42))R^(b42),NR^(c42)S(O)NR^(c42)R^(d42), NR^(c42)S(O)R^(b42), NR^(c42)S(O)₂R^(b42),NR^(c42)S(O)(═NR^(e42))R^(b42), NR^(c42)S(O)₂NR^(c42)R^(d42),S(O)R^(b42), S(O)NR^(c42)R^(d42), S(O)₂R^(b42), S(O)₂NR^(c42)R^(d42),OS(O)(═NR^(e42))R^(b42), OS(O)₂R^(b42), S(O)(═NR^(e42))R^(b42), SF₅,P(O)R^(f42)R^(g42), OP(O)(OR^(h42))(OR^(i42)), P(O)(OR^(h42))(OR^(i42)),and BR^(j42)R^(k42), wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1,2, 3, or 4 independently selected R^(4C) substituents; each R^(a42),R^(c42), and R^(d42) is independently selected from H, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(4C) substituents; or, anyR^(c42) and R^(d42) attached to the same N atom, together with the Natom to which they are attached, form a 4-7 membered heterocycloalkylgroup, wherein the 4-7 membered heterocycloalkyl group is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(4C)substituents; each R^(b42) is independently selected from C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl, which are each optionallysubstituted with 1, 2, 3, or 4 independently selected R^(4C)substituents; each R^(e42) is independently selected from H, OH, CN,C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl,5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl,4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 memberedheteroaryl-C₁₋₄ alkyl; each R^(f42) and R^(g42) are independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl; each R^(h42) and R^(i42) isindependently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl,5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl,4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 memberedheteroaryl-C₁₋₄ alkyl; each R^(j42) and R^(k42) is independentlyselected from OH, C₁₋₆ alkoxy, and C₁₋₆ haloalkoxy; or any R^(j42) andR^(k42) attached to the same B atom, together with the B atom to whichthey are attached, form a 5- or 6-membered heterocycloalkyl groupoptionally substituted with 1, 2, 3, or 4 substituents independentlyselected from C₁₋₆ alkyl and C₁₋₆ haloalkyl; each R^(4C) isindependently selected from H, D, halo, CN, NO₂, C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a43), SR^(a43), NHOR^(a43),C(O)R^(b43), C(O)NR^(c43)R^(d43), C(O)NR^(c43)(OR^(a43)), C(O)OR^(a43),OC(O)R^(b43), OC(O)NR^(c43)R^(d43), NR^(c43)R^(d43),NR^(c43)NR^(c43)R^(d43), NR^(c43)C(O)R^(b43), NR^(c43)C(O)OR^(a43),NR^(c43)C(O)NR^(c43)R^(d43), C(═NR^(e43))R^(b43),C(═NR^(e43))NR^(c43)R^(d43), NR^(c43)C(═NR^(e43))NR^(c43)R^(d43),NR^(c43)C(═NR^(e43))R^(b43), NR^(c43)S(O)NR^(c43)R^(d43),NR^(c43)S(O)R^(b43), NR^(c43)S(O)₂R^(b43),NR^(c43)S(O)(═NR^(e43))R^(b43), NR^(c43)S(O)₂NR^(c43)R^(d43),S(O)R^(b43), S(O)NR^(c43)R^(d43), S(O)₂R^(b43), S(O)₂NR^(c43)R^(d43),OS(O)(═NR^(e43))R^(b43), OS(O)₂R^(b43), S(O)(═NR^(e43))R^(b43), SF₅,P(O)R^(f43)R^(g43), OP(O)(OR^(h43))(OR^(i43)), P(O)(OR^(h43))(OR^(i43))and BR^(j43)R^(k43), wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1,2, 3, or 4 independently selected R^(G) substituents; each R^(a43),R^(c43), and R^(d43) is independently selected from H, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(G) substituents; or, any R^(c43)and R^(d43) attached to the same N atom, together with the N atom towhich they are attached, form a 4-7 membered heterocycloalkyl group,wherein the 4-7 membered heterocycloalkyl group is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(G)substituents; each R^(b43) is independently selected from C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl, which are each optionallysubstituted with 1, 2, 3, or 4 independently selected R^(G)substituents; each R^(e43) is independently selected from H, OH, CN,C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl,5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl,4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 memberedheteroaryl-C₁₋₄ alkyl; each R^(f43) and R^(g43) are independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆haloalkoxy, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl; each R^(h43) and R^(i43) isindependently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl,5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl,4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 memberedheteroaryl-C₁₋₄ alkyl; each R^(j43) and R^(k43) is independentlyselected from OH, C₁₋₆ alkoxy, and C₁₋₆ haloalkoxy; or any R^(j43) andR^(k43) attached to the same B atom, together with the B atom to whichthey are attached, form a 5- or 6-membered heterocycloalkyl groupoptionally substituted with 1, 2, 3, or 4 substituents independentlyselected from C₁₋₆ alkyl and C₁₋₆ haloalkyl; Z is CR⁵ or N; R⁵ isindependently selected from H, D, halo, CN, OH, NO₂, C₁₋₄ alkyl, C₁₋₄haloalkyl, C₂-4 alkenyl, C₂₋₄ alkynyl, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy,amino, C₁₋₄ alkylamino, di(C₁₋₄ alkyl)amino, cyano-C₁₋₄ alkyl, HO—C₁₋₄alkyl, C₁₋₄ alkoxy-C₁₋₄ alkyl, C₃₋₄ cycloalkyl, thio, C₁₋₄ alkylthio,C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, carbamyl, C₁₋₄ alkylcarbamyl,di(C₁₋₄ alkyl)carbamyl, carboxy, C₁₋₄ alkylcarbonyl, C₁₋₄alkoxycarbonyl, C₁₋₄ alkylcarbonyloxy, C₁₋₄ alkylcarbonylamino, C₁₋₄alkoxycarbonylamino, C₁₋₄ alkylaminocarbonyloxy, C₁₋₄alkylsulfonylamino, aminosulfonyl, C₁₋₄ alkylaminosulfonyl, di(C₁₋₄alkyl)aminosulfonyl, aminosulfonylamino, C₁₋₄ alkylaminosulfonylamino,di(C₁₋₄ alkyl)aminosulfonylamino, aminocarbonylamino, C₁₋₄alkylaminocarbonylamino, and di(C₁₋₄ alkyl)aminocarbonylamino; and eachR^(G) is independently selected from OH, NO₂, CN, halo, C₁₋₃ alkyl, C₂₋₃alkenyl, C₂₋₃ alkynyl, C₁₋₃ haloalkyl, cyano-C₁₋₃ alkyl, HO—C₁₋₃ alkyl,C₁₋₃ alkoxy-C₁₋₃ alkyl, C₃₋₇ cycloalkyl, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy,amino, C₁₋₃ alkylamino, di(C₁₋₃ alkyl)amino, thio, C₁₋₃ alkylthio, C₁₋₃,alkylsulfinyl, C₁₋₃ alkylsulfonyl, carbamyl, C₁₋₃ alkylcarbamyl, di(C₁₋₃alkyl)carbamyl, carboxy, C₁₋₃ alkylcarbonyl, C₁₋₃ alkoxycarbonyl, C₁₋₃alkylcarbonyloxy, C₁₋₃ alkylcarbonylamino, C₁₋₃, alkoxycarbonylamino,C₁₋₃ alkylaminocarbonyloxy, C₁₋₃ alkylsulfonylamino, aminosulfonyl,C₁₋₃, alkylaminosulfonyl, di(C₁₋₃ alkyl)aminosulfonyl,aminosulfonylamino, C₁₋₃ alkylaminosulfonylamino, di(C₁₋₃alkyl)aminosulfonylamino, aminocarbonylamino, C₁₋₃,alkylaminocarbonylamino, and di(C₁₋₃ alkyl)aminocarbonylamino.
 2. Thecompound of claim 1, or a pharmaceutically acceptable salt thereof,wherein:

is a double bond; n is 0, 1, 2, 3, or 4; Y is CR^(1a), wherein Y isadjacent to the carbon ring member attaching Ring moiety A to the —NH—in Formula (I); Ring moiety A is selected from phenyl and 5-10 memberedheteroaryl, wherein Ring moiety A is attached to the —NH— in Formula (I)through a carbon atom; R^(1a) is selected from halo, CN, C₁₋₄ alkyl, andC₁₋₄ haloalkyl; or R^(1a) and an R² on an adjacent ring member of Ringmoiety A, together with the ring atoms to which they are attached, formRing moiety B; Ring moiety B is selected from phenyl or 5-6 memberedheteroaryl, each of which is optionally substituted by 1, 2, 3, or 4independently selected R³ substituents; each R² and R³ is independentlyselected from H, D, halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl,OR^(a2), SR^(a2), C(O)R^(b2), C(O)NR^(c2)R^(d2), C(O)OR^(a2),OC(O)R^(b2), OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2), NR^(c2)C(O)R^(b2),NR²C(O)OR^(a2), NR^(c2)C(O)NR^(c2)R^(d2), NR^(c2)S(O)₂R^(b2),NR^(c2)S(O)₂NR^(c2)R^(d2), S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2), whereinsaid C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with 1,2, 3, or 4 independently selected R^(2A) substituents; each R^(a2),R^(c2), and R^(d2) is independently selected from H, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl,OR^(a22), SR^(a22), C(O)R^(b22), C(O)NR^(c22)R^(d22), C(O)OR^(a22),OC(O)R^(b22), OC(O)NR^(c22)R^(d22), NR^(c22)R^(d22),NR^(c22)C(O)R^(b22), NR^(c22)C(O)OR^(a22), NR^(c22)C(O)NR^(c22)R^(d22),NR^(c22)S(O)₂R^(b22), NR^(c22)S(O)₂NR^(c22)R^(d22), S(O)₂R^(b22), andS(O)₂NR^(c22)R^(d22), wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents; each R^(a22), R^(c22), and R^(d22) is independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl,4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(G) substituents; each R^(b22) isindependently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(G) substituents; R⁴ is independently selected from phenyl,4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, OR^(a4), andNR^(c4)R^(d4), wherein said phenyl, 4-10 membered heterocycloalkyl, and5-10 membered heteroaryl are each optionally substituted with 1, 2, 3,or 4 independently selected R^(4A) substituents; each R^(a4), R^(c4),and R^(d4) is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(4A) substituents; or, any R^(c4)and R^(d4) attached to the same N atom, together with the N atom towhich they are attached, form a 4-10 membered heterocycloalkyl group,wherein the 4-10 membered heterocycloalkyl group is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(4A)substituents; each R^(4A) is independently selected from halo, CN, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a41), SR^(a41), C(O)R^(b41),C(O)NR^(c41)R^(d41), C(O)OR^(a41), OC(O)R^(b41), OC(O)NR^(c41)R^(d41),NR^(c41)R^(d41), NR^(c41)C(O)R^(b41), NR^(c41)C(O)OR^(a41),NR^(c41)C(O)NR^(c41)R^(d41), NR^(c41)S(O)NR^(c41)R^(d41),NR^(c41)S(O)R^(b41), NR^(c41)S(O)₂R^(b41), NR^(c41)S(O)₂NR^(c41)R^(d41),S(O)₂R^(b41), and S(O)₂NR^(c41)R^(d41), wherein said C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄alkyl are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4B) substituents; each R^(a41), R^(c41), and R^(d41) isindependently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl,C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄alkyl are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4B) substituents; each R^(b41) is independently selectedfrom C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(4B) substituents; eachR^(4B) is independently selected from H, D, halo, CN, NO₂, C₁₋₆ alkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a42), SR^(a42), C(O)R^(b42),C(O)NR^(b42)R^(c42), C(O)OR^(a42), OC(O)R^(b42), OC(O)NR^(c42)R^(d42),NR^(c42)R^(d42), NR^(c42)C(O)R^(b42), NR^(c42)C(O)OR^(a42),NR^(c42)C(O)NR^(c42)R^(d42), NR^(c42)S(O)₂R^(b42),NR^(c42)S(O)₂NR^(c42)R^(d42), S(O)₂R^(b42), and S(O)₂NR^(c42)R^(d42),wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4C) substituents; each R^(a42), R^(c42), and R^(d42) is independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4C) substituents; each R^(b42) is independently selected from C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4C) substituents; each R^(4C) is independently selected fromH, D, halo, CN, NO₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7membered heterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄alkyl, OR^(a43), SR^(a43), C(O)R^(b43), C(O)NR^(c43)R^(d43),C(O)OR^(a43), OC(O)R^(b43), OC(O)NR^(c43)R^(d43), NR^(c43)R^(d43),NR^(c43)C(O)R^(b43), NR^(d43), C(O)OR^(a43),NR^(c43)C(O)NR^(c43)R^(d43), NR^(c43)S(O)₂R^(b43),NR^(c43)S(O)(═NR^(e43))R^(b43), NR^(c43)S(O)₂NR^(c43)R^(d43),S(O)₂R^(b43), and S(O)₂NR^(c43)R^(d43), wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(G) substituents; each R^(a43),R^(c43), and R^(d43) is independently selected from H, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₂₋₆alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(G) substituents; each R^(b43) isindependently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl,5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl,4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 memberedheteroaryl-C₁₋₄ alkyl, which are each optionally substituted with 1, 2,3, or 4 independently selected R^(G) substituents; Z is CR⁵ or N; R⁵ isindependently selected from H, halo, CN, C₁₋₄ alkyl, C₁₋₄ haloalkyl, OH,C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, amino, C₁₋₃ alkylamino, di(C₁₋₃alkyl)amino, cyano-C₁₋₄ alkyl, HO—C₁₋₄ alkyl, C₁₋₃ alkoxy-C₁₋₄ alkyl,and C₃₋₄ cycloalkyl; and each R^(G) is independently selected from OH,NO₂, CN, halo, C₁₋₃ alkyl, C₂₋₃ alkenyl, C₂₋₃, alkynyl, C₁₋₃ haloalkyl,cyano-C₁₋₃ alkyl, HO—C₁₋₃ alkyl, C₁₋₃ alkoxy-C₁₋₃ alkyl, C₃₋₇cycloalkyl, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, amino, C₁₋₃ alkylamino,di(C₁₋₃ alkyl)amino, thio, C₁₋₃ alkylthio, C₁₋₃, alkylsulfinyl, C₁₋₃alkylsulfonyl, carbamyl, C₁₋₃ alkylcarbamyl, di(C₁₋₃ alkyl)carbamyl,carboxy, C₁₋₃ alkylcarbonyl, C₁₋₃ alkoxycarbonyl, C₁₋₃ alkylcarbonyloxy,C₁₋₃ alkylcarbonylamino, C₁₋₃, alkoxycarbonylamino, C₁₋₃alkylaminocarbonyloxy, C₁₋₃ alkylsulfonylamino, aminosulfonyl, C₁₋₃,alkylaminosulfonyl, di(C₁₋₃ alkyl)aminosulfonyl, aminosulfonylamino,C₁₋₃, alkylaminosulfonylamino, di(C₁₋₃ alkyl)aminosulfonylamino,aminocarbonylamino, C₁₋₃, alkylaminocarbonylamino, and di(C₁₋₃alkyl)aminocarbonylamino.
 3. The compound of claim 1, or apharmaceutically acceptable salt thereof, wherein:

is a double bond; n is 0, 1, 2, 3, or 4; Y is CR^(1a), wherein Y isadjacent to the carbon ring member attaching Ring moiety A to the —NH—in Formula (I); Ring moiety A is selected from phenyl and 5-10 memberedheteroaryl, wherein Ring moiety A is attached to the —NH— in Formula (I)through a carbon atom; R^(1a) is selected from halo, CN, C₁₋₄ alkyl, andC₁₋₄ haloalkyl; or R^(1a) and an R² on an adjacent ring member of Ringmoiety A, together with the ring atoms to which they are attached, formRing moiety B; Ring moiety B is selected from phenyl or 5-6 memberedheteroaryl, each of which is optionally substituted by 1, 2, 3, or 4independently selected R³ substituents; each R² and R³ is independentlyselected from H, D, halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₄cycloalkyl, OR^(a2), SR^(a2), C(O)R^(b2), C(O)NR^(c2)R^(d2),C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2),NR^(c2)C(O)R^(b2), NR²C(O)OR^(a2), NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)S(O)₂R^(b2), NR^(c2)S(O)₂NR^(c2)R^(d2), S(O)₂R^(b2), andS(O)₂NR^(c2)R^(d2), wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₃₋₄cycloalkyl are each optionally substituted with 1, 2, 3, or 4independently selected R^(2A) substituents; each R^(a2), R^(c2), andR^(d2) is independently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl,wherein said C₁₋₆ alkyl and C₁₋₆ haloalkyl are each optionallysubstituted with 1, 2, 3, or 4 independently selected R^(2A)substituents; each R^(b2) is independently selected from C₁₋₆ alkyl andC₁₋₆ haloalkyl, which are each optionally substituted with 1, 2, 3, or 4independently selected R^(2A) substituents; each R^(2A) is independentlyselected from halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₄, cycloalkyl,OR^(a21), SR^(a21), C(O)R^(b21), C(O)NR^(c21)R^(d21), C(O)OR^(a21),OC(O)R^(b21), OC(O)NR^(c21)R^(d21), NR^(c21)R^(d21),NR^(c21)C(O)R^(b21), NR^(c21)C(O)OR^(a21), NR^(c21)C(O)NR^(c21)R^(d21),NR^(c21)S(O)NR^(c21)R^(d21), NR^(c21)S(O)R^(b21), NR^(c21)S(O)₂R^(b21),NR^(c21)S(O)₂NR^(c21)R^(d21), S(O)₂R^(b21), and S(O)₂NR^(c21)R^(d21),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₃₋₄ cycloalkyl are eachoptionally substituted with 1, 2, 3, or 4 independently selected R^(2B)substituents; each R^(a21), R^(c21), and R^(d21) is independentlyselected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl, wherein said C₁₋₆ alkyland C₁₋₆ haloalkyl are each optionally substituted with 1, 2, 3, or 4independently selected R^(2B) substituents; each R^(b21) isindependently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2B) substituents; each R^(2B) is independently selected fromH, halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, OR^(a22), SR^(a22),C(O)R^(b22), C(O)NR^(c22)R^(d22), C(O)OR^(a22), OC(O)R^(b22),OC(O)NR^(c22)R^(d22), NR^(c22)R^(d22), NR^(c22)C(O)R^(b22),NR^(c22)C(O)OR^(a22), NR^(c22)C(O)NR^(c22)R^(d22), NR^(c22)S(O)₂R^(b22),NR^(c22)S(O)₂NR^(c22)R^(d22), S(O)₂R^(b22), and S(O)₂NR^(c22)R^(d22);each R^(a22), R^(c22), and R^(d22) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl; each R^(b22) is independently selectedfrom C₁₋₆ alkyl and C₁₋₆ haloalkyl; R⁴ is independently selected fromphenyl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, andOR^(a4), wherein said phenyl, 4-10 membered heterocycloalkyl, and 5-10membered heteroaryl are each optionally substituted with 1, 2, 3, or 4independently selected R^(4A) substituents; each R^(a4), R^(c4), andR^(d4) is independently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(4A) substituents; or, any R^(c4)and R^(d4) attached to the same N atom, together with the N atom towhich they are attached, form a 4-10 membered heterocycloalkyl group,wherein the 4-10 membered heterocycloalkyl group is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(4A)substituents; each R^(4A) is independently selected from halo, CN, C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl,C₃₋₆ cycloalkyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl,OR^(a41), NR^(c41)R^(d41) and S(O)₂R⁴¹, wherein said C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, C₃₋₆cycloalkyl-C₁₋₄ alkyl, and 4-6 membered heterocycloalkyl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents; each R^(a41), R^(c41), and R^(d41) is independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl,4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(4B) substituents; each R^(b41)is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4B) substituents; each R^(4B) is independently selected fromH, D, halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₄, cycloalkyl, OR^(a42),NR^(c42)R^(d42), and S(O)₂R^(b42); each R^(a42), R^(c42), and R^(d42) isindependently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl; eachR^(b42) is independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl; Zis CR⁵ or N; and R⁵ is selected from H, halo, CN, C₁₋₃ alkyl, and C₁₋₃haloalkyl.
 4. The compound of claim 1, or a pharmaceutically acceptablesalt thereof, wherein Ring moiety A is selected from phenyl and 5-10membered heteroaryl, wherein Ring moiety A is attached to the —NH— inFormula (I) through a carbon atom.
 5. The compound of claim 1, or apharmaceutically acceptable salt thereof, wherein Ring moiety A isphenyl, pyridin-4-yl, or imidazo[1,2-a]pyridin-6-yl.
 6. The compound ofclaim 1, or a pharmaceutically acceptable salt thereof, wherein Y isCR^(1a).
 7. The compound of claim 1, or a pharmaceutically acceptablesalt thereof, wherein R^(1a) is selected from halo, CN, C₁₋₄ alkyl, andC₁₋₄ haloalkyl.
 8. The compound of claim 1, or a pharmaceuticallyacceptable salt thereof, wherein R^(1a) is selected from halo and C₁₋₄alkyl.
 9. The compound of claim 1, or a pharmaceutically acceptable saltthereof, wherein R^(1a) is selected from F and CH₃.
 10. The compound ofclaim 1, or a pharmaceutically acceptable salt thereof, wherein R^(1a)and an R² on an adjacent ring member of Ring moiety A, together with thering atoms to which they are attached, form Ring moiety B.
 11. Thecompound of claim 10, or a pharmaceutically acceptable salt thereof,wherein Ring moiety B is selected from phenyl or 5-6 memberedheteroaryl, each of which is optionally substituted by 1, 2, 3, or 4independently selected R³ substituents.
 12. The compound of claim 10, ora pharmaceutically acceptable salt thereof, wherein Ring moiety B isphenyl.
 13. The compound of claim 1, or a pharmaceutically acceptablesalt thereof, wherein each R², and R³ is independently selected from H,D, halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a2), SR^(a2), C(O)R^(b2),C(O)NR^(c2)R^(d2), C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R²,NR^(c2)R^(d2), NR^(c2)C(O)R^(b2), NR^(c2)C(O)OR^(a2),NR^(c2)C(O)NR^(c2)R^(d2) NR^(c2)S(O)₂R^(b2), NR^(c2)S(O)₂NR^(c2)R^(d2),S(O)₂R^(b2), and S(O)₂NR^(c2)R^(d2), wherein said C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄alkyl are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2A) substituents.
 14. The compound of claim 1, or apharmaceutically acceptable salt thereof, wherein each R², and R³ isindependently selected from H, D, halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₄ cycloalkyl, OR^(a2), SR^(a2), C(O)R^(b2), C(O)NR^(c2)R^(d2),C(O)OR^(a2), OC(O)R^(b2), OC(O)NR^(c2)R^(d2), NR^(c2)R^(d2),NR^(c2)C(O)R^(b2), NR^(c2)C(O)OR^(a2), NR^(c2)C(O)NR^(c2)R^(d2),NR^(c2)S(O)₂R^(b2), NR^(c2)S(O)₂NR^(c2)R^(d2), S(O)₂R^(b2), andS(O)₂NR^(c2)R^(d2), wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₃₋₄cycloalkyl are each optionally substituted with 1, 2, 3, or 4independently selected R^(2A) substituents.
 15. The compound of claim 1,or a pharmaceutically acceptable salt thereof, wherein each R², and R³is independently selected from halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl,OR^(a2), S(O)₂R^(b2), and NR^(c2)R^(d2), wherein said C₁₋₆ alkyl andC₁₋₆ haloalkyl are each optionally substituted with 1 or 2,independently selected R^(2A) substituents.
 16. The compound of claim 1,or a pharmaceutically acceptable salt thereof, wherein each R², isindependently selected from H, CH₃, HO—CH₂—, (CH₃)₂N—CH₂—, andCH₃S(O)₂-.
 17. The compound of claim 1, or a pharmaceutically acceptablesalt thereof, wherein: each R^(a2), R^(c2), and R^(d2) is independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2A) substituents; and each R^(b2) is independently selected from C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2A) substituents.
 18. The compound of claim 1, or apharmaceutically acceptable salt thereof, wherein each R^(a2), R^(c2),and R^(d2) is independently selected from H, C₁₋₆ alkyl, and C₁₋₆haloalkyl, wherein said C₁₋₆ alkyl and C₁₋₆ haloalkyl are eachoptionally substituted with 1, 2, 3, or 4 independently selected R^(2A)substituents; and each R^(b2) is independently selected from C₁₋₆ alkyland C₁₋₆ haloalkyl, which are each optionally substituted with 1, 2, 3,or 4 independently selected R^(2A) substituents.
 19. The compound ofclaim 1, or a pharmaceutically acceptable salt thereof, wherein eachR^(a2), R^(c2), and R^(d2) is independently selected from H, C₁₋₆ alkyl,and C₁₋₆ haloalkyl; and each R^(b2) is independently selected from C₁₋₆alkyl and C₁₋₆ haloalkyl.
 20. The compound of claim 1, or apharmaceutically acceptable salt thereof, wherein each R^(2A) isindependently selected from halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl,OR^(a21), SR^(a21), C(O)R^(b21), C(O)NR^(c21)R^(d21), C(O)OR^(a21),OC(O)R^(b21), OC(O)NR^(c21)R^(d21), NR^(c21)R^(d21),NR^(c21)C(O)R^(b21), NR^(c21)C(O)OR^(a21), NR^(c21)C(O)NR^(c21)R^(d21),NR^(c21)S(O)NR^(c21)R^(d21), NR^(c21)S(O)R^(b21), NR^(c21)S(O)₂R^(b21),NR^(c21)S(O)₂NR^(c21)R^(d21), S(O)₂R^(b21), and S(O)₂NR^(c21)R^(d21),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(2B) substituents.
 21. Thecompound of claim 1, or a pharmaceutically acceptable salt thereof,wherein each R^(2A) is independently selected from halo, CN, C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₄ cycloalkyl, OR^(a21), SR^(a21), C(O)R^(b21),C(O)NR^(c21)R^(d21), C(O)OR^(a21), OC(O)R^(b21), OC(O)NR^(c21)R^(d21),NR^(c21)R^(d21), NR^(c21)C(O)R^(b21), NR^(c21)C(O)OR^(a21),NR^(c21)C(O)NR^(c21)R^(d21), NR^(c21)S(O)NR^(c21)R^(d21),NR^(c21)S(O)R^(b21), NR^(c21)S(O)₂R^(b21), NR^(c21)S(O)₂NR^(c21)R^(d21),S(O)₂R^(b21), and S(O)₂NR^(c21)R^(d21), wherein said C₁₋₆ alkyl, C₁₋₆haloalkyl, and C₃₋₄ cycloalkyl are each optionally substituted with 1,2, 3, or 4 independently selected R^(2B) substituents.
 22. The compoundof claim 1, or a pharmaceutically acceptable salt thereof, wherein eachR^(2A) is independently selected from halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, C₃₋₆cycloalkyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl,OR^(a21), NR^(c21)R^(d21) and S(O)₂R^(b21), wherein said C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, C₃₋₆cycloalkyl-C₁₋₄ alkyl, and 4-6 membered heterocycloalkyl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(2B) substituents.
 23. The compound of claim 1, or a pharmaceuticallyacceptable salt thereof, wherein each R^(2A) is independently selectedfrom halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, OR^(a)21, andNR^(c21)R^(d21), wherein said C₁₋₆ alkyl and C₁₋₆ haloalkyl are eachoptionally substituted with 1, 2, 3, or 4 independently selected R^(2B)substituents.
 24. The compound of claim 1, or a pharmaceuticallyacceptable salt thereof, wherein: each R^(a21), R^(c21), and R^(d21) isindependently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(2B) substituents; each R^(b21)is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2B) substituents; each R^(2B) is independently selected fromH, D, halo, CN, NO₂, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl,OR^(a22), SR^(a22), C(O)R^(b22), C(O)NR^(c22)R^(d22), C(O)OR^(a22),OC(O)R^(b22), OC(O)NR^(c22)R^(d22), NR^(c22)R^(d22),NR^(c22)C(O)R^(b22), NR^(c22)C(O)OR^(a22), NR^(c22)C(O)NR^(c22)R^(d22),NR^(c22)S(O)₂R^(b22), NR^(c22)S(O)₂NR^(c22)R^(d22), S(O)₂R^(b22), andS(O)₂NR^(c22)R^(d22), wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents; each R^(a22), R^(c22), and R^(d22) is independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl,4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered alkyl, and 5-6 memberedheteroaryl-C₁₋₄ alkyl are each optionally substituted with 1, 2, 3, or 4independently selected R^(2A) substituents; each R^(b2) is independentlyselected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2A) substituents; each R^(2A) is independently selected fromhalo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a21), SR^(a21), C(O)R^(b21),C(O)NR^(c21)R^(d21), C(O)OR^(a21), OC(O)R^(b21), OC(O)NR^(c21)R^(d21),NR^(c21)R^(d21), NR^(c21)C(O)R^(b21), NR^(c21)C(O)OR^(a21),NR^(c21)C(O)NR^(c21)R^(d21), NR^(c21)S(O)NR^(c21)R^(d21),NR^(c21)S(O)R^(b21), NR^(c21)S(O)₂R^(b21), NR^(c21)S(O)₂NR^(c21)R^(d21),S(O)₂R^(b21), and S(O)₂NR^(c21)R^(d21), wherein said C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄alkyl are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2B) substituents; each R^(a21), R^(c21), and R^(d21) isindependently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(2B) substituents; each R^(b21)is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2B) substituents; each R^(2B) is independently selected fromH, D, halo, CN, NO₂, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents; and each R^(b22) is independently selected from C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(G) substituents.
 25. Thecompound of claim 1, or a pharmaceutically acceptable salt thereof,wherein: each R^(a21), R^(c21), and R^(d21) is independently selectedfrom H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄alkyl are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2B) substituents; each R^(b21) is independently selectedfrom C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(2B) substituents; eachR^(2B) is independently selected from H, D, halo, CN, NO₂, C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl,5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl,4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄alkyl, OR^(a22), SR^(a22), C(O)R^(b22), C(O)NR^(c22)R^(d22),C(O)OR^(a22), OC(O)R^(b22), OC(O)NR^(c22)R^(d22), NR^(c22)R^(d22),NR^(c22)C(O)R^(b22), NR^(c22)C(O)OR^(a22), NR^(c22)C(O)NR^(c22)R^(d22),NR^(c22)S(O)₂R^(b22), NR^(c22)S(O)₂NR^(c22)R^(d22), S(O)₂R^(b22), andS(O)₂NR^(c22)R^(d22); each R^(a22), R^(c22), and R^(d22) isindependently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl; andeach R^(b22) is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl. 26.The compound of claim 1, or a pharmaceutically acceptable salt thereof,wherein: each R^(a21), R^(c21), and R^(d21) is independently selectedfrom H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl, wherein said C₁₋₆ alkyl and C₁₋₆haloalkyl are each optionally substituted with 1, 2, 3, or 4independently selected R^(2B) substituents; each R^(b21) isindependently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(2B) substituents; each R^(2B) is independently selected fromH, halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, OR^(a22), SR^(a22),C(O)R^(b22), C(O)NR^(c22)R^(d22), C(O)OR^(a22), OC(O)R^(b22),OC(O)NR^(c22)R^(d22), NR^(c22)R^(d22), NR^(c22)C(O)R^(b22),NR^(c22)C(O)OR^(a22), NR^(c22)C(O)NR^(c22)R^(d22), NR^(c22)S(O)₂R^(b22),NR^(c22)S(O)₂NR^(c22)R^(d22), S(O)₂R^(b22), and S(O)₂NR^(c22)R^(d22);each R^(a22), R^(c22), and R^(d22) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and each R^(b22) is independentlyselected from C₁₋₆ alkyl and C₁₋₆ haloalkyl.
 27. The compound of claim1, or a pharmaceutically acceptable salt thereof, wherein: each R^(a21),R^(c21), and R^(d21) is independently selected from H, C₁₋₆ alkyl, andC₁₋₆ haloalkyl, wherein said C₁₋₆ alkyl and C₁₋₆ haloalkyl are eachoptionally substituted with 1 or 2, independently selected R^(2B)substituents; each R^(b21) is independently selected from C₁₋₆ alkyl andC₁₋₆ haloalkyl, which are each optionally substituted with 1 or 2independently selected R^(2B) substituents; and each R^(2B) isindependently selected from H, D, halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl,C₃₋₄, cycloalkyl, OH, and N(C₁₋₆ alkyl)₂.
 28. The compound of claim 1,or a pharmaceutically acceptable salt thereof, wherein each R^(a21),R^(c21), and R^(d21) is independently selected from H, C₁₋₆ alkyl, andC₁₋₆ haloalkyl; and each R^(b21) is independently selected from C₁₋₆alkyl and C₁₋₆ haloalkyl.
 29. The compound of claim 1, or apharmaceutically acceptable salt thereof, wherein R⁴ is independentlyselected from phenyl, 4-10 membered heterocycloalkyl, 5-10 memberedheteroaryl, OR^(a4), and NR^(c4)R^(d4), wherein said phenyl, 4-10membered heterocycloalkyl, and 5-10 membered heteroaryl are eachoptionally substituted with 1, 2, 3, or 4 independently selected R^(4A)substituents.
 30. The compound of claim 1, or a pharmaceuticallyacceptable salt thereof, wherein R⁴ is independently selected from 4-10membered heterocycloalkyl and OR^(a4), wherein said 4-10 memberedheterocycloalkyl is optionally substituted with 1, 2, 3, or 4independently selected R^(4A) substituents.
 31. The compound of claim 1,or a pharmaceutically acceptable salt thereof, wherein R⁴ isindependently selected from phenyl, 4-10 membered heterocycloalkyl, 5-10membered heteroaryl, and OR^(a4), wherein said phenyl, 4-10 memberedheterocycloalkyl, and 5-10 membered heteroaryl are each optionallysubstituted with 1, 2, 3, or 4 independently selected R^(4A)substituents.
 32. The compound of claim 1, or a pharmaceuticallyacceptable salt thereof, wherein R⁴ is selected from isopropoxy, phenyl,pyridin-4-yl, 2-oxy-benzo[d]oxazol-(3H)-7-yl, and 1H-indazol-5-yl,wherein said phenyl, pyridin-4-yl, 2-oxy-benzo[d]oxazol-(3H)-7-yl, and1H-indazol-5-yl are each optionally substituted with 1, 2, 3, or 4independently selected R^(4A) substituents.
 33. The compound of claim 1,or a pharmaceutically acceptable salt thereof, wherein each R^(4A) isindependently selected from halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄ alkyl,OR^(a41), SR^(a41), C(O)R^(b41), C(O)NR^(c41)R^(d41), C(O)OR^(a41),OC(O)R^(b41), OC(O)NR^(c41)R^(d41), NR^(c41)R^(d41),NR^(c41)C(O)R^(b41), NR^(c41)C(O)OR^(a41), NR^(c41)C(O)NR^(c41)R^(d41),NR^(c41)S(O)NR^(c41)R^(d41), NR^(c41)S(O)R^(b41), NR^(c41)S(O)₂R^(b41)NR^(c41)S(O)₂NR^(c41)R^(d41), S(O)₂R^(b41), and S(O)₂NR^(c41)R^(d41),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(4B) substituents.
 34. Thecompound of claim 1, or a pharmaceutically acceptable salt thereof,wherein each R^(4A) is independently selected from halo, CN, C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, C₃₋₆cycloalkyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl,OR^(a41), NR^(c41)R^(d41) and S(O)₂R^(b41), wherein said C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, 4-6 membered heterocycloalkyl, C₃₋₆cycloalkyl-C₁₋₄ alkyl, and 4-6 membered heterocycloalkyl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents.
 35. The compound of claim 1, or a pharmaceuticallyacceptable salt thereof, wherein each R^(4A) is independently selectedfrom halo, CN, C₁₋₆ alkyl, and 4-6 membered heterocycloalkyl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl and 4-6 membered heterocycloalkyl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents.
 36. The compound of claim 1, or a pharmaceuticallyacceptable salt thereof, wherein each R^(a4), R^(c4), and R^(d4) isindependently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(4A) substituents; or, any R^(c4)and R^(d4) attached to the same N atom, together with the N atom towhich they are attached, form a 4-10 membered heterocycloalkyl group,wherein the 4-10 membered heterocycloalkyl group is optionallysubstituted with 1, 2, 3, or 4 independently selected R^(4A)substituents.
 37. The compound of claim 1, or a pharmaceuticallyacceptable salt thereof, wherein each R^(a4), R^(c4), and R^(d4) isindependently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₃₋₄cycloalkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₃₋₄ cycloalkylare each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4A) substituents; or, any R^(c4) and R^(d4) attached to thesame N atom, together with the N atom to which they are attached, form a4-7 membered heterocycloalkyl group, wherein the 4-7 memberedheterocycloalkyl group is optionally substituted with 1, 2, 3, or 4independently selected R^(4A) substituents.
 38. The compound of claim 1,or a pharmaceutically acceptable salt thereof, wherein each R^(a4),R^(c4), and R^(d4) is independently selected from H, C₁₋₆ alkyl, andC₁₋₆ haloalkyl.
 39. The compound of claim 1, or a pharmaceuticallyacceptable salt thereof, wherein: each R^(a41), R^(c41), and R^(d41) isindependently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl,C₂₋₆ alkynyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10membered aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl,C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 membered aryl-C₁₋₄ alkyl, 4-10membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10 membered heteroaryl-C₁₋₄alkyl are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4B) substituents; each R^(b41) is independently selectedfrom C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₁₀cycloalkyl, 6-10 membered aryl, 4-10 membered heterocycloalkyl, 5-10membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl, 6-10 memberedaryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-10membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(4B) substituents; eachR^(4B) is independently selected from H, D, halo, CN, NO₂, C₁₋₆ alkyl,C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a42), SR^(a42), C(O)R^(b42),C(O)NR^(c42)R^(d42), C(O)OR^(a42), OC(O)R^(b42), OC(O)NR^(c42)R^(d42),NR^(c42)R^(d42), NR^(c42)C(O)R^(b42), NR^(c42)C(O)OR^(a42),NR^(c42)C(O)NR^(c42)R^(d42), NR^(c42)S(O)₂R^(b42),NR^(c42)S(O)₂NR^(c42)R^(d42), S(O)₂R^(b42), and S(O)₂NR^(c42)R^(d42),wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4C) substituents; each R^(a42), R^(c42), and R^(d42) is independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4C) substituents; each R^(b42) is independently selected from C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4C) substituents; each R^(4C) is independently selected fromH, D, halo, CN, NO₂, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7membered heterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄alkyl, OR^(a43), SR^(a43), C(O)R^(b43), C(O)NR^(c43)R^(d43),C(O)OR^(a43), OC(O)R^(b43), OC(O)NR^(c43)R^(d43), NR^(c43)R^(d43),NR^(c43)C(O)R^(b43), NR^(c43)C(O)OR^(a43), NR^(c43)C(O)NR^(c43)R^(d43),NR^(c43)S(O)₂R^(b43), NR^(c43)S(O)(═NR^(e43))R^(b43),NR^(c43)S(O)₂NR^(c43)R^(d43), S(O)₂R^(b43), and S(O)₂NR^(c43)R^(d43),wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents; each R^(a43), R^(c43), and R^(d43) is independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl,C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(G) substituents; and each R^(b43) is independently selected from C₁₋₆alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl,phenyl, 4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(G) substituents.
 40. The compound of claim 1, or apharmaceutically acceptable salt thereof, wherein: each R^(a41),R^(c41), and R^(d41) is independently selected from H, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl, wherein said C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl are each optionallysubstituted with 1, 2, 3, or 4 independently selected R^(4B)substituents; each R^(b41) is independently selected from C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, 6-10 membered aryl, 4-10 memberedheterocycloalkyl, 5-10 membered heteroaryl, C₃₋₁₀ cycloalkyl-C₁₋₄ alkyl,6-10 membered aryl-C₁₋₄ alkyl, 4-10 membered heterocycloalkyl-C₁₋₄alkyl, and 5-10 membered heteroaryl-C₁₋₄ alkyl, which are eachoptionally substituted with 1, 2, 3, or 4 independently selected R^(4B)substituents; each R^(4B) is independently selected from H, D, halo, CN,NO₂, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6membered heteroaryl-C₁₋₄ alkyl, OR^(a42), SR^(a42), C(O)R^(b42),C(O)NR^(c42)R^(d42), C(O)OR^(a42), OC(O)R^(b42), OC(O)NR^(c42)R^(d42),NR^(c42)R^(d42), NR^(c42)C(O)R^(b42), NR^(c42)C(O)OR^(a42),NR^(c42)C(O)NR^(c42)R^(d42), NR^(c42)S(O)₂R^(b42),NR^(c42)S(O)₂NR^(c42)R^(d42), S(O)₂R^(b42), and S(O)₂NR^(c42)R^(d42),wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(4C) substituents; each R^(a42),R^(c42), and R^(d42) is independently selected from H, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl,4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4C) substituents; each R^(b42) is independently selected from C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(4C) substituents; eachR^(4C) is independently selected from H, D, halo, CN, C₁₋₆ alkyl, C₁₋₆haloalkyl, and C₃₋₄ cycloalkyl, OR^(a43), NR^(c43)R^(d43) and S(O)₂R⁴³;each R^(a43), R^(c43), and R^(d43) is independently selected from H,C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and each R^(b43) is independentlyselected from C₁₋₆ alkyl and C₁₋₆ haloalkyl.
 41. The compound of claim1, or a pharmaceutically acceptable salt thereof, wherein: each R^(a41),R^(c41), and R^(d41) is independently selected from H, C₁₋₆ alkyl, C₁₋₆haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄alkyl, wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl,4-6 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4B) substituents; each R^(b41) is independently selected from C₁₋₆alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6 memberedheterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl,phenyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl, and 5-6membered heteroaryl-C₁₋₄ alkyl, which are each optionally substitutedwith 1, 2, 3, or 4 independently selected R^(4B) substituents; eachR^(4B) is independently selected from H, D, halo, CN, NO₂, C₁₋₆ alkyl,C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7 membered heterocycloalkyl,5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl,4-7 membered heterocycloalkyl-C₁₋₄ alkyl, 5-6 membered heteroaryl-C₁₋₄alkyl, OR^(a42), SR^(a42), C(O)R^(b42), C(O)NR^(c42)R^(d42),C(O)OR^(a42), OC(O)R^(b42), OC(O)NR^(c42)R^(d42), NR^(c42)R^(d42),NR^(c42)C(O)R^(b42), NR^(c42)C(O)OR^(a42), NR^(c42)C(O)NR^(c42)R^(d42),NR^(c42)S(O)₂R^(b42), NR^(c42)S(O)₂NR^(c42)R^(d42), S(O)₂R^(b42), andS(O)₂NR^(c42)R^(d42), wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl areeach optionally substituted with 1, 2, 3, or 4 independently selectedR^(4C) substituents; each R^(a42), R^(c42), and R^(d42) is independentlyselected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl,4-7 membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇ cycloalkyl, phenyl, 4-7membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₇ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-7 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(4C) substituents; each R^(b42)is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₇cycloalkyl, phenyl, 4-7 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₇ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-7 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4C) substituents; each R^(4C) is independently selected fromH, D, halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, and C₃₋₄ cycloalkyl,OR^(a43), NR^(c43)R^(d43), and S(O)₂R⁴³; each R^(a43), R^(c43), andR^(d43) is independently selected from H, C₁₋₆ alkyl, and C₁₋₆haloalkyl; and each R^(b43) is independently selected from C₁₋₆ alkyland C₁₋₆ haloalkyl.
 42. The compound of claim 1, or a pharmaceuticallyacceptable salt thereof, wherein: each R^(a41), R^(c41), and R^(d41) isindependently selected from H, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,wherein said C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4-6membered heterocycloalkyl, 5-6 membered heteroaryl, C₃₋₆ cycloalkyl-C₁₋₄alkyl, phenyl-C₁₋₄ alkyl, 4-6 membered heterocycloalkyl-C₁₋₄ alkyl, and5-6 membered heteroaryl-C₁₋₄ alkyl are each optionally substituted with1, 2, 3, or 4 independently selected R^(4B) substituents; each R^(b41)is independently selected from C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₆cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6 memberedheteroaryl, C₃₋₆ cycloalkyl-C₁₋₄ alkyl, phenyl-C₁₋₄ alkyl, 4-6 memberedheterocycloalkyl-C₁₋₄ alkyl, and 5-6 membered heteroaryl-C₁₋₄ alkyl,which are each optionally substituted with 1, 2, 3, or 4 independentlyselected R^(4B) substituents; each R^(4B) is independently selected fromH, D, halo, CN, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₃₋₄, cycloalkyl, OR^(a42),NR^(c42)R^(d42), and S(O)₂R^(b42); each R^(a42), R^(c42), and R^(d42) isindependently selected from H, C₁₋₆ alkyl, and C₁₋₆ haloalkyl; and eachR^(b42) is independently selected from C₁₋₆ alkyl and C₁₋₆ haloalkyl.43. The compound of claim 1, or a pharmaceutically acceptable saltthereof, wherein each R^(4A) is independently selected from F, CN, CH₃,HO—CH₂—, and pyrrolidinyl-CH₂-.
 44. The compound of claim 1, or apharmaceutically acceptable salt thereof, wherein n is 0 or
 1. 45. Thecompound of claim 1, or a pharmaceutically acceptable salt thereof,wherein Z is CR⁵.
 46. The compound of claim 1, or a pharmaceuticallyacceptable salt thereof, wherein Z is CH.
 47. The compound of claim 1,or a pharmaceutically acceptable salt thereof, wherein Z is N.
 48. Thecompound of claim 1, wherein the compound is a compound of Formula (II):

or a pharmaceutically acceptable salt thereof.
 49. The compound of claim1, wherein the compound is a compound of Formula (III):

or a pharmaceutically acceptable salt thereof.
 50. The compound of claim1, selected from:6-(2-((2,3-dimethylpyridin-4-yl)amino)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-3-methylbenzo[d]oxazol-2(3H)-one;3-(2-((2,3-dimethylpyridin-4-yl)amino)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-4-fluorobenzonitrile;N-(2,3-dimethylpyridin-4-yl)-8-(1-methyl-1H-indazol-5-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine;(4-(2-((2,3-dimethylpyridin-4-yl)amino)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-3-fluorophenyl)methanol;N-(2,3-dimethylpyridin-4-yl)-8-(3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine;N-(2,3-dimethylpyridin-4-yl)-8-(5-fluoro-2-methylpyridin-4-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine;4-(7-(1H-pyrazol-4-yl)-2-(quinolin-4-ylamino)-[1,2,4]triazolo[1,5-a]pyridin-8-yl)-5-fluoro-2-methylbenzonitrile;N-(2-((dimethylamino)methyl)-3-methylpyridin-4-yl)-8-isopropoxy-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-2-amine;(4-((8-isopropoxy-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)amino)-3-methylpyridin-2-yl)methanol;N-(2,3-dimethylpyridin-4-yl)-8-isopropoxy-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-2-amine;8-isopropoxy-N-(5-methylimidazo[1,2-a]pyridin-6-yl)-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-2-amine;andN-(2-fluoro-4-(methylsulfonyl)phenyl)-8-isopropoxy-7-(1H-pyrazol-4-yl)-[1,2,4]triazolo[1,5-c]pyrimidin-2-amine;or a pharmaceutically acceptable salt thereof.
 51. A pharmaceuticalcomposition comprising the compound of claim 1, or a pharmaceuticallyacceptable salt thereof, and a pharmaceutically acceptable carrier. 52.A method of inhibiting CDK2, comprising contacting the CDK2 with thecompound of claim 1, or a pharmaceutically acceptable salt thereof. 53.A method of inhibiting CDK2 in a patient, comprising administering tothe patient a compound of claim 1, or a pharmaceutically acceptable saltthereof.
 54. A method of treating a disease or disorder associated withCDK2 in a patient, comprising administering to the patient atherapeutically effective amount of the compound of claim 1, orpharmaceutically acceptable salt thereof.
 55. The method of claim 54,wherein the disease or disorder is associated with an amplification ofthe cyclin E1 (CCNE1) gene and/or overexpression of CCNE1.
 56. A methodof treating a human subject having a disease or disorder associated withcyclin-dependent kinase 2 (CDK2), comprising administering to the humansubject a compound of claim 1, or a pharmaceutically acceptable saltthereof, wherein the human subject has been previously determined to:(i) (a) have a nucleotide sequence encoding a p16 protein comprising theamino acid sequence of SEQ ID NO:1; and/or (b) have a cyclin dependentkinase inhibitor 2A (CDKN2A) gene lacking one or more inactivatingnucleic acid substitutions and/or deletions; (ii) (a) have anamplification of the cyclin E1 (CCNE1) gene; and/or (b) have anexpression level of CCNE1 in a biological sample obtained from the humansubject that is higher than a control expression level of CCNE1.
 57. Amethod of treating a human subject having a disease or disorderassociated with cyclin-dependent kinase 2 (CDK2), comprising: (i)identifying, in a biological sample obtained from the human subject: (a)a nucleotide sequence encoding a p16 protein comprising the amino acidsequence of SEQ ID NO:1; and/or (b) a cyclin dependent kinase inhibitor2A (CDKN2A) gene lacking one or more inactivating nucleic acidsubstitutions; (ii) identifying, in a biological sample obtained fromthe human subject: (a) an amplification of the cyclin E1 (CCNE1) gene;and/or (b) an expression level of CCNE1 that is higher than a controlexpression level of CCNE1; and (iii) administering a compound of claim1, or a pharmaceutically acceptable salt thereof, to the human subject.58. The method of claim 57, comprising: (i) identifying, in a biologicalsample obtained from the human subject: (a) a nucleotide sequenceencoding a p16 protein comprising the amino acid sequence of SEQ IDNO:1; and/or (b) a CDKN2A gene lacking one or more inactivating nucleicacid substitutions and/or deletions; (ii) identifying, in a biologicalsample obtained from the human subject: (a) an amplification of theCCNE1 gene; and (iii) administering the compound or the salt to thehuman subject.
 59. A method of evaluating the response of a humansubject having a disease or disorder associated with cyclin-dependentkinase 2 (CDK2) to a compound of claim 1, or a pharmaceuticallyacceptable salt thereof, comprising: (a) administering the compound orthe salt, to the human subject, wherein the human subject has beenpreviously determined to have an amplification of the cyclin E1 (CCNE1)gene and/or an expression level of CCNE1 that is higher than a controlexpression level of CCNE1; (b) measuring, in a biological sample ofobtained from the subject subsequent to the administering of step (a),the level of retinoblastoma (Rb) protein phosphorylation at the serinecorresponding to amino acid position 780 of SEQ ID NO:3, wherein areduced level of Rb phosphorylation at the serine corresponding to aminoacid position 780 of SEQ ID NO:3, as compared to a control level of Rbphosphorylation at the serine corresponding to amino acid position 780of SEQ ID NO:3, is indicative that the human subject responds to thecompound or the salt.
 60. The method of claim 59, wherein the disease ordisorder is cancer.